

10/598,888

=> d his

(FILE 'HOME' ENTERED AT 12:30:08 ON 26 AUG 2008)

FILE 'REGISTRY' ENTERED AT 12:30:16 ON 26 AUG 2008

L1 STRUCTURE UPLOADED
L2 43429 S C6-C6N/EA
L3 41 S C3-C6-C6N/EA
L4 81 S C4-C6-C6N/EA
L5 713 S C5-C6-C6N/EA
L6 16282 S C6-C6-C6N/EA
L7 82 S C6-C6N-C7/EA
L8 17199 S L3 OR L4 OR L5 OR L6 OR L7
L9 909 S L8 AND SPIRO
L10 44338 S L9 OR L2
L11 50 S L1 SUB=L10 SAM
L12 13163 S L1 SUB=L10 FUL

FILE 'CAPLUS' ENTERED AT 12:41:55 ON 26 AUG 2008

FILE 'REGISTRY' ENTERED AT 12:43:25 ON 26 AUG 2008

FILE 'CAPLUS' ENTERED AT 12:45:01 ON 26 AUG 2008

FILE 'REGISTRY' ENTERED AT 12:53:09 ON 26 AUG 2008

FILE 'CAPLUS' ENTERED AT 12:57:40 ON 26 AUG 2008

FILE 'REGISTRY' ENTERED AT 12:58:59 ON 26 AUG 2008

FILE 'CAPLUS' ENTERED AT 13:02:26 ON 26 AUG 2008

FILE 'REGISTRY' ENTERED AT 13:05:19 ON 26 AUG 2008

FILE 'CAPLUS' ENTERED AT 13:16:02 ON 26 AUG 2008

FILE 'REGISTRY' ENTERED AT 13:18:27 ON 26 AUG 2008

FILE 'CAPLUS' ENTERED AT 13:25:07 ON 26 AUG 2008

FILE 'REGISTRY' ENTERED AT 13:25:41 ON 26 AUG 2008

FILE 'CAPLUS' ENTERED AT 13:26:43 ON 26 AUG 2008

FILE 'REGISTRY' ENTERED AT 13:31:16 ON 26 AUG 2008

L13 STRUCTURE UPLOADED
L14 1876 S L13 SUB=L12 FUL
L15 STRUCTURE UPLOADED
L16 1110 S L15 SUB=L12 FUL
L17 1069 S L16 AND CAPLUS/LC
L18 41 S L16 NOT L17


FILE 'CAPLUS' ENTERED AT 13:45:05 ON 26 AUG 2008

L19 75 S L16
L20 68 S L19 NOT (2008/SO OR 2007/SO OR 2006/SO OR 2005/SO)

=> d l1

10/598,888

L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> d l15
L15 HAS NO ANSWERS
L15 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> d ibib abs hitstr total

L20 ANSWER 1 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:529900 CAPLUS

DOCUMENT NUMBER: 148:538288

TITLE: Preparation of fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met kinase inhibitors

INVENTOR(S): Ahmed, Gulzar; Bohnstedt, Adolph; Breslin, Henry Joseph; Burke, Jason; Curry, Matthew A.; Diebold, James L.; Dorsey, Bruce; Dugan, Benjamin J.; Feng, Daming; Gingrich, Diane E.; Guo, Tao; Ho, Koc-Kan; Learn, Keith S.; Lisko, Joseph G.; Liu, Rong-Qiang; Mesaros, Eugen F.; Milkiewicz, Karen; Ott, Gregory R.; Parrish, Jonathan; Theroff, Jay P.; Thieu, Tho V.; Tripathy, Rabindranath; Underiner, Theodore L.; Wagner, Jason C.; Weinberg, Linda; Wells, Gregory J.; You, Ming; Zificsak, Craig A.

PATENT ASSIGNEE(S): Cephalon, Inc., USA; Pharmacoepia Drug Discovery, Inc.
SOURCE: PCT Int. Appl., 1297pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008051547	A1	20080502	WO 2007-US22496	20071023
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2006-853562P P 20061023

OTHER SOURCE(S): MARPAT 148:538288

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I and II [R1 = H, halo, NO2, OH and derivs., aryl, alkyl, etc.; R2 = (un)substituted alk(en/yn)yl, (hetero)aryl, R3-R5 = independently H, CO2H and derivs., NH2 and derivs., OCHF2, etc.; A1-A5 = independently (CH2)1-2 and derivs., CO, NH and derivs., S, SO, SO2, O, with provisos; with the exception of specified compds.; and their pharmaceutically acceptable salts] were prepared as ALK and c-Met kinase inhibitors for treating proliferative disorders. Thus, nitration of 1,3,4,5-tetrahydrobenzo[b]azepin-2-one with HNO3/H2SO4, alkylation with Me iodide, reduction of the nitro intermediate and amination of

2-[(2,5-dichloropyrimidin-4-yl)amino]-N-methylbenzamide gave benzazepinylaminopyrimidine III. III inhibited ALK and C-Met kinases with $IC_{50} < 0.1 \mu M$.


IT 1022967-14-1P, N-[2-[7-[[5-Chloro-4-[[[(1R,2R)-2-[(methylsulfonyl)amino]cyclohexyl]amino]pyrimidin-2-yl]amino]-8-methoxy-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl]ethyl]acetamide
1022967-26-5P, N-[2-[7-[[5-Chloro-4-[[2-methoxy-4-(morpholin-4-yl)phenyl]amino]pyrimidin-2-yl]amino]-8-methoxy-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl]ethyl]acetamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of fused bicyclic derivs. of 2,4-diaminopyrimidine as ALK and c-Met kinase inhibitors)

RN 1022967-14-1 CAPLUS


CN Acetamide, N-[2-[7-[[5-chloro-4-[[[(1R,2R)-2-[(methylsulfonyl)amino]cyclohexyl]amino]-2-pyrimidinyl]amino]-1,2,4,5-tetrahydro-8-methoxy-3H-3-benzazepin-3-yl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1022967-26-5 CAPLUS

CN Acetamide, N-[2-[7-[[5-chloro-4-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-2-pyrimidinyl]amino]-1,2,4,5-tetrahydro-8-methoxy-3H-3-benzazepin-3-yl]ethyl]- (CA INDEX NAME)



IT 1022967-18-5P, N-[2-(7-Methoxy-8-nitro-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl)ethyl]acetamide 1022967-22-1P, N-[2-(7-Amino-8-methoxy-1,2,4,5-tetrahydrobenzo[d]azepin-3-


yl)ethyl]acetamide

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of fused bicyclic derivs. of 2,4-diaminopyrimidine as ALK and c-Met kinase inhibitors)


RN 1022967-18-5 CAPLUS

CN Acetamide, N-[2-(1,2,4,5-tetrahydro-7-methoxy-8-nitro-3H-3-benzazepin-3-yl)ethyl]- (CA INDEX NAME)



RN 1022967-22-1 CAPLUS

CN Acetamide, N-[2-(7-amino-1,2,4,5-tetrahydro-8-methoxy-3H-3-benzazepin-3-yl)ethyl]- (CA INDEX NAME)



REFERENCE COUNT:


3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L20 ANSWER 2 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2008:411959 CAPLUS
 DOCUMENT NUMBER: 148:403094
 TITLE: Preparation of benzazepine carboxamides as ion channel modulators useful in the prophylaxis and treatment of inflammatory and immunological diseases
 INVENTOR(S): Lawton, Geoff; Kozlowski, Roland; Hogg, Dayle
 PATENT ASSIGNEE(S): Lectus Therapeutics Limited, UK
 SOURCE: PCT Int. Appl., 69pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008038051	A2	20080403	WO 2007-GB50591	20070928
WO 2008038051	A3	20080619		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
WO 2008038053	A1	20080403	WO 2007-GB50593	20070928
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: GB 2006-19176 A 20060929
 OTHER SOURCE(S): MARPAT 148:403094
 GI



I



II

AB The title compds. I [A and B = CH₂ or CH₂CH₂; R₁ = H, alkyl, cycloalkyl, aryl, aralkyl or heteroaralkyl; R₂-R₄ = H, alkyl, halo, haloalkyl, alkoxy, alkoxycarbonyl, carboxyl, hydroxyl or cyano; X = R₅CO, R₅SO₂, R₅R₇NCO, R₅R₇NSO₂, R₅SO₂NR₇/CO or CO₂R₈; Y = R₆CO, R₆SO₂, R₆R₇NCO, R₆R₇NSO₂, R₆SO₂NR₇/CO or CO₂R₈; R₅ and R₆ = H, alkyl, aryl, aralkyl, heteroaryl or heteroaralkyl; R₇ = H, alkyl, aryl or aralkyl; R₈ = alkyl, aryl, aralkyl, alkoxyalkyl, heteroaryl or heteroarylalkyl; provided that when X is R₅CO or R₅SO₂, then Y is not R₆CO, R₆SO₂ or R₆R₇NCO], useful in the manufacture of a medicament for the prophylaxis or treatment of inflammatory or immunol. disease (alone or in combination with other therapeutic agents), were prepared. Thus, treating 7-amino-1,2,4,5-tetrahydro-3H-3-benzazepine with trimethylsilyl isocyanate in CHCl₃ followed by the addition of p-toluenesulfonyl isocyanate afforded II as triethylamine salt.


IT 1016265-18-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzazepine carboxamides as ion channel modulators useful in the prophylaxis and treatment of inflammatory and immunol. diseases)

RN 1016265-18-1 CAPLUS

CN Benzenesulfonamide, 4-methyl-N-[[[2,3,4,5-tetrahydro-3-(1-oxo-3-phenylpropyl)-1H-3-benzazepin-7-yl]amino]carbonyl]- (CA INDEX NAME)




IT 1016265-70-5P 1016265-77-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzazepine carboxamides as ion channel modulators useful in the prophylaxis and treatment of inflammatory and immunol. diseases)


RN 1016265-70-5 CAPLUS

CN 1-Propanone, 3-phenyl-1-(1,2,4,5-tetrahydro-7-nitro-3H-3-benzazepin-3-yl)-
(CA INDEX NAME)



RN 1016265-77-2 CAPLUS



CN 1-Propanone, 1-(7-amino-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-3-phenyl-
(CA INDEX NAME)



L20 ANSWER 3 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:1176022 CAPLUS
 DOCUMENT NUMBER: 147:469249
 TITLE: Benzazepinyloxyacetic acid derivatives as PPAR-delta agonists used for the increase of HDL-C, lower LDL-C and lower cholesterol and their preparation
 INVENTOR(S): Kuo, Gee-Hong; Zhang, Yan; Shen, Lan; Lu, Songfeng; Demarest, Keith T.; Peiton, Patricia
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 113pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070244094	A1	20071018	US 2007-736221	20070417
WO 2007121432	A2	20071025	WO 2007-US66772	20070417
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2006-793001P P 20060418
 OTHER SOURCE(S): MARPAT 147:469249
 GI



AB The invention is directed to compds. of formula I useful as PPAR agonists. Pharmaceutical compns. and methods of treating one or more conditions including, but not limited to, diabetes, nephropathy, neuropathy, retinopathy, polycystic ovary syndrome, hypertension, ischemia, stroke, irritable bowel disorder, inflammation, cataract, cardiovascular diseases, Metabolic X Syndrome, hyper-LDL-cholesterolemia, dyslipidemia (including hypertriglyceridemia, hypercholesterolemia, mixed hyperlipidemia, and hypo-HDL-cholesterolemia), atherosclerosis, obesity, and other disorders related to lipid metabolism and energy homeostasis complications thereof, using compds. of the invention are also described. Compds. of formula I wherein X is a covalent bond, O and S; R1 and R2 are independently H, and (un)substituted C1-8 alkyl; R1R2 and the carbon they are attached together may form C3-7 cycloalkyl; R3 is H; R4 and R5 are independently H, halo, C1-8 alkyl, C3-7 cycloalkyl, etc.; R5 and R7 are independently H, halo, C1-3 (halo)alkyl and C1-3 (halo)alkoxy; n is 1; Q is (un)substituted 5- to 6-membered heteroarom. ring; and their enantiomers, diastereoisomers, tautomers, solvates and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multistep procedure (detailed procedure given). All the invention compds. were evaluated for their PPAR- δ agonistic activity. From the assay, it was determined that compound II exhibited EC50 value of 34.1 nM against PPAR δ .


IT 952709-69-2P 952709-76-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzazepinyloxyacetic acid derivs. as PPAR- δ agonists useful for increasing HDL-C, lower LDL-C and lower cholesterol)


RN 952709-69-2 CAPLUS

CN Acetic acid, 2-[[[2,3,4,5-tetrahydro-3-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-1H-3-benzazepin-7-yl]oxy]- (CA INDEX NAME)



RN 952709-76-1 CAPLUS

CN Acetic acid, 2-[[[2,3,4,5-tetrahydro-3-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-1H-3-benzazepin-7-yl]oxy]- (CA INDEX NAME)



IT 952710-86-0P 952710-87-1P 952710-88-2P

952711-05-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(intermediate; preparation of benzazepinyloxyacetic acid derivs. as PPAR-delta agonists useful for increasing HDL-C, lower LDL-C and lower cholesterol)


RN 952710-86-0 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 952710-87-1 CAPLUS

CN 1H-3-Benzazepin-7-ol, 2,3,4,5-tetrahydro-3-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 952710-88-2 CAPLUS

CN Acetic acid, 2-[[2,3,4,5-tetrahydro-3-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-1H-3-benzazepin-7-yl]oxy]-, ethyl ester (CA INDEX NAME)




RN 952711-05-6 CAPLUS

CN Acetic acid, 2-[[2,3,4,5-tetrahydro-3-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]-1H-3-benzazepin-7-yl]oxy]-, ethyl ester (CA INDEX NAME)



L20 ANSWER 4 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:1016569 CAPLUS
 DOCUMENT NUMBER: 148:503081
 TITLE: Novel drug delivery system
 INVENTOR(S): Nadkarni, Sunil Sadanand; Vaya, Navin; Karan, Rajesh
 Singh; Gupta, Vinod Kumar
 PATENT ASSIGNEE(S): Torrent Pharmaceuticals Limited, India
 SOURCE: Indian Pat. Appl., 80pp., Addn. of Indian Appl. No.
 2004MU198.
 CODEN: INXXBQ
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2005MU01012	A	20070831	IN 2005-MU1012	20050826
PRIORITY APPLN. INFO.:			IN 2004-MU198	A0 20040220
AB A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise addnl. another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.				
IT 67394-31-4, Verilopam Hydrochloride				
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (novel drug delivery system)				
RN 67394-31-4 CAPLUS				
CN Benzenamine, 4-[2-(1,2,4,5-tetrahydro-7,8-dimethoxy-3H-3-benzazepin-3-yl)ethyl]-, hydrochloride (1:2) (CA INDEX NAME)				



● 2 HCl

L20 ANSWER 5 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:769872 CAPLUS
 DOCUMENT NUMBER: 148:387155
 TITLE: Novel dosage form
 INVENTOR(S): Nadkarni, Sunil Sadanand; Vaya, Navin; Karan, Rajesh
 Singh; Gupta, Vinod Kumar
 PATENT ASSIGNEE(S): Torrent Pharmaceuticals Limited, India
 SOURCE: Indian Pat. Appl., 96pp.
 CODEN: INXXBQ
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2005MU01013	A	20070629	IN 2005-MU1013	20050826


PRIORITY APPLN. INFO.: IN 2005-MU1013 20050826

AB A dosage form comprising of a high-dose, high-solubility active ingredient for modified release and a low-dose active ingredient for immediate release wherein the weight ratio of immediate-release active ingredient and modified-release active ingredient is from 1:10 to 1:15000 and the weight of modified-release active ingredient per unit is from 500 mg to 1500 mg. A process for preparing the dosage form is provided.

IT 67394-31-4, Verilopam hydrochloride
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (novel dosage form containing modified-release and immediate-release active ingredients)

RN 67394-31-4 CAPLUS

CN Benzenamine, 4-[2-(1,2,4,5-tetrahydro-7,8-dimethoxy-3H-3-benzazepin-3-yl)ethyl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

L20 ANSWER 6 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:437585 CAPLUS
 DOCUMENT NUMBER: 144:467911
 TITLE: Preparation of diphenylalkyl cyclohexyl urea derivatives as muscarinic acetylcholine receptor antagonists
 INVENTOR(S): Busch-Petersen, Jakob; Boehm, Jeffrey Charles; Li, Huijie; Taggart, John J.; Yan, Hongxing
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., '79 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006050239	A2	20060511	WO 2005-US39209	20051027
WO 2006050239	A3	20061012		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM EP 1824483 A2 20070829 EP 2005-824984 20051028 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR JP 2008518939 T 20080605 JP 2007-539227 20051028 PRIORITY APPLN. INFO.: US 2004-623558P P 20041029 WO 2005-US39209 W 20051027				

OTHER SOURCE(S): MARPAT 144:467911
 GI




I

AB Muscarinic acetylcholine receptor antagonists are prepared E.g., I was

prepared by a series of reactions starting with tert-Bu [4-(2-oxoethyl)cyclohexyl]carbamate and dicyclohexylamine. In vitro and iv vivo functional assays for muscarinic acetylcholine receptor inhibitory activity are given. Also pharmaceutical formulations are given.


IT 886850-17-5P 886850-45-9P 886850-62-0P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of diphenylalkyl cyclohexyl urea derivs. as muscarinic acetylcholine receptor antagonists)
 RN 886850-17-5 CAPLUS
 CN Urea, N-[(1R)-2-hydroxy-1-methyl-2,2-diphenylethyl]-N'-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 886850-45-9 CAPLUS
 CN Urea, N-[(1S)-2-hydroxy-1-methyl-2,2-diphenylethyl]-N'-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 886850-62-0 CAPLUS
 CN 1H-3-Benzazepinium, 2,3,4,5-tetrahydro-3-[2-[trans-4-[[(1R)-2-hydroxy-1-methyl-2,2-diphenylethyl]amino]carbonyl]amino]cyclohexyl]ethyl]-3-methyl-7-(2-methyl-1-oxopropyl)-, iodide (1:1) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 7 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:100738 CAPLUS
 DOCUMENT NUMBER: 144:198849
 TITLE: Novel dosage form comprising modified-release and immediate-release active ingredients
 INVENTOR(S): Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil; Gupta, Vinod Kumar
 PATENT ASSIGNEE(S): India
 SOURCE: U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No. 630,446.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060024365	A1	20060202	US 2005-134633	20050519
IN 2002MU00697	A	20040529	IN 2002-MU697	20020805
IN 193042	A1	20040626		
IN 2002MU00699	A	20040529	IN 2002-MU699	20020805
IN 2003MU00080	A	20050204	IN 2003-MU80	20030122
IN 2003MU00082	A	20050204	IN 2003-MU82	20030122
US 20040096499	A1	20040520	US 2003-630446	20030729
PRIORITY APPLN. INFO.:			IN 2002-MU697	A 20020805
			IN 2002-MU699	A 20020805
			IN 2003-MU80	A 20030122
			IN 2003-MU82	A 20030122
			US 2003-630446	A2 20030729


AB A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form. Tablets containing 10 mg sodium pravastatin and 1000 mg niacin were prepared. The release of sodium pravastatin after 24 h was 67.7%, and the release of niacin after 1 h was 84.1%.

IT 67394-31-4, Verilopam hydrochloride
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (novel dosage form comprising modified-release and immediate-release active ingredients)

RN 67394-31-4 CAPLUS

CN Benzenamine, 4-[2-(1,2,4,5-tetrahydro-7,8-dimethoxy-3H-3-benzazepin-3-yl)ethyl]-, hydrochloride (1:2) (CA INDEX NAME)

10/598,888



● 2 HCl

L20 ANSWER 8 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:1152762 CAPLUS
 DOCUMENT NUMBER: 143:440448
 TITLE: Preparation of 3-piperidin-4-yl-1,3,4,5-tetrahydro-1,3-benzodiazepin-2-ones and related compounds as CGRP antagonists
 INVENTOR(S): Mueller, Stephan Georg; Rudolf, Klaus; Lustenberger, Philipp; Stenkamp, Dirk; Arndt, Kirsten; Doods, Henri; Schaenzle, Gerhard
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany
 SOURCE: Ger. Offen., 51 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 102004018795	A1	20051027	DE 2004-102004018795	20040415
CA 2562526	A1	20051027	CA 2005-2562526	20050409
WO 2005100343	A1	20051027	WO 2005-EP3741	20050409
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1737842	A1	20070103	EP 2005-731650	20050409
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, HR, YU			
JP 2007532600	T	20071115	JP 2007-507723	20050409
US 20050282857	A1	20051222	US 2005-107195	20050415
US 20070238715	A1	20071011	US 2007-688123	20070319
PRIORITY APPLN. INFO.:			DE 2004-102004018795A	20040415
			US 2004-570005P	P 20040511
			WO 2005-EP3741	W 20050409
			US 2005-107195	B1 20050415
OTHER SOURCE(S):	MARPAT 143:440448			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = substituted Ph, i.e., CF₃, NH₂, Cl, etc.; X = O, CH₂, NH; R₁ = 3,4-dihydro-2(1H)-quinazolinonyl, 1,3,4,5-tetrahydro-2H-benzo-1,3-diazepin-2-onyl; NR₂R₃ = 1,4'-bipiperidinyl, 1-methyl-4-(4-piperidinyl)piperazinyl, 1-(1-methyl-4-piperidinyl)piperazinyl, etc.] and

their pharmaceutically acceptable salts and formulations were prepared For example, coupling of 4-(2-piperidin-1-yl-ethyl)piperidine and acid II afforded benzodiazepin-2-one III in 64% yield. In human cgrp receptor assays, compds. I exhibited IC50 values ≤ 1000 nM.

IT 868383-68-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzodiazepin-2-ones and related compds. as CGRP antagonists)

RN 868383-68-0 CAPLUS



CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, (1R)-1-[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-2-[7-[(dimethylamino)methyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2-oxoethyl ester (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 9 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:1103585 CAPLUS
 DOCUMENT NUMBER: 143:386758
 TITLE: Preparation of benzazepines as muscarinic
 acetylcholine receptor antagonists
 INVENTOR(S): Busch-Petersen, Jakob; Cooper, Anthony W. J.; Laine,
 Dramane I.; Palovich, Michael R.; Davis, Roderick S.;
 Fu, Wei
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 47 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005094834	A1	20051013	WO 2004-US8026	20040317
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1725240	A1	20061129	EP 2004-821845	20040317
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LT, LV			
JP 2007529512	T	20071025	JP 2007-503876	20040317
US 20070185090	A1	20070809	US 2006-598887	20060914
PRIORITY APPLN. INFO.:			WO 2004-US8026	W 20040317
OTHER SOURCE(S):			CASREACT 143:386758; MARPAT 143:386758	
GI				



AB Title compds. I [R1 = (un)substituted alkanoyl, aroyl and aroylalkyl; G = alkyl, substituted cyclohexyl or alkylamide; R2 = H or alkyl; A = (un)substituted alkyl, X-AR, CH=CH-Ar, etc.; X = bond, O, S, etc.; Ar = (un)substituted Ph, aromatic heterocycle or bicyclic heterocycle] and their pharmaceutically acceptable salts, are prepared and disclosed as antagonists of muscarinic acetylcholine receptors. Thus, e.g., II was prepared by cyclization of 3-aminobenzoic acid with sodium 3-nitrobenzene sulfonate and subsequent amidation/oxidation sequence using 4-amino-1-butanol followed by coupling with 2-methyl-1-(2,3,4,5-tetrahydro-1H-3H-benzazepin-7-yl)-propan-1-one (preparation given). The inhibitory activity of I was evaluated using receptor-activated calcium mobilization assay (no data). I as antagonist of muscarinic acetylcholine receptor should prove useful in the treatment of chronic obstructive lung disease, chronic bronchitis and asthma. Pharmaceutical compns. comprising I are disclosed.

II 264262-69-3P 264263-29-8P 264263-31-2P
 264263-32-3P 264263-41-4P 264263-42-5P
 264263-43-6P 264263-44-7P 264263-50-5P
 264263-51-6P 264263-52-7P 264263-53-8P
 264263-55-0P 264263-59-4P 866627-69-2P
 866627-70-5P 866627-71-6P 866627-72-7P
 866627-73-8P 866627-74-9P 866627-75-0P
 866627-76-1P 866627-77-2P 866627-78-3P
 866627-79-4P 866627-80-7P 866627-81-8P
 866627-82-9P 866627-83-0P 866627-84-1P
 866627-85-2P 866627-86-3P 866627-87-4P
 866627-88-5P 866627-89-6P 866627-90-9P
 866627-91-0P 866627-92-1P 866627-93-2P
 866627-94-3P 866627-95-4P 866627-96-5P
 866627-97-6P 866627-98-7P 866627-99-8P
 866628-00-4P 866628-01-5P 866628-02-6P
 866628-03-7P 866628-04-8P 866628-05-9P
 866628-06-0P 866628-07-1P 866628-08-2P
 866628-09-3P 866628-10-6P 866628-11-7P
 866628-12-8P 866628-13-9P 866628-14-0P
 866628-15-1P 866628-16-2P 866628-17-3P
 866628-18-4P 866628-19-5P 866628-20-8P

866628-21-9P 866628-22-0P 866628-23-1P
 866628-24-2P 866628-25-3P 866628-27-5P
 866628-29-7P 866628-31-1P 866628-33-3P
 866628-35-5P 866628-38-8P 866628-40-2P
 866628-42-4P 866628-44-6P 866628-46-8P
 866628-47-9P 866628-48-0P 866628-49-1P
 866628-50-4P 866628-51-5P 866628-52-6P
 866628-53-7P 866628-54-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzazepines as muscarinic acetylcholine receptor antagonists)

RN 264262-29-3 CAPLUS

CN 5-Quinolinescarboxamide, N-[trans-4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 264263-29-8 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[trans-4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 264263-31-2 CAPLUS

CN Benzamide, N-[trans-4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(5-methyl-1,2,4-oxadiazol-3-yl)- (CA INDEX NAME)

Relative stereochemistry.




RN 264263-32-3 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(4-fluorophenyl)-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 264263-41-4 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(3-methoxyphenyl)-, (2E)- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 264263-42-5 CAPLUS


CN 2-Propenamide, N-[trans-4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(2-cyanophenyl)-, (2E)- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 264263-43-6 CAPLUS
CN 2-Propenamide, N-[trans-4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(3-thienyl)-, (2E)- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 264263-44-7 CAPLUS
CN 2-Propenamide, N-[trans-4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(1,2-dihydro-2-oxo-8-quinolinyl)-, (2E)- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 264263-50-5 CAPLUS

CN Benzo[b]thiophene-3-acetamide, N-[trans-4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 264263-51-6 CAPLUS

CN 2-Propenamide, 3-[4-(acetylamino)phenyl]-N-[trans-4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 264263-52-7 CAPLUS

CN 6-Benzothiazoleacetamide, N-[trans-4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-2-amino- (CA INDEX NAME)

Relative stereochemistry.




RN 264263-53-8 CAPLUS

CN 8-Quinolinescarboxamide, N-[trans-4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-

benzazepin-3-yl)ethyl]cyclohexyl]-1,4-dihydro-4-oxo- (CA INDEX NAME)

Relative stereochemistry.




RN 264263-55-0 CAPLUS

CN 2-Propenamide, 3-(2-acetylphenyl)-N-[trans-4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 264263-59-4 CAPLUS

CN Benzo[b]thiophene-2-acetamide, N-[trans-4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 866627-69-2 CAPLUS

CN 5-Quinolinescarboxamide, 2-methyl-N-[2-oxo-2-[[[trans-4-[[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-

yl)methyl)cyclohexyl)methyl]amino]ethyl]- (CA INDEX NAME)

Relative stereochemistry.




PAGE 1-B

—Pr-i

RN 866627-70-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(2-methyl-5-quinoliny)carbonyl]-N-[[trans-4-[[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl)methyl]cyclohexyl)methyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 866627-71-6 CAPLUS

CN 5-Quinolinecarboxamide, 2-methyl-N-[3-oxo-3-[[[trans-4-[[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl)methyl]cyclohexyl)methyl]amino]propyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 866627-72-7 CAPLUS

CN 5-Quinolinecarboxamide, 2,8-dimethyl-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(1-oxobutyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 866627-73-8 CAPLUS

CN 5-Quinolinecarboxamide, 8-methoxy-2-methyl-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(1-oxobutyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 866627-74-9 CAPLUS

CN 5-Quinolinecarboxamide, 8-chloro-2-methyl-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(1-oxobutyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 866627-75-0 CAPLUS

CN 5-Quinolincarboxamide, 2-methyl-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(1-oxobutyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 866627-76-1 CAPLUS

CN 5-Quinolincarboxamide, 2-methyl-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 866627-77-2 CAPLUS

CN Benzeneacetamide, N-[trans-4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)

benzazepin-3-yl)ethyl]cyclohexyl]-4-fluoro- (CA INDEX NAME)


Relative stereochemistry.



RN 866627-78-3 CAPLUS

CN Butanamide, 4-amino-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 866627-79-4 CAPLUS

CN 2-Pyrazinecarboxamide, N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 866627-80-7 CAPLUS

CN 4-Pyridineacetamide, N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-

oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 866627-81-8 CAPLUS

CN 2-Propenamide, 3-(1H-imidazol-5-yl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 866627-82-9 CAPLUS

CN Benzeneacetamide, alpha-amino-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, (alphaR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 866627-83-0 CAPLUS

CN 1H-Indole-2-carboxamide, N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 866627-84-1 CAPLUS

CN 3-Butenamide, 4-phenyl-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, (3E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 866627-85-2 CAPLUS

10/598,888

CN Benzamide, 2-(dimethylamino)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 866627-86-3 CAPLUS

CN Benzamide, 3-(dimethylamino)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 866627-87-4 CAPLUS

CN 3-Pyridinepropanamide, α -amino-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, (α R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 866627-88-5 CAPLUS

CN 4-Pyridinecarboxamide, N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 866627-89-6 CAPLUS

CN 2-Quinolinecarboxamide, N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 866627-90-9 CAPLUS

CN 5-Quinoxalinecarboxamide, N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 866627-91-0 CAPLUS

CN 1,8-Naphthyridine-2-carboxamide, N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 866627-92-1 CAPLUS

CN 1,6-Naphthyridine-2-carboxamide, N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 866627-93-2 CAPLUS

CN 1H-Indole-3-acetamide, N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 866627-94-3 CAPLUS

CN 1H-Indole-2-carboxamide, 1-methyl-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




10/598,888

RN 866627-95-4 CAPLUS

CN 2-Butenamide, 4-oxo-4-phenyl-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry unknown.



RN 866627-96-5 CAPLUS

CN Benzeneacetamide, 4-(dimethylamino)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 866627-97-6 CAPLUS

CN Acetamide, 2-[(phenylmethyl)thio]-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 866627-98-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, 1-oxide (CA INDEX NAME)


Relative stereochemistry.



RN 866627-99-8 CAPLUS

CN Benzamide, 2-(1H-pyrrol-1-yl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



10/598,888


RN 866628-00-4 CAPLUS
CN Benzamide, 4-(1H-pyrrol-1-yl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 866628-01-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-(1H-pyrrol-1-yl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 866628-02-6 CAPLUS
CN 1H-indole-3-propanamide, N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.

— Pr-i

RN 866628-05-9 CAPLUS

CN Benzenebutanamide, 4-methoxy-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 866628-06-0 CAPLUS

CN Propanamide, 2-amino-3-(phenylmethoxy)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 866628-07-1 CAPLUS

CN 5-Quinolincarboxamide, 2,8-dimethyl-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 866628-08-2 CAPLUS

CN 2H-1,2,3-Triazole-4-carboxamide, 5-methyl-2-phenyl-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 866628-09-3 CAPLUS

CN Carbamic acid, [4-oxo-4-[[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]amino]butyl]-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 866628-10-6 CAPLUS

CN 4-Thiazolecarboxamide, 2-(3-pyridinyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 866628-11-7 CAPLUS

CN 1H-Indole-3-carboxamide, N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 866628-12-8 CAPLUS

CN Butanediamide, N1-(phenylmethyl)-N4-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 866628-13-9 CAPLUS

CN 5-Quinolinecarboxamide, 8-chloro-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 866628-14-0 CAPLUS

CN Benzenepropanamide, 3,4-dimethoxy-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 866628-15-1 CAPLUS

CN Benzeneacetamide, α-phenyl-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 866628-16-2 CAPLUS

CN Benzamide, 2-[(methylsulfonyl)amino]-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.

10/598,888

RN 866628-19-5 CAPLUS

CN 1-Isoquinolinecarboxamide, N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 866628-20-8 CAPLUS

CN Acetic acid, 2-[[[3-oxo-3-[[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]amino]propyl]thio]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Relative stereochemistry.



PAGE 1-A


PAGE 1-B

Pr-i

RN 866628-21-9 CAPLUS

CN Benzamide, N-[5-oxo-5-[[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]amino]pentyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 866628-22-0 CAPLUS

CN 5-Quinolinecarboxamide, 8-chloro-2-methyl-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 866628-23-1 CAPLUS

CN Benzoic acid, 2-[[[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]amino]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Relative stereochemistry.




RN 866628-24-2 CAPLUS

10/598,888

CN 3-Pyridinecarboxamide, N-[2-oxo-2-[[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]amino]ethyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 866628-25-3 CAPLUS

CN Benzenepropanamide, β -phenyl-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 866628-27-5 CAPLUS

CN 2-Naphthaleneacetamide, N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 866628-29-7 CAPLUS

CN Carbamic acid, [(1R)-2-oxo-1-phenyl-2-[[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866628-31-1 CAPLUS

CN Propanamide, 3-[[[(4-methylphenyl)sulfonyl]amino]-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




PAGE 1-A

Pr-i

RN 866628-33-3 CAPLUS
 CN Carbamic acid, [(1R)-2-oxo-1-(3-pyridinylmethyl)-2-[[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 866628-35-5 CAPLUS
 CN Carbamic acid, [(1R)-2-oxo-1-[(phenylmethoxy)methyl]-2-[[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/598,888



RN 866628-38-8 CAPLUS


CN Carbamic acid, [(1S)-2-oxo-1-[(phenylmethoxy)methyl]-2-[[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]amino]ethyl]-, 1,1-dimethylethyl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 866628-37-7

CMF C37 H53 N3 O5

Absolute stereochemistry.



CM 2

CRN 64-18-6

CMF C H2 O2


O=CH-OH

10/598,888

RN 866628-40-2 CAPLUS

CN Propanamide, 2-amino-3-(phenylmethoxy)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 866628-42-4 CAPLUS


CN Formic acid, compd. with N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-1-isoquinolinecarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 866628-19-5

CMF C32 H39 N3 O2

Relative stereochemistry.



CM 2

CRN 64-18-6

CMF C H2 O2

O=CH-OH


10/598,888

RN 866628-44-6 CAPLUS
CN Formic acid, compd. with N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-2-naphthaleneacetamide
(1:1) (CA INDEX NAME)

CM 1

CRN 866628-27-5
CMF C34 H42 N2 O2

Relative stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH


RN 866628-46-8 CAPLUS
CN Formic acid, compd. with N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-4-pyridinecarboxamide
(1:1) (CA INDEX NAME)

CM 1

CRN 866627-88-5
CMF C28 H37 N3 O2

Relative stereochemistry.

10/598,888




CM 2
CRN 64-18-6
CMF C H2 O2

$\text{O}=\text{CH}-\text{OH}$

RN 866628-47-9 CAPLUS
CN Formic acid, compd. with N-[2-oxo-2-[[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]amino]ethyl]-3-pyridinecarboxamide (1:1) (CA INDEX NAME)

CM 1
CRN 866628-24-2
CMF C30 H40 N4 O3

Relative stereochemistry.




CM 2
CRN 64-18-6
CMF C H2 O2

10/598,888



RN 866628-48-0 CAPLUS
CN Formic acid, compd. with N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-3-pyridinecarboxamide 1-oxide (1:1) (CA INDEX NAME)
CM 1
CRN 866627-98-7
CMF C28 H37 N3 O3

Relative stereochemistry.




CM 2
CRN 64-18-6
CMF C H2 O2



RN 866628-49-1 CAPLUS
CN Carbamic acid, [(1R)-2-oxo-1-(3-pyridinylmethyl)-2-[[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]amino]ethyl]-, 1,1-dimethylethyl ester, monoformate (9CI) (CA INDEX NAME)
CM 1
CRN 866628-33-3
CMF C35 H50 N4 O4

Absolute stereochemistry.



CM 2

CRN 64-18-6

CMF C H2 O2

O=CH-OH

RN 866628-50-4 CAPLUS


CN Formic acid, compd. with N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-1H-indole-3-carboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 866628-11-7

CMF C31 H39 N3 O2

Relative stereochemistry.



10/598,888

CM 2

CRN 64-18-6

CMF C H2 O2

O=CH-OH

RN 866628-51-5 CAPLUS

CN Formic acid, compd. with 3-[[[4-methylphenyl)sulfonyl]amino]-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]propanamide (1:1) (CA INDEX NAME)


CM 1

CRN 866628-31-1

CMF C32 H45 N3 O4 S

Relative stereochemistry.

PAGE 1-A



PAGE 1-B

Pr-i

CM 2

CRN 64-18-6

CMF C H2 O2

O=CH-OH

RN 866628-52-6 CAPLUS

CN Formic acid, compd. with 2-(2-pyrimidinylthio)-N-[trans-4-[2-[1,2,4,5-

10/598,888


tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]acetamide (1:1) (CA INDEX NAME)

CM 1

CRN 866628-17-3

CMF C28 H38 N4 O2 S

Relative stereochemistry.



CM 2

CRN 64-18-6


CMF C H2 O2

O=CH-OH

RN 866628-53-7 CAPLUS

CN Benamide, N-[trans-4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-4-fluoro- (CA INDEX NAME)


Relative stereochemistry.



RN 866628-54-8 CAPLUS


CN 2-Propenamide, N-[trans-4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-benzo[b]thien-3-yl-, (2E)- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




IT 264264-30-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzazepines as muscarinic acetylcholine receptor antagonists)
RN 264264-30-4 CAPLUS
CN Ethanone, 1-[3-[2-(trans-4-aminocyclohexyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]- (CA INDEX NAME)

Relative stereochemistry.



IT 866628-68-4P 866628-70-8P 866628-72-0P
866628-74-2P 866628-76-4P 866628-81-1P
866628-83-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of benzazepines as muscarinic acetylcholine receptor antagonists)
RN 866628-68-4 CAPLUS
CN Carbamic acid, [[trans-4-[[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]methyl]cyclohexyl]methyl]-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 866628-70-8 CAPLUS

CN 1-Propanone, 1-[3-[[trans-4-(aminomethyl)cyclohexyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-2-methyl- (CA INDEX NAME)


Relative stereochemistry.



RN 866628-72-0 CAPLUS

CN Carbamic acid, [2-oxo-2-[[[trans-4-[[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]methyl]cyclohexyl]methyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 866628-74-2 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[[trans-4-[[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]methyl]cyclohexyl]methyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 866628-76-4 CAPLUS

CN Carbamic acid, [3-oxo-3-[[[trans-4-[[[1,2,4,5-tetrahydro-7-(2-methyl-1-oxopropyl)-3H-3-benzazepin-3-yl]methyl]cyclohexyl]methyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 866628-81-1 CAPLUS


CN 1-Butanone, 1-[3-[2-(trans-4-aminocyclohexyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 866628-80-0

CMF C22 H34 N2 O

Relative stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2


10/598,888



RN 866628-83-3 CAPLUS

CN 1-Propanone, 1-[3-[2-(trans-4-aminocyclohexyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-2-methyl- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT:



3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 10 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:1026931 CAPLUS
 DOCUMENT NUMBER: 143:326211
 TITLE: Preparation of aryl 5-acylindolinones as inhibitors of GSK-3
 INVENTOR(S): Heckel, Armin; Roth, Gerald Juergen; Kley, Joerg; Hoerer, Stefan; Uphues, Ingo
 PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
 SOURCE: PCT Int. Appl., 99 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005087726	A1	20050922	WO 2005-EP2405	20050305
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 102004012069	A1	20050929	DE 2004-102004012069	20040312
CA 2559115	A1	20050922	CA 2005-2559115	20050305
EP 1727798	A1	20061206	EP 2005-715810	20050305
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2007528882	T	20071018	JP 2007-502260	20050305
US 20050234120	A1	20051020	US 2005-77259	20050310
US 7176231	B2	20070213		
PRIORITY APPLN. INFO.:			DE 2004-102004012069A	20040312
			US 2004-558262P	P 20040331
			WO 2005-EP2405	W 20050305
OTHER SOURCE(S):	MARPAT 143:326211			

GI



AB Title compds. I [R1 = (un)substituted alkyl, Ph or naphthyl; R2 = alkyl, cycloalkyl or (un)substituted aryl; R3 = (un)substituted Ph, naphthyl or heteroaryl] and their pharmaceutically acceptable salts, are prepared and disclosed as glycogen synthase kinase (GSK-3) inhibitors. Thus, e.g., II was prepared by substitution of 1,5-diacetyl-3-(phenyl-ethoxy-methylidene)-2-indolinone (preparation given) with 4-dimethylaminomethyl-phenylamine. The ability of I to inhibit GSK-3's phosphorylation capability was evaluated and it was revealed that selected compds. of the invention possessed IC50 values in the range of 0.0001 μ M up to 1 μ M. I as inhibitor of GSK-3 should prove useful in the treatment of diabetes and diabetic neuropathy. Pharmaceutical compns. comprising I are disclosed.

IT 865261-23-0P 865261-35-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aryl acylindolinones as inhibitors of GSK-3)

RN 865261-23-0 CAPLUS

CN 2H-Indol-2-one, 5-acetyl-1,3-dihydro-3-[phenyl[[4-[(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]phenyl]amino]methylene]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.




10/598,888

RN 865261-35-4 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-(1-oxopropyl)-3-[phenyl[[4-[(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]phenyl]amino]methylene]-, (3Z)-
(CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 11 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:570815 CAPLUS
 DOCUMENT NUMBER: 143:97282
 TITLE: Tetrahydrobenzazepines as dopamine D3 receptor
 modulators, their preparation, pharmaceutical
 compositions and use in the treatment of CNS disorders
 and renal function disorders
 INVENTOR(S): Braje, Wilfried; Haupt, Andreas; Lubisch, Wilfried;
 Grandel, Roland; Drescher, Karla; Geneste, Herve;
 Unger, Liliane; Sauer, Daryl R.
 PATENT ASSIGNEE(S): Abbott G.m.b.H. & Co. K.-G., Germany
 SOURCE: PCT Int. Appl., 66 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058328	A1	20050630	WO 2004-EP14428	20041217
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20050137186	A1	20050623	US 2003-740092	20031218
CA 2550053	A1	20050630	CA 2004-2550053	20041217
EP 1694334	A1	20060830	EP 2004-820441	20041217
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS			
JP 2007514696	T	20070607	JP 2006-544363	20041217
MX 2006PA06858	A	20060904	MX 2006-PA6858	20060616
PRIORITY APPLN. INFO.:			US 2003-530806P	P 20031218
			US 2003-740092	A 20031218
			WO 2004-EP14428	W 20041217
OTHER SOURCE(S):		CASREACT 143:97282; MARPAT 143:97282		
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to tetrahydrobenzazepines I, which are selective modulators of dopamine D3 receptors. In compds. I, A is a bond or CH₂; B is a bond or (un)substituted N; Y is a bond, CH₂, or (un)substituted N, where A, B, and Y are not simultaneously a bond; Ar is (un)substituted aryl or (un)substituted 5- or 6-membered heteroaryl containing 1-4 heteroatoms, independently selected from O, N, and S; R₁ is (un)substituted C1-8 alkyl, H, C1-8 haloalkyl, C2-8 alkenyl, etc.; and R₂ is H, halo, C1-4 alkyl, C1-4

alkoxy, OH, nitro, cyano, etc.; including the corresponding N-oxides of I and all physiol. tolerated acid addition salts. The invention also relates to pharmaceutical compns. that comprise at least one tetrahydrobenzazepine I, the physiol. tolerated acid addition salt of I, the N-oxide of compound I and/or the physiol. tolerated acid addition salts of the N-oxides of I, together with physiol. acceptable carriers and/or excipients, as well as to the use of compound I for treating disorders that respond beneficially to dopamine D3 receptor antagonists or dopamine D3 receptor agonists. The compds. of the invention are preferably useful for the treatment of disorders of the central nervous system such as schizophrenia and depression and for the treatment of renal function disorders. 1,2-Benzenediacetic acid was esterified, followed by reduction, mesylation and heterocyclization with n-propylamine to give benzazepine II. II underwent carboxylation with oxalyl chloride and hydride reduction to give alc. III. Chlorination of III followed by substitution with (4-isopropyl)thiophenol, oxidation to the sulfone, and salt formation with hydrochloric acid resulted in the formation of compound IV. The compds. of the invention have a high affinity for dopamine D3 receptors with many of the compds. exhibiting K_i values lower than 5 nM, and many of them having a 100-fold selectivity for D3 receptors over D2L receptors [$K_i(D2L)/K_i(D3)$]. Compound IV has a K_i value for binding to dopamine D3 receptors of 1 nM and 446-fold selectivity for D3 over D2L.


- IT 854680-44-7P, N-[3-(Cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethoxy)benzenesulfonamide hydrochloride
 854680-48-1P, N-[3-(Cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide
 854681-92-8P, N-[3-[2-(4-Fluorophenyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide hydrochloride
 854681-96-2P, N-[3-(3-Phenylpropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide hydrochloride
 854682-00-1P, N-[3-(Cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-isopropylbenzenesulfonamide hydrochloride
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of tetrahydrobenzazepines as dopamine D3 receptor modulators)
 RN 854680-44-7 CAPLUS
 CN Benzenesulfonamide, N-[3-(cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethoxy)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


- RN 854680-48-1 CAPLUS
 CN Benzenesulfonamide, N-[3-(cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-

benzazepin-7-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 854681-92-8 CAPLUS


CN Benzenesulfonamide, N-[3-[2-(4-fluorophenyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 854681-96-2 CAPLUS


CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(3-phenylpropyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854682-00-1 CAPLUS

CN Benzenesulfonamide, N-[3-(cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


IT 695811-96-2P, 3-Benzyl-2,3,4,5-tetrahydro-1H-3-benzazepine
 854678-25-4P, 3-(Cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepine 854678-94-7P, 7-Nitro-3-(cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepine 854679-29-1P, 3-(Cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-amine
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of tetrahydrobenzazepines as dopamine D3 receptor modulators)
 RN 695811-96-2 CAPLUS
 CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)- (CA INDEX NAME)



RN 854678-25-4 CAPLUS
 CN 1H-3-Benzazepine, 3-(cyclohexylmethyl)-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 854678-94-7 CAPLUS
 CN 1H-3-Benzazepine, 3-(cyclohexylmethyl)-2,3,4,5-tetrahydro-7-nitro- (CA INDEX NAME)



RN 854679-29-1 CAPLUS
 CN 1H-3-Benzazepine, 3-(cyclohexylmethyl)-2,3,4,5-tetrahydro- (CA INDEX NAME)

10/598,888

INDEX NAME)



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 12 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:547254 CAPLUS

DOCUMENT NUMBER: 143:59852

TITLE: A preparation of tetrahydrobenzazepine derivatives,
useful as dopamine D3 receptor ligandsINVENTOR(S): Braje, Wilfried M.; Haupt, Andreas; Lubisch, Wilfried;
Grandel, Roland; Drescher, Karla; Geneste, Herve;
Unger, Liliane; Sauer, Daryl R.

PATENT ASSIGNEE(S): Abbott G.m.b.H. & Co. Kg., Germany

SOURCE: U.S. Pat. Appl. Publ., 23 pp.

CODEN: USXXCO



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050137186	A1	20050623	US 2003-740092	20031218
CA 2550053	A1	20050630	CA 2004-2550053	20041217
WO 2005058328	A1	20050630	WO 2004-EP14428	20041217
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1694334	A1	20060830	EP 2004-820441	20041217
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS			
JP 2007514696	T	20070607	JP 2006-544363	20041217
MX 2006PA06858	A	20060904	MX 2006-PA6858	20060616
PRIORITY APPLN. INFO.:			US 2003-530806P	P 20031218
			US 2003-740092	A 20031218
			WO 2004-EP14428	W 20041217
OTHER SOURCE(S):		CASREACT 143:59852; MARPAT 143:59852		
GI				



AB The invention relates to a preparation of tetrahydrobenzazepines of formula I [wherein: A is a single bond or CH₂; B is a single bond, NH, or N(alkyl), etc.; Y is a single bond, CH₂, NH, or n(alkyl), etc.; Ar is (hetero)aryl; R₁ is H, (halo)alkyl, or alk(en/yn)yl, etc.; R₂ is H, halogen, (halo)alkyl, or alkoxy, etc.], useful as dopamine D₃ receptor ligands.

The invention also relates to a pharmaceutical composition that comprises at least one tetrahydrobenzazepine compound of the formula I, phys. tolerated acid addition salt of I, N-oxide of compound of the formula I and/or phys. tolerated acid addition salts of the N-oxides of I, and further to the use of a compound according to the present invention for treating disorders that respond beneficially to dopamine D₃ receptor antagonists or dopamine D₃ agonists. The compds. according to the invention are preferably useful for the treatment of disorders of the central nervous system such as schizophrenia and depression and for the treatment of renal function disorders. For instance, tetrahydrobenzazepine derivative II [K_i(D₃) = 4.1 nM] was prepared via amidation of 4-chlorobenzenesulfonyl chloride by 3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-amine.


IT 854680-44-7P 854680-48-1P 854681-92-8P
854681-96-2P 854682-00-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tetrahydrobenzazepine derivs. useful as selective dopamine D₃ receptor ligands)

RN 854680-44-7 CAPLUS


CN Benzenesulfonamide, N-[3-(cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethoxy)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854680-48-1 CAPLUS

CN Benzenesulfonamide, N-[3-(cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 854681-92-8 CAPLUS


CN Benzenesulfonamide, N-[3-[2-(4-fluorophenyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 854681-96-2 CAPLUS


CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(3-phenylpropyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 854682-00-1 CAPLUS

CN Benzenesulfonamide, N-[3-(cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 695811-96-2P 854678-25-4P 854678-94-7P


854679-29-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of tetrahydrobenzazepine derivs. useful as selective dopamine D3 receptor ligands)


RN 695811-96-2 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)- (CA INDEX NAME)



RN 854678-25-4 CAPLUS


CN 1H-3-Benzazepine, 3-(cyclohexylmethyl)-2,3,4,5-tetrahydro- (CA INDEX NAME)



10/598,888


RN 854678-94-7 CAPLUS

CN 1H-3-Benzazepine, 3-(cyclohexylmethyl)-2,3,4,5-tetrahydro-7-nitro- (CA
INDEX NAME)




RN 854679-29-1 CAPLUS

CN 1H-3-Benzazepine-7-amine, 3-(cyclohexylmethyl)-2,3,4,5-tetrahydro- (CA
INDEX NAME)



L20 ANSWER 13 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:497495 CAPLUS
 DOCUMENT NUMBER: 143:43783
 TITLE: Preparation of (guanidinophenyl)isoquinolines and related compounds as MC4-R agonists
 INVENTOR(S): Boyce, Rustum; Chu, Daniel
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 36 pp., Cont.-in-part of U.S. Ser. No. 351,574.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050124652	A1	20050609	US 2005-503392	20050126
US 20030195187	A1	20031016	US 2003-351574	20030127
WO 2003066597	A2	20030814	WO 2003-US1078	20030203
WO 2003066597	A3	20040401		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:				
			US 2002-353188P	P 20020204
			US 2003-351574	A2 20030127
			WO 2003-US1078	W 20030203
OTHER SOURCE(S): CASREACT 143:43783; MARPAT 143:43783				
GI				



AB Title compds. I [A1 = NR₄C(=NR₃)NR₁R₂, N=C(NR₃R₄)(NR₁R₂); R₁ = H, (un)substituted alkyl, alkenyl, etc.; R₂ = (un)substituted alkyl, alkenyl, alkynyl, etc.; R₃ = (un)substituted aryl, alkyl, alkenyl, etc.; R₄ = H, (un)substituted alkyl, alkenyl, etc.; A₂ = (un)substituted aryl, heteroaryl; A₃ = covalent bond, linking group, e.g., O, S, CO, etc.; A₄ = (un)substituted arylalkyl, heteroarylalkyl, aryl, etc.] and their pharmaceutically acceptable salts were prepared. For example, trimethylphosphine mediated reduction of phenylazide II followed by the sequential addition of (1S,2S,3S,5S)-2,6,6-trimethylbicyclo[3.1.1]heptan-3-isocyanate and (S)-(+)-2-methylpiperazine, afforded (guanidinophenyl)isoquinoline III. Compds. I are claimed to be useful for the treatment of obesity and type II diabetes.


IT 581101-67-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (guanidinophenyl)isoquinolines and related compds. as MC4-R agonists)

RN 581101-67-9 CAPLUS

CN 1-Piperazinecarboximidamide, 3-methyl-N-[4-[(1,2,4,5-tetrahydro-7-methoxy-3H-3-benzazepin-3-yl)carbonyl]phenyl]-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 402832-78-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of (guanidinophenyl)isoquinolines and related compds. as MC4-R agonists)

RN 402832-78-4 CAPLUS

CN Methanone, (4-azidophenyl) (1,2,4,5-tetrahydro-7-methoxy-3H-3-benzazepin-3-yl)- (CA INDEX NAME)



L20 ANSWER 14 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:474617 CAPLUS

DOCUMENT NUMBER: 143:26492

TITLE: Preparation of benzofuran derivatives as adrenaline α_2 c receptor antagonists

INVENTOR(S): Iida, Kyoichiro; Hagiwara, Koji; Kashima, Shu; Nonaka, Hiromi; Uchida, Shinichi; Kurokawa, Masako; Shiozaki, Shizuo; Shimada, Junichi

PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 184 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005139106	A	20050602	JP 2003-375822	20031105
PRIORITY APPLN. INFO.:			JP 2003-375822	20031105
OTHER SOURCE(S):	MARPAT 143:26492			

GI



I

AB The title compds. I [R1 = H, (un)substituted alkyl; R2 = (un)substituted aryl, etc.; R3, R4 = H, (un)substituted alkyl, etc.; or NR3R4 = (un)substituted heterocyclyl] are prepared. Thus, 4-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-ylmethyl)-2-(2-furyl)-7-methoxybenzofuran 1 fumaric acid salt was prepared in a multistep process starting from 6-bromo-3-methoxysalicylaldehyde. In an in vitro assay for adrenaline α_2 c receptor binding inhibition, compds. of this invention at 10⁻⁷ mol/L showed 60% to 97% inhibition of binding.


IT 852606-03-2P 852606-04-3P 852606-10-1P
852606-27-0P 852606-28-1P 852606-29-2P
852608-25-4P 852608-26-5P 852608-40-3P
852608-41-4P 852608-42-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzofuran derivs. as adrenaline α_2 c receptor antagonists)


RN 852606-03-2 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7,8-dimethoxy-3-[(7-methoxy-2-phenyl-4-benzofuran-1-yl)methyl]- (CA INDEX NAME)




RN 852606-04-3 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-[(7-methoxy-2-phenyl-4-benzofuranyl)methyl]- (CA INDEX NAME)




RN 852606-10-1 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6,8-dimethoxy-3-[(7-methoxy-2-phenyl-4-benzofuranyl)methyl]- (CA INDEX NAME)




RN 852606-27-0 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7,8-dimethoxy-3-[(7-methoxy-2-phenyl-5-benzofuranyl)methyl]- (CA INDEX NAME)




RN 852606-28-1 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6,8-dimethoxy-3-[(7-methoxy-2-phenyl-5-benzofuranyl)methyl]- (CA INDEX NAME)




RN 852606-29-2 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-[(7-methoxy-2-phenyl-5-benzofuranyl)methyl]- (CA INDEX NAME)




RN 852608-25-4 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7,8-dimethoxy-3-[(7-methoxy-2-phenyl-4-benzofuranyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 852608-26-5 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-[(7-methoxy-2-phenyl-4-benzofuranyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 852608-40-3 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7,8-dimethoxy-3-[(7-methoxy-2-phenyl-5-benzofuranyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 852608-41-4 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6,8-dimethoxy-3-[(7-methoxy-2-phenyl-5-benzofuranyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 852608-42-5 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-[(7-methoxy-2-phenyl-5-benzofuranyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

L20 ANSWER 15 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:1038229 CAPLUS
 DOCUMENT NUMBER: 143:153380
 TITLE: Preparation of hydrochloride salt of a tetrahydrobenzazepine compound as dopamine D3 antagonist
 INVENTOR(S): Burpitt, Brian E.; Johnson, Christopher Norbert; Macdonald, Gregor James; Mann, Inderjit Singh; Share, Andrew Colin; Stemp, Geoffrey
 PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK
 SOURCE: Can. Pat. Appl., 28 pp.
 CODEN: CPXXEB
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2342432	A1	20020928	CA 2001-2342432	20010328


PRIORITY APPLN. INFO.:
 GI



AB The present invention provides a hydrochloride (HCl) salt of the compound I, especially the monohydrochloride salt thereof; pharmaceutical preps. including such salts; and use of the salts in the treatment and prophylaxis of disorders including psychotic disorders, substance abuse or addiction, dyskinetic disorders, depression, anxiety, cognitive impairment, eating disorders, sexual dysfunction, sleep disorders, emesis, movement disorders, obsessive-compulsive disorders, amnesia, aggression, autism, vertigo, dementia, circadian rhythm disorders, or gastric motility disorders. A multi-step synthesis of I and its HCl salt, starting from 1,2-phenylenediacetonitrile, was given. The monohydrochloride salt of I showed pKi of 8.4 and of 6.4 against D3 dopamine receptor and D2 dopamine receptor, resp. It showed D3 vs. D2 selectivity of 100.

IT 264262-71-7P 628297-87-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of hydrochloride salt of a tetrahydrobenzazepine compound as dopamine D3 antagonist)
 RN 264262-71-7 CAPLUS
 CN Benzamide, 3-(5-methyl-1,2,4-oxadiazol-3-yl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 628297-87-0 CAPLUS

CN Benzamide, 3-(5-methyl-1,2,4-oxadiazol-3-yl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

IT 264264-44-0P 264264-45-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of hydrochloride salt of a tetrahydrobenzazepine compound as dopamine D3 antagonist)

RN 264264-44-0 CAPLUS

CN Carbamic acid, [trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/598,888



RN 264264-45-1 CAPLUS

CN Cyclohexanamine, 4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.



L20 ANSWER 16 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:701803 CAPLUS

DOCUMENT NUMBER: 141:225160

TITLE: Preparation of 2-(aminomethyl) arylamide analgesics

INVENTOR(S): Ho, Koc-kan; Baldwin, John J.; Bohnstedt, Adolph C.;

Kultgen, Steven G.; McDonald, Edward; Guo, Tao;

Morphy, John Richard; Rankovic, Zoran; Horlick,

Robert; Appell, Kenneth C.

PATENT ASSIGNEE(S): Pharmacopeia, Inc, USA

SOURCE: U.S. Pat. Appl. Publ., 77 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040167119	A1	20040826	US 2003-364039	20030211
US 7084154	B2	20060801		
WO 2004071445	A2	20040826	WO 2004-US4017	20040211
WO 2004071445	A3	20040916		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			


PRIORITY APPLN. INFO.: US 2003-364039 A 20030211

OTHER SOURCE(S): MARPAT 141:225160

GI



I



II

AB Title compds. represented by the formula I [wherein $R^1 = H$ or alkyl; R^2 , R^3 , $R^5 =$ independently H , halo, (fluoro)alkyl, (fluoro)alkoxy, NO_2 ; $R^4 = -B-Ar^2$; $U = CH, N, CR^5$; $A =$ (fluoro)alkylene, alkenylene, alkynylene, oxyalkylene, thioalkylene; $B =$ a direct bond or (un)substituted (aza)alkylene; Ar^1 , $Ar^2 =$ independently (un)substituted (hetero)aryl] were prepared For example, II was obtained from cleavage of the resin-bound product, which was given in a multiple-step synthesis. I showed inhibition of glycine transport with IC_{50} values less than $10 \mu M$. Thus, I and their pharmaceutical compns. are useful as analgesic agents.

IT 678174-49-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-(aminomethyl) arylamide as analgesic agents)

RN 678174-49-7 CAPLUS

CN Benzamide, N-[(3E)-4-phenyl-3-buten-1-yl]-2-[(1,2,4,5-tetrahydro-7-hydroxy-3H-3-benzazepin-3-yl)methyl]- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/598,888

L20 ANSWER 17 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:587882 CAPLUS
 DOCUMENT NUMBER: 141:140439
 TITLE: Preparation of substituted 2-phenylbenzimidazoles as antidiabetics
 INVENTOR(S): Streicher, Ruediger; Mack, Juergen; Walter, Rainer; Konetzki, Ingo; Trieselmann, Thomas; Austel, Volkhard
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & Co. KG, Germany
 SOURCE: Ger. Offen., 63 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10300398	A1	20040722	DE 2003-10300398	20030109
CA 2512813	A1	20040729	CA 2003-2512813	20031223
WO 2004062663	A1	20040729	WO 2003-EP14760	20031223
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003292263	A1	20040810	AU 2003-292263	20031223
US 20050014810	A1	20050120	US 2003-744830	20031223
US 7151114	B2	20061219		
EP 1585517	A1	20051019	EP 2003-767827	20031223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK JP 2006515857 T 20060608 JP 2004-566023 20031223				
PRIORITY APPLN. INFO.:				
			DE 2003-10300398	A 20030109
			US 2003-499522P	P 20030902
			WO 2003-EP14760	W 20031223
OTHER SOURCE(S): MARPAT 141:140439				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Benzimidazoles I [R1 = substituted Ph; R2 = (un)substituted aryl, heteroaryl, CONH2, NO2; R3 = H; R2R3 = (un)substituted N:CHN:CH; R4-R6 = H, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy] were prepared for use as glucagon receptor antagonists in the treatment of diabetes. Thus, the benzimidazole II was prepared by amidating 4,3-F(O2N)C6H3CO2H with 1-aminoethylcyclohexene, amination with (+)-dehydroabietylamine, reduction of the nitro group and the cyclohexene ring, and cyclization with 3-OCH2C6H4OCH2CO2H.

IT 727396-97-6P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of substituted 2-phenylbenzimidazoles as antidiabetics)

RN 727396-97-6 CAPLUS

CN Acetic acid, 2-[3-[1-[[[(1R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-1-phenanthrenyl]methyl]-5-[(1,2,4,5-tetrahydro-7,8-dimethoxy-3H-3-benzazepin-3-yl)carbonyl]-1H-benzimidazol-2-yl]phenoxy]-

(CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 18 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:370923 CAPLUS

DOCUMENT NUMBER: 140:391302

TITLE: Preparation of benzo-1,3-diazepin-2-ones and related compounds as CGRP receptor antagonists for the treatment of migraine headaches

INVENTOR(S): Rudolf, Klaus; Mueller, Stephan Georg; Stenkamp, Dirk; Lustenberger, Philipp; Dreyer, Alexander; Bauer, Eckhart; Schindler, Marcus; Arndt, Kirsten; Doods, Henri

PATENT ASSIGNEE(S): Boehringer Ingelheim, Germany

SOURCE: PCT Int. Appl., 254 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037811	A1	20040506	WO 2003-EP11763	20031023
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10250082	A1	20040513	DE 2002-10250082	20021025
US 20040132716	A1	20040708	US 2003-685921	20031015
CA 2503462	A1	20040506	CA 2003-2503462	20031023
AU 2003276157	A1	20040513	AU 2003-276157	20031023
EP 1558601	A1	20050803	EP 2003-809318	20031023
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015642	A	20050830	BR 2003-15642	20031023
CN 1708492	A	20051214	CN 2003-80101980	20031023
JP 2006505573	T	20060216	JP 2004-545964	20031023
NZ 540006	A	20070531	NZ 2003-540006	20031023
ZA 2005002247	A	20050919	ZA 2005-2247	20050317
MX 2005PA04188	A	20051005	MX 2005-PA4188	20050420
IN 2005DN01641	A	20070119	IN 2005-DN1641	20050421
NO 2005002493	A	20050524	NO 2005-2493	20050524
IN 2006DN05460	A	20070803	IN 2006-DN5460	20060920
US 20070244099	A1	20071018	US 2007-757743	20070604
PRIORITY APPLN. INFO.:			DE 2002-10250082	A 20021025
			US 2002-426167P	P 20021114
			US 2003-685921	B1 20031015
			WO 2003-EP11763	W 20031023
			DE 2004-102004015723A	20040329


OTHER SOURCE(S): MARPAT 140:391302

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

- AB Title compds. I [A = O, S, phenylsulfonylimino, etc.; X = O, S, substituted imino, etc.; Y, Z = alkyl, difluoromethyl, trifluoromethyl, etc.; R1 = 5-7 membered aza, diaza, triaza, etc. heterocycle; R2 = H, phenylmethyl, alkyl, etc.; R3 = H, Ph, pyridinyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, benzo-1,3-diazepin-2-one II was prepared from 1-(3,4-diethylphenyl)ethanone in 8-steps. In human CGRP receptor binding affinity assays, compds. I exhibited IC50 values < 10000 nM. Compds. I are claimed useful for the treatment of migraine headaches.
- IT 686297-16-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of benzo-1,3-diazepin-2-ones and related compds. as CGRP receptor antagonists for the treatment of migraine headaches)
- RN 686297-16-5 CAPLUS
- CN 1-Piperidinecarboxamide, N-[(1R)-1-[(3,4-diethylphenyl)methyl]-2-[7-[(dimethylamino)methyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2-oxoethyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 19 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:370922 CAPLUS

DOCUMENT NUMBER: 140:391301

TITLE: Preparation of benzo-1,3-diazepin-2-ones and related compounds as CGRP receptor antagonists for the treatment of migraine headaches

INVENTOR(S): Rudolf, Klaus; Mueller, Stephan Georg; Stenkamp, Dirk; Lustenberger, Philipp; Dreyer, Alexander; Bauer, Eckhart; Schindler, Marcus; Kirsten, Arndt; Doods, Henri

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany

SOURCE: PCT Int. Appl., 315 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037810	A1	20040506	WO 2003-EP11762	20031023
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10250080	A1	20040513	DE 2002-10250080	20021025
US 20060079504	A1	20060413	US 2003-687262	20031016
CA 2503455	A1	20040506	CA 2003-2503455	20031023
AU 2003276156	A1	20040513	AU 2003-276156	20031023
EP 1558600	A1	20050803	EP 2003-809317	20031023
EP 1558600	B1	20080507		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015665	A	20050830	BR 2003-15665	20031023
CN 1708493	A	20051214	CN 2003-80102004	20031023
JP 2006516244	T	20060629	JP 2004-545963	20031023
NZ 540051	A	20080229	NZ 2003-540051	20031023
AT 394392	T	20080515	AT 2003-809317	20031023
ZA 2005002248	A	20060830	ZA 2005-2248	20050317
IN 2005DN01640	A	20070323	IN 2005-DN1640	20050421
MX 2005PA04375	A	20050705	MX 2005-PA4375	20050425
NO 2005002496	A	20050624	NO 2005-2496	20050524
IN 2008DN00756	A	20080711	IN 2008-DN756	20080128
PRIORITY APPLN. INFO.:			DE 2002-10250080	A 20021025
			US 2002-426168P	P 20021114
			WO 2003-EP11762	W 20031023
			DE 2005-102005038831A	20050817


OTHER SOURCE(S): MARPAT 140:391301

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

- AB Title compds. I [A = O, S, phenylsulfonylimino, etc.; X = O, S, substituted imino, etc.; U = alkyl, alkenyl, alkynyl, etc.; V = Cl, Br, amino, etc.; W = H, halo, difluoromethyl, etc.; R1 = 5-7 membered aza, diaza, triaza, etc. heterocycle; R2 = H, phenylmethyl, alkyl, etc.; R3 = H, Ph, pyridinyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared. For example, benzo-1,3-diazepin-2-one II was prepared from 4-amino-3-chloro-5-trifluoromethylbenzoic acid in 9-steps. In human CGRP receptor binding affinity assays, compds. I exhibited IC50 values < 10000 nM. Compds. I are claimed useful for the treatment of migraine headaches.
- IT 688018-67-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of benzo-1,3-diazepin-2-ones and related compds. as CGRP receptor antagonists for the treatment of migraine headaches)
- RN 688018-67-9 CAPLUS
- CN 1,4-Butanedione, 2-[[[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-1-[7-[(dimethylamino)methyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-4-[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]-, (2S)- (CA INDEX NAME)



Absolute stereochemistry.




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 20 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:370903 CAPLUS
 DOCUMENT NUMBER: 140:375087
 TITLE: Preparation of bicyclic benzamides as histamine H3
 receptor ligands useful in the treatment of
 neurological diseases
 INVENTOR(S): Best, Desmond John; Orlek, Barry Sidney
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 51 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037788	A1	20040506	WO 2003-EP11650	20031020
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003278119	A1	20040513	AU 2003-278119	20031020
EP 1554243	A1	20050720	EP 2003-769430	20031020
EP 1554243	B1	20061122		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006505623	T	20060216	JP 2005-501524	20031020
AT 346044	T	20061215	AT 2003-769430	20031020
ES 2276125	T3	20070616	ES 2003-769430	20031020
US 20070105838	A1	20070510	US 2005-532373	20050421
PRIORITY APPLN. INFO.:			GB 2002-24557	A 20021022
			GB 2003-6328	A 20030319
			WO 2003-EP11650	W 20031020
OTHER SOURCE(S):		MARPAT 140:375087		
GI				




- AB The title compds. [I; R1, R2 = halo, OH, CN, etc.; a, b = 0-2 (a and b cannot both = 0); R3 = halo, alkyl, alkoxy, CN, NH2, CF3; m, n = 0-2; p = 0-3 (when p = > 1 then two R1 may instead be linked to form a heterocyclyl); R4 = (CH2)qNR11R12, II (wherein q = 2-4; R11, R12 = alkyl; or NR11R12 = (un)substituted heterocyclyl; R13 = H, alkyl, cycloalkyl, alkylaryl, heterocyclyl; R14 = halo, alkyl, haloalkyl, OH, dialkylamino, alkoxy; f, k = 0-2 and h = 0-3 (g and h cannot both be 0))], useful in the treatment of neurol. and psychiatric disorders, were prepared Thus, reacting 4-[3-(piperidin-1-yl)propoxy]benzoic acid hydrochloride (preparation given) with indoline afforded III which exhibited pKb ≥ 8.5 in the histamine H3 functional antagonist assay. The pharmaceutical composition comprising the compound I is claimed.
- IT 685564-61-8P 685564-62-9P 685564-79-8P
685564-80-1P 685564-81-2P 685564-82-3P
685564-90-3P 685564-96-9P 685565-54-2P
685565-56-4P 685565-57-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of bicyclic benzamides as histamine H3 receptor ligands useful in the treatment of neurol. diseases)
- RN 685564-61-8 CAPLUS
- CN Methanone, [4-[3-(1-piperidinyl)propoxy]phenyl](1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 685564-62-9 CAPLUS


CN Methanone, [4-[3-(1-piperidiny)propoxy]phenyl][1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 685564-79-8 CAPLUS

CN Methanone, [4-[3-(1-piperidiny)propoxy]phenyl][1,2,4,5-tetrahydro-7-methoxy-3H-3-benzazepin-3-yl]- (CA INDEX NAME)




RN 685564-80-1 CAPLUS

CN Ethanone, 1-[2,3,4,5-tetrahydro-3-[4-[3-(1-piperidiny)propoxy]benzoyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 685564-81-2 CAPLUS

CN Acetamide, N-[2,3,4,5-tetrahydro-8-methoxy-3-[4-[3-(1-piperidiny)propoxy]benzoyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 685564-82-3 CAPLUS

CN Methanesulfonamide, N-[2,3,4,5-tetrahydro-8-methoxy-3-[4-[3-(1-piperidiny)propoxy]benzoyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 685564-90-3 CAPLUS

CN Methanone, (6-bromo-1,2,4,5-tetrahydro-7,8-dimethoxy-3H-3-benzazepin-3-yl)[4-[3-(1-piperidiny)propoxy]phenyl]- (CA INDEX NAME)



RN 685564-96-9 CAPLUS


CN 1H-3-Benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro-3-[4-[3-(1-piperidiny)propoxy]benzoyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 685565-54-2 CAPLUS


CN Methanone, [4-[3-(1-piperidiny)propoxy]phenyl][1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]- (CA INDEX NAME)



RN 685565-56-4 CAPLUS


CN Methanone, [4-[3-(1-piperidiny)propoxy]phenyl][1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]- (CA INDEX NAME)

10/598,888



RN 685565-57-5 CAPLUS

CN 1H-3-Benzazepine-7-carbonitrile, 2,3,4,5-tetrahydro-3-[4-[3-(1-piperidinyl)propoxy]benzoyl]- (CA INDEX NAME)



L20 ANSWER 21 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:354915 CAPLUS
 DOCUMENT NUMBER: 140:375086
 TITLE: A preparation of benzo[d]azepine derivatives as a histamine H3 receptor antagonists useful for the treatment of neurological and psychiatric disorders
 INVENTOR(S): Heightman, Thomas Daniel; Wilson, David Matthew
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 33 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004035544	A1	20040429	WO 2003-EP11421	20031014
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003278084	A1	20040504	AU 2003-278084	20031014
PRIORITY APPLN. INFO.:			GB 2002-24083	A 20021016
			WO 2003-EP11421	W 20031014
OTHER SOURCE(S):	MARPAT 140:375086			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


- AB The invention relates to novel benzoazepine derivs. of formula I [wherein: R1 = H, (un)substituted (cyclo)alkyl, (hetero)aryl, or alkyl-aryl, etc.; R2 = H, alkyl, alkoxy, CN, NH2, or CF3; R3 represents -(CH2)2-4-NR4R5 or a group of formula II; R4 and R5 independently represent alkyl or, together with the nitrogen atom to which they are attached, represent an N-linked nitrogen-containing (un)substituted heterocycle; X represents bond, alkyl, C(O), or SO2, etc.; Z = (CH2)0-3; Y = (CH2)0-2; R6 = H, (cyclo)alkyl, alkyl-aryl, or heterocyclyl; R7 = halogen, (halo)alkyl, or OH, etc.] useful for the treatment of neurol. and psychiatric disorders. The invented compds. were screened for histamine H3 receptor activity (histamine H3 binding assay and functional antagonist assay). The prepared compds. exhibited antagonism in the range 6.0-10.0 pKb. For instance, compound III (8.0-10.0 pKb) was prepared via decarboxylation of the prepared benzoazepine IV by treatment with CF3CO2H in CH2Cl2 at 0 °C (example 1, no yield data).
- IT 667398-74-5P, 3-Cyclohexylmethyl-7-[3-(piperidin-1-yl)propoxy]-1,2,4,5-tetrahydro-1H-benzo[d]azepine 667398-78-9P, 3-(Phenylmethyl)-7-[13-(1-piperidinyl)propyl]oxy]-2,3,4,5-tetrahydro-1H-3-

benzazepine 684250-34-8P, 3-(4-Methoxybenzyl)-7-[3-piperidin-1-yl-propoxy]-1,2,4,5-tetrahydro-1H-benzo[d]azepine 684250-36-0P, 3-(2-Naphthalenylmethyl)-7-[3-[1-piperidinyl]propyl]oxy]-2,3,4,5-tetrahydro-1H-3-benzazepine 684250-38-2P 684250-40-6P 684250-41-7P, 4-[[7-[[3-(1-Piperidinyl)propyl]oxy]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]benzonitrile 684250-42-8P, N,N-Dimethyl-4-[[7-[[3-(1-piperidinyl)propyl]oxy]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]aniline 684250-43-9P, N-[[4-[[7-[[3-(1-Piperidinyl)propyl]oxy]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]phenyl]acetamide 684250-59-7P, 7-[[1-(1-Methylethyl)-4-piperidinyl]oxy]-3-(phenylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepine 684250-69-9P, 3-[[3,4-Dichlorophenyl]carbonyl]-7-[[3-(1-piperidinyl)propyl]oxy]-2,3,4,5-tetrahydro-1H-3-benzazepine 684250-75-7P, 3-(Phenylcarbonyl)-7-[[3-(1-piperidinyl)propyl]oxy]-2,3,4,5-tetrahydro-1H-3-benzazepine 696607-66-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzo[d]azepine derivs. useful for treatment of neurol. and psychiatric disorders)


RN 667398-74-5 CAPLUS

CN 1H-3-Benzazepine, 3-(cyclohexylmethyl)-2,3,4,5-tetrahydro-7-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)




RN 667398-78-9 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)




RN 684250-34-8 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-7-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)




RN 684250-36-0 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(2-naphthalenylmethyl)-7-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)




RN 684250-38-2 CAPLUS

CN Methanone, 1-naphthalenyl[1,2,4,5-tetrahydro-7-[3-(1-piperidinyl)propoxy]-3H-3-benzazepin-3-yl]- (CA INDEX NAME)




RN 684250-40-6 CAPLUS

CN Methanone, (4-methoxyphenyl)[1,2,4,5-tetrahydro-7-[3-(1-piperidinyl)propoxy]-3H-3-benzazepin-3-yl]- (CA INDEX NAME)




RN 684250-41-7 CAPLUS

CN Benzonitrile, 4-[[1,2,4,5-tetrahydro-7-[3-(1-piperidinyl)propoxy]-3H-3-benzazepin-3-yl]methyl]- (CA INDEX NAME)




RN 684250-42-8 CAPLUS

CN Benzenamine, N,N-dimethyl-4-[[1,2,4,5-tetrahydro-7-[3-(1-piperidinyl)propoxy]-3H-3-benzazepin-3-yl]methyl]- (CA INDEX NAME)




RN 684250-43-9 CAPLUS

CN Acetamide, N-[4-[[1,2,4,5-tetrahydro-7-[3-(1-piperidinyl)propoxy]-3H-3-benzazepin-3-yl]methyl]phenyl]- (CA INDEX NAME)




RN 684250-59-7 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-[[1-(1-methylethyl)-4-piperidinyl]oxy]-3-(phenylmethyl)- (CA INDEX NAME)




RN 684250-69-9 CAPLUS

CN Methanone, (3,4-dichlorophenyl)[1,2,4,5-tetrahydro-7-[3-(1-piperidinyl)propoxy]-3H-3-benzazepin-3-yl]- (CA INDEX NAME)




RN 684250-75-7 CAPLUS

CN Methanone, phenyl[1,2,4,5-tetrahydro-7-[3-(1-piperidinyl)propoxy]-3H-3-benzazepin-3-yl]- (CA INDEX NAME)



RN 696607-66-6 CAPLUS

CN Methanone, 1,3-benzodioxol-5-yl[1,2,4,5-tetrahydro-7-[3-(1-piperidinyl)propoxy]-3H-3-benzazepin-3-yl]- (CA INDEX NAME)




IT 684250-60-0P, 3-[(3,4-Dichlorophenyl)methyl]-7-[[1-(1-methylethyl)-4-piperidinyl]oxy]-2,3,4,5-tetrahydro-1H-3-benzazepine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(reactant; preparation of benzo[d]azepine derivs. useful for treatment of neurol. and psychiatric disorders)

RN 684250-60-0 CAPLUS

CN 1H-3-Benzazepine, 3-[(3,4-dichlorophenyl)methyl]-2,3,4,5-tetrahydro-7-[[1-(1-methylethyl)-4-piperidinyl]oxy]- (CA INDEX NAME)



REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/598,888

L20 ANSWER 22 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:267241 CAPLUS

DOCUMENT NUMBER: 140:303538

TITLE: Preparation of [(aminoalkyl)aryl]oxy]nicotinamides and analogs as opioid receptor antagonist for treatment of obesity and related conditions

INVENTOR(S): Blanco-Fillado, Maria-Jesus; Chappell, Mark Donald; Garcia De la Torre, Marta; Diaz Buezo, Nuria; Frits, James Erwin; Holloway, William Glen; Matt, James Edward, Jr.; Mitch, Charles Howard; Pedregal-Tercero, Concepcion; Quimby, Steven James; Siegel, Miles Goodman; Smith, Dana Rae; Stucky, Russell Dean; Takeuchi, Kumiko; Thomas, Elizabeth Marie; Wolfe, Chad Nolan

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 559 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026305	A1	20040401	WO 2003-US26300	20030917
WO 2004026305	A9	20040513		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2499690	A1	20040401	CA 2003-2499690	20030917
AU 2003269980	A1	20040408	AU 2003-269980	20030917
BR 2003014308	A	20050705	BR 2003-14308	20030917
EP 1562595	A1	20050817	EP 2003-751877	20030917
EP 1562595	B1	20080521		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1681498	A	20051012	CN 2003-822241	20030917
JP 2006511474	T	20060406	JP 2004-537682	20030917
NZ 538459	A	20080430	NZ 2003-538459	20030917
AT 395915	T	20080615	AT 2003-751877	20030917
TW 287012	B	20070921	TW 2003-92125729	20030918
US 20060217372	A1	20060928	US 2005-526960	20050303
US 7381719	B2	20080603		
MX 2005PA03093	A	20050713	MX 2005-PA3093	20050318
IN 2005KN00457	A	20060303	IN 2005-KN457	20050318
NO 2005001871	A	20050418	NO 2005-1871	20050418
PRIORITY APPLN. INFO.:			US 2002-412158P	P 20020919
			WO 2003-US26300	W 20030917

OTHER SOURCE(S): MARPAT 140:303538

GI



AB Title diaryl ethers I [wherein X1-X10 = independently C, CH, or N; provided that each of rings A or B has no more than 2 N atoms; E = O or NH; R1 and R2 = independently H or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, (alkyl)aryl, (aryl)heterocyclyl, (cyclo)alkylheterocyclyl, (cyclo)alkanoylalkyl, aroylalkyl, aryloxyalkyl, benzhydryl, bicycyl(alkyl), benzoyl(alkyl), alkoxyalkyl, alkoxycarbonyl, (aryl)alkylsulfonyl, heterocyclylalkylsulfonyl, cycloalkylalkyl, carboxyalkyl, carbamoylalkyl, etc.; R3 and R3' = independently H, alkyl, alkenyl, alkynyl, (alkyl)aryl, or alkylcycloalkyl; R4 and R5 = independently H, (halo)alkyl, alkenyl, alkynyl, alkoxy(halo)alkyl, thioalkyl, halo, aryl(alkyl), alkanoyl, alkoxycarbonyl, aminoalkyl, cycloalkylalkyl, etc.; R6 and R7 = independently H, (cyclo)alkyl, alkenyl, alkynyl, alkanoyl, OH, alkoxy, (aryl)alkylsulfonyl, heterocyclylalkylsulfonyl, aryl(alkyl), carbamoyl(alkyl), etc.; m = 1-3; n = 0-3; p = 0-3; or pharmaceutically acceptable salts, solvates, enantiomers, racemates, diastereomers, or mixts. thereof] were prepared as μ -, κ -, and δ -opioid receptor antagonists. For example, reductive amination of 6-(2-fluoro-4-formylphenoxy)nicotinamide and 3-methylbutylamine provided II (99%). The latter inhibited ex vivo binding of [3 H]-diprenorphine in rat striatum/nucleus accumbens by >65% at a concentration of 7 mg/kg. In an acute feeding rat obesity assay, II

suppressed

opioid receptors at a dose of 0.3 μ g/kg. In addition, diet-induced obese rats achieved an energy balance (caloric intake minus utilization) of -81 kcal/kg/day upon administration of 0.3 mg/kg p.o. of II in an indirect calorimetry assay. Thus, I and their pharmaceutical compns. are useful for the treatment, prevention, or amelioration of obesity and related diseases.


IT 676496-18-7P, 6-[(3-Phenethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)oxy]nicotinamide 676496-21-2P, 6-[(3-Benzyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)oxy]nicotinamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(opioid receptor antagonist; preparation of (aryloxy)nicotinamides and analogs as opioid receptor antagonist for treatment of obesity and

related conditions)


RN 676496-18-7 CAPLUS

CN 3-Pyridinecarboxamide, 6-[[2,3,4,5-tetrahydro-3-(2-phenylethyl)-1H-3-benzazepin-7-yl]oxy]- (CA INDEX NAME)



RN 676496-21-2 CAPLUS

CN 3-Pyridinecarboxamide, 6-[[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]oxy]- (CA INDEX NAME)





REFERENCE COUNT:

8


THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 23 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:182847 CAPLUS
 DOCUMENT NUMBER: 140:235617
 TITLE: Preparation of substituted azepines as histamine H3
 receptor antagonists
 INVENTOR(S): Gadski, Robert Alan; Hipskind, Philip Arthur;
 Jesudason, Cynthia Darshini; Pickard, Richard Todd;
 Beavers, Lisa Selsam
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 65 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018432	A1	20040304	WO 2003-US23266	20030815
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003256793	A1	20040311	AU 2003-256793	20030815
EP 1539704	A1	20050615	EP 2003-792991	20030815
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006500376	T	20060105	JP 2004-530848	20030815
US 20060089347	A1	20060427	US 2005-523071	20051018
PRIORITY APPLN. INFO.:			US 2002-405053P	P 20020820
			WO 2003-US23266	W 20030815
OTHER SOURCE(S):		MARPAT 140:235617		
GI				



- AB Title compds. I [R1-2 = H, alkoxy, amino, etc.; X = CH₂, CO; Y, Z = CH₂, N, provided only one of Y, Z can be N; R6-7 = H, alkyl, carboxy, etc.] are prepared For instance, 2,3,4,5-tetrahydro-1H-benzo[c]azepine-7-ol•HBr (preparation given) is protected (CH₂Cl₂, Et₃N, Boc₂O) and alkylated with 1-(3-chloropropyl)piperidine (DMF, NaH) to give II. II has Ki = 5.1 for the histamine H₃ receptor and Ki ≥ 20,000, 648 and 813 for the histamine H₄, H₁ and H₂ receptors resp. I are useful for the treatment of obesity.
- IT 667398-74-5P, 3-Cyclohexylmethyl-7-[3-(piperidinyl)propoxy]-2,3,4,5-tetrahydro-1H-benzo[d]azepine 667398-75-6P, 3-Cyclohexylmethyl-7-[3-(piperidinyl)propoxy]-2,3,4,5-tetrahydro-1H-benzo[d]azepine dimaleate 667398-78-9P, 3-Benzyl-7-[3-(piperidinyl)propoxy]-2,3,4,5-tetrahydro-1H-benzo[d]azepine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of substituted azepines as histamine H₃ receptor antagonists)
- RN 667398-74-5 CAPLUS
- CN 1H-3-Benzazepine, 3-(cyclohexylmethyl)-2,3,4,5-tetrahydro-7-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)




- RN 667398-75-6 CAPLUS
- CN 1H-3-Benzazepine, 3-(cyclohexylmethyl)-2,3,4,5-tetrahydro-7-[3-(1-piperidinyl)propoxy]-, (2Z)-2-butenedioate (1:2) (CA INDEX NAME)

10/598,888

CM 1

CRN 667398-74-5

CMF C25 H40 N2 O




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 667398-78-9 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[3-(1-piperidinyl)propoxy]- (CA INDEX NAME)




REFERENCE COUNT:

8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 24 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:1002008 CAPLUS
 DOCUMENT NUMBER: 140:314417
 TITLE: 2-(Aminomethyl)-benzamide-based glycine transporter type-2 inhibitors
 AUTHOR(S): Ho, Koc-Kan; Appell, Kenneth C.; Baldwin, John J.; Bohnstedt, Adolph C.; Dong, Guizhen; Guo, Tao; Horlick, Robert; Islam, Khondaker R.; Kultgen, Steven G.; Masterson, Christopher M.; McDonald, Edward; McMillan, Kirk; Morphy, J. Richard; Rankovic, Zoran; Sundaram, Hardy; Webb, Maria
 CORPORATE SOURCE: Pharmacopeia, Inc., Princeton, NJ, 08543-5350, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(2), 545-548
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 140:314417
 AB Structure-activity studies on 2-aminomethylbenzamide analogs obtained from library screening led to the discovery of a novel series of potent and selective glycine transporter type-2 inhibitors.
 IT 678174-49-7P
 RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
 (preparation of 2-(aminomethyl)benzamide-based glycine transporter type-2 inhibitors)
 RN 678174-49-7 CAPLUS
 CN Benzamide, N-[(3E)-4-phenyl-3-buten-1-yl]-2-[(1,2,4,5-tetrahydro-7-hydroxy-3H-3-benzazepin-3-yl)methyl]- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 25 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:877311 CAPLUS

DOCUMENT NUMBER: 140:128315

TITLE: Synthesis and biological evaluation of benzazepine oxazolidinone antibacterials

AUTHOR(S): Johnson, Paul D.; Aristoff, Paul A.; Zurenko, Gary E.; Schaadt, Ronda D.; Yagi, Betty H.; Ford, Charles W.; Hamel, Judith C.; Stapert, Douglas; Moerman, Judy K.

CORPORATE SOURCE: Discovery-Chemistry, Pharmacia Corporation, Kalamazoo, MI, 49001, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(23), 4197-4200

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.


DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 140:128315

- AB Novel benzazepine oxazolidinone antibacterials were synthesized and evaluated against relevant susceptible and resistant organisms. The effect of ring nitrogen position and N-substitution on antibacterial activity is examined. Compds. thus tested included N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1H-1-benzazepin-7-yl)-5-oxazolidinyl]methyl]acetamide, N-[[[(5S)-3-(1-formyl-2,3,4,5-tetrahydro-1H-1-benzazepin-7-yl)-2-oxo-5-oxazolidinyl]methyl]acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-2-(hydroxyacetyl)-1H-2-benzazepin-7-yl]-5-oxazolidinyl]methyl]acetamide, and N-[[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-5-oxazolidinyl]methyl]acetamide.
- IT 444587-62-6, N-[[[(5S)-3-(3-Benzoyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxo-5-oxazolidinyl]methyl]acetamide 444587-68-2, N-[[[(5S)-2-Oxo-3-[2,3,4,5-tetrahydro-3-(phenylacetyl)-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]acetamide
- RL: PAC (Pharmacological activity); BIOL (Biological study)
(preparation and antibacterial activity of N-[[[oxo(tetrahydrobenzazepinyl)oxazolidinyl]methyl]acetamide derivs.)
- RN 444587-62-6 CAPLUS
- CN Acetamide, N-[[[(5S)-3-(3-benzoyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 444587-68-2 CAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-3-(2-phenylacetyl)-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT:

23

THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 26 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:806660 CAPLUS
DOCUMENT NUMBER: 140:16637
TITLE: Design and Synthesis of trans-3-(2-(4-((3-(3-(5-Methyl-1,2,4-oxadiazolyl))-phenyl)carboxamido)cyclohexyl)ethyl)-1-(7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): A Potent and Selective Dopamine D3 Receptor Antagonist
AUTHOR(S): Macdonald, Gregor J.; Branch, Clive L.; Hadley, Michael S.; Johnson, Christopher N.; Nash, David J.; Smith, Alexander B.; Stemp, Geoffrey; Thewlis, Kevin M.; Vong, Antonio K. K.; Austin, Nigel E.; Jeffrey, Phillip; Winborn, Kim Y.; Boyfield, Izzy; Hagan, Jim J.; Middlemiss, Derek N.; Reavill, Charlie; Riley, Graham J.; Watson, Jeannette M.; Wood, Martyn; Parker, Steve G.; Ashby, Charles R., Jr.
CORPORATE SOURCE: GlaxoSmithKline Pharmaceuticals, Essex, CM19 5AW, UK
SOURCE: Journal of Medicinal Chemistry (2003), 46(23), 4952-4964
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 140:16637
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

- AB At their clin. doses, current antipsychotic agents share the property of both dopamine D2 and D3 receptor blockade. However, a major disadvantage of many current medications are the observed extrapyramidal side-effects (EPS), postulated to arise from D2 receptor antagonism. Consequently, a selective dopamine D3 receptor antagonist could offer an attractive antipsychotic therapy, devoid of the unwanted EPS. Using SAR information gained in two previously reported series of potent and selective D3 receptor antagonists, as exemplified by the 2,3,4,5-tetrahydro-1H-3-benzazepine I and the 2,3-dihydro-1H-isoindoline II, a range of 7-sulfonyloxy- and 7-sulfonylbenzazepines has been prepared. Compds. of this type combine a high level of D3 affinity and selectivity vs. D2 with an excellent pharmacokinetic profile in the rat. Subsequent optimization of this series to improve selectivity over a range of receptors and reduce cytochrome P 450 inhibitory potential gave trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (III, SB-414796). III is a potent and selective dopamine D3 receptor antagonist with high oral bioavailability and is CNS penetrant in the rat. Subsequent evaluation in the rat has shown that III preferentially reduces firing of dopaminergic cells in the ventral tegmental area (A10) compared to the substantia nigra (A9), an observation consistent with a prediction for atypical antipsychotic efficacy. In a sep. study, III has been shown to block expression of the conditioned place preference (CPP) response to cocaine in male rats, suggesting that it may also have a role in the treatment of cue-induced relapse in drug-free cocaine addicts.
- IT 264262-70-6P 264262-71-7P, SB 414796


264262-79-5P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of aminocyclohexylethyl-substituted methylsulfonyloxy and methylsulfonyl tetrahydrobenzazepines as dopamine receptor antagonists and antipsychotics)

RN 264262-70-6 CAPLUS

CN 5-Quinolinecarboxamide, 2-methyl-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 264262-71-7 CAPLUS

CN Benzamide, 3-(5-methyl-1,2,4-oxadiazol-3-yl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 264262-79-5 CAPLUS


CN 5-Quinolinecarboxamide, 2-methyl-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-[(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



IT 628297-63-2P 628297-81-4P 628297-87-0P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of aminocyclohexylethyl-substituted methylsulfonyloxy and methylsulfonyl tetrahydrobenzazepines as dopamine receptor antagonists and antipsychotics)
 RN 628297-63-2 CAPLUS
 CN 5-Quinolinecarboxamide, 2-methyl-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-[(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, hydrochloride (1:1) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 628297-81-4 CAPLUS
 CN 5-Quinolinecarboxamide, 2-methyl-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-[(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 628297-87-0 CAPLUS

CN Benzamide, 3-(5-methyl-1,2,4-oxadiazol-3-yl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

IT 264263-94-7P 264263-99-2P 264264-21-3P
 628297-21-2P 628297-22-3P 628297-23-4P
 628297-24-5P 628297-25-6P 628297-26-7P
 628297-27-8P 628297-28-9P 628297-29-0P
 628297-30-3P 628297-31-4P 628297-32-5P
 628297-33-6P 628297-34-7P 628297-35-8P
 628297-41-6P 628297-42-7P 628297-43-8P
 628297-44-9P 628297-45-0P 628297-46-1P
 628297-47-2P 628297-48-3P 628297-49-4P
 628297-50-7P 628297-51-8P 628297-52-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of aminocyclohexylethyl-substituted methylsulfonyloxy and


methylsulfonyl tetrahydrobenzazepines as dopamine receptor antagonists
and antipsychotics)

RN 264263-94-7 CAPLUS

CN 2-Propenamide, 3-(2-fluorophenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 264263-99-2 CAPLUS

CN 5-Quinolinecarboxamide, 8-fluoro-2-methyl-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 264264-21-3 CAPLUS

CN Benzamide, 3-(5-methyl-2-oxazolyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-[(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 628297-21-2 CAPLUS

CN 2-Propenamide, 3-(4-fluorophenyl)-N-[trans-4-{2-[(1,2,4,5-tetrahydro-7-(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl)ethyl}cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 628297-22-3 CAPLUS

CN 2-Propenamide, 3-(3-fluorophenyl)-N-[trans-4-{2-[(1,2,4,5-tetrahydro-7-(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl)ethyl}cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 628297-23-4 CAPLUS

10/598,888


CN 2-Propenamide, 3-(2-fluorophenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-
[(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, (2E)- (CA
INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 628297-24-5 CAPLUS
CN 2-Propenamide, 3-(4-methoxyphenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-
[(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, (2E)- (CA
INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 628297-25-6 CAPLUS
CN 2-Propenamide, 3-(3-methoxyphenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-
[(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, (2E)- (CA
INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 628297-26-7 CAPLUS

CN 2-Propenamide, 3-(2-methoxyphenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-[(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 628297-27-8 CAPLUS

CN 1-Naphthalenecarboxamide, N-[trans-4-[2-[1,2,4,5-tetrahydro-7-[(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 628297-28-9 CAPLUS

CN 5-Quinolinecarboxamide, N-[trans-4-[2-[1,2,4,5-tetrahydro-7-[(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.


10/598,888

RN 628297-31-4 CAPLUS

CN Benzamide, 3-(2-methyl-5-oxazolyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-
[(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX
NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 1-B

Me

RN 628297-32-5 CAPLUS

CN Benzamide, 3-(1H-pyrrol-1-yl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-
[(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX
NAME)


Relative stereochemistry.



RN 628297-33-6 CAPLUS

CN Benzamide, 3-(4-methyl-2-oxazolyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-
[(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX
NAME)


Relative stereochemistry.



RN 628297-41-6 CAPLUS

CN 2-Propenamide, 3-(4-fluorophenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 628297-42-7 CAPLUS

CN 2-Propenamide, 3-(3-fluorophenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




10/598,888

RN 628297-43-8 CAPLUS

CN 2-Propenamide, 3-(3,5-difluorophenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 628297-44-9 CAPLUS

CN 2-Propenamide, 3-(2,6-difluorophenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 628297-45-0 CAPLUS

CN 2-Propenamide, 3-(4-cyanophenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 628297-46-1 CAPLUS

CN 2-Propenamide, 3-(3-cyanophenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 628297-47-2 CAPLUS

CN 2-Propenamide, 3-(2-cyanophenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 628297-48-3 CAPLUS

CN 1-Naphthalenecarboxamide, N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 628297-49-4 CAPLUS

CN Benzamide, 3-(2-methyl-5-oxazolyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 628297-50-7 CAPLUS

CN Benzamide, 3-(1-methyl-1H-pyrazol-5-yl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 628297-51-8 CAPLUS

CN Benamide, 3-(5-methyl-2-oxazolyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 628297-52-9 CAPLUS


CN Benamide, 3-(3-methyl-5-isoxazolyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



IT 628297-53-0P 628297-56-3P 628297-57-4P
 628297-58-5P 628297-59-6P 628297-60-9P
 628297-61-0P 628297-62-1P 628297-64-3P
 628297-65-4P 628297-66-5P 628297-67-6P
 628297-68-7P 628297-69-8P 628297-70-1P
 628297-71-2P 628297-72-3P 628297-73-4P
 628297-74-5P 628297-75-6P 628297-76-7P
 628297-77-8P 628297-78-9P 628297-79-0P
 628297-80-3P 628297-82-5P 628297-83-6P
 628297-84-7P 628297-85-8P 628297-86-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)
 (preparation of aminocyclohexylethyl-substituted methylsulfonyloxy and
 methylsulfonyl tetrahydrobenzazepines as dopamine receptor antagonists
 and antipsychotics)
 RN 628297-53-0 CAPLUS
 CN 2-Propenamide, 3-(4-fluorophenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-
 [(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-,
 hydrochloride (1:1), (2E)- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



● HCl

RN 628297-56-3 CAPLUS
 CN 2-Propenamide, 3-(3-fluorophenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-
 [(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-,
 hydrochloride (1:1), (2E)- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




● HCl

RN 628297-57-4 CAPLUS

CN 2-Propenamide, 3-(2-fluorophenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-[(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




● HCl

RN 628297-58-5 CAPLUS

CN 2-Propenamide, 3-(4-methoxyphenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-[(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



● HCl

RN 628297-59-6 CAPLUS
 CN 2-Propenamide, 3-(3-methoxyphenyl)-N-[trans-4-[2-(1,2,4,5-tetrahydro-7-[(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, hydrochloride (1:1), (2E)- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



● HCl

RN 628297-60-9 CAPLUS
 CN 2-Propenamide, 3-(2-methoxyphenyl)-N-[trans-4-[2-(1,2,4,5-tetrahydro-7-[(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




● HCl

RN 628297-61-0 CAPLUS

CN 1-Naphthalenecarboxamide, N-[trans-4-[2-[1,2,4,5-tetrahydro-7-[(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 628297-62-1 CAPLUS

CN 5-Quinolinecarboxamide, N-[trans-4-[2-[1,2,4,5-tetrahydro-7-[(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 628297-64-3 CAPLUS

CN 4-Quinolinecarboxamide, 2-methyl-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-[(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 628297-65-4 CAPLUS

CN Benzamide, 3-(5-methyl-1,2,4-oxadiazol-3-yl)-N-[trans-4-[(1,2,4,5-tetrahydro-7-[(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



● HCl


PAGE 1-B

Me

RN 628297-66-5 CAPLUS
 CN Benzamide, 3-(2-methyl-5-oxazolyl)-N-[trans-4-[2-(1,2,4,5-tetrahydro-7-
 [(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-,
 hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



● HCl

PAGE 1-B


Me

RN 628297-67-6 CAPLUS

10/598,888

CN Benzamide, 3-(1H-pyrrol-1-yl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-
[(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-,
hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 628297-68-7 CAPLUS

CN Benzamide, 3-(4-methyl-2-oxazolyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-
[(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-,
hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

PAGE 1-A

PAGE 1-B

Me

RN 628297-69-8 CAPLUS


CN Benzamide, 3-(3-methyl-5-isoxazolyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-
[(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-,

10/598,888

hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



● HCl


PAGE 1-B

Me

RN 628297-70-1 CAPLUS

CN Benzamide, 3-(5-methyl-2-oxazolyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-[(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 628297-71-2 CAPLUS

CN Benzamide, 3-(2-pyrimidinyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-[(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, hydrochloride (1:1) (CA INDEX NAME)

10/598,888

Relative stereochemistry.




● HCl

RN 628297-72-3 CAPLUS

CN 2-Propenamide, 3-(4-fluorophenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




● HCl

RN 628297-73-4 CAPLUS

CN 2-Propenamide, 3-(3-fluorophenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



● HCl

RN 628297-74-5 CAPLUS
 CN 2-Propenamide, 3-(2-fluorophenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, hydrochloride (1:1), (2E)- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



● HCl

RN 628297-75-6 CAPLUS
 CN 2-Propenamide, 3-(3,5-difluorophenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, hydrochloride (1:1), (2E)- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



● HCl

RN 628297-76-7 CAPLUS
 CN 2-Propenamide, 3-(2,6-difluorophenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, hydrochloride (1:1), (2E)- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



● HCl

RN 628297-77-8 CAPLUS
 CN 2-Propenamide, 3-(4-cyanophenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, hydrochloride (1:1), (2E)- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



● HCl

RN 628297-78-9 CAPLUS
 CN 2-Propenamide, 3-((3-cyanophenyl)-N-((trans-4-(2-((1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl)ethyl)cyclohexyl))-hydrochloride (1:1), (2E)- (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



● HCl

RN 628297-79-0 CAPLUS
 CN 2-Propenamide, 3-((2-cyanophenyl)-N-((trans-4-(2-((1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl)ethyl)cyclohexyl))-hydrochloride (1:1), (2E)- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.




● HCl

RN 628297-83-6 CAPLUS

CN Benzamide, 3-(2-methyl-5-oxazolyl)-N-[trans-4-[2-(1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 628297-84-7 CAPLUS

CN Benzamide, 3-(1-methyl-1H-pyrazol-5-yl)-N-[trans-4-[2-(1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, hydrochloride (1:1) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 628297-85-8 CAPLUS
 CN Benzamide, 3-(5-methyl-2-oxazolyl)-N-[trans-4-[2-(1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, hydrochloride (1:1) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 628297-86-9 CAPLUS
 CN Benzamide, 3-(3-methyl-5-isoxazolyl)-N-[trans-4-[2-(1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

IT 264264-44-0P 264264-45-1P 264264-52-0P

264264-53-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aminocyclohexylethyl-substituted methylsulfonyloxy and methylsulfonyl tetrahydrobenzazepines as dopamine receptor antagonists and antipsychotics)

RN 264264-44-0 CAPLUS

CN Carbamic acid, [trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 264264-45-1 CAPLUS

CN Cyclohexanamine, 4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]-, trans- (CA INDEX NAME)


Relative stereochemistry.



RN 264264-52-0 CAPLUS

CN Carbamic acid, [trans-4-[2-[1,2,4,5-tetrahydro-7-[(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 264264-53-1 CAPLUS

CN 1H-3-Benzazepin-7-ol, 3-[2-(trans-4-aminocyclohexyl)ethyl]-2,3,4,5-tetrahydro-, 7-methanesulfonate (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT:

34

THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 27 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:656751 CAPLUS

DOCUMENT NUMBER: 139:197391

TITLE: Preparation of N-heterocyclyl benzenesulfonamides as antipsychotic agents

INVENTOR(S): Bromidge, Steven Mark; Cooper, David Gwyn; Forbes, Ian Thomson; Gribble, Andrew Derrick; Johnson, Christopher Norbert; Lightfoot, Andrew P.; Moss, Stephen Frederick; Payne, Andrew H.; Rahman, Shahzad Sharooq; Witty, David R.

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003068752	A1	20030821	WO 2003-EP1545	20030213
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2475783	A1	20030821	CA 2003-2475783	20030213
AU 2003215558	A1	20030904	AU 2003-215558	20030213
EP 1474399	A1	20041110	EP 2003-739495	20030213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003007557	A	20050104	BR 2003-7557	20030213
CN 1630642	A	20050622	CN 2003-803746	20030213
JP 2005526724	T	20050908	JP 2003-567883	20030213
IN 2004DN02106	A	20050401	IN 2004-DN2106	20040721
MX 2004PA07920	A	20041126	MX 2004-PA7920	20040813
NO 2004003794	A	20040910	NO 2004-3794	20040910
US 20050222124	A1	20051006	US 2005-504111	20050315
ZA 2004005804	A	20060531	ZA 2004-5804	20060317
PRIORITY APPLN. INFO.:			GB 2002-3437	A 20020213
			GB 2002-3438	A 20020213
			GB 2002-4758	A 20020228
			GB 2002-4784	A 20020228
			GB 2002-12548	A 20020530
			GB 2002-19711	A 20020823
			GB 2002-24466	A 20021021
			WO 2003-EP1545	W 20030213

OTHER SOURCE(S): MARPAT 139:197391

GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; A and B = (CH₂)_m and (CH₂)_n, resp.; R₁ = H, alkyl; R₂ = H, halo, OH, CN, etc.; R₃ = H, alkyl; Ar = (un)substituted Ph, monocyclic heteroaryl; R₄ = (un)substituted aryl or heteroaryl; Z = a bond, O, alkyl; Y = H, alkyl; m, n = 1-2; q = 1-3; r = 1-4] and their pharmaceutically acceptable salts, useful in therapy, in particular as antipsychotic agents, were prepared. Thus, amidation of the amine II (preparation given) with 4'-chloro-biphenyl-4-sulfonyl chloride followed by trifluoroacetyl group removal afforded III. The exemplified compds. I have pK_i values within the range of 6.6-9.6 at the dopamine D₃ receptor, and pK_i values within the range of 5.3-9.3 at the dopamine D₂ receptor. Pharmaceutical composition comprising the compound I was claimed.

IT 583046-97-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of benzenesulfonamides as antipsychotic agents)

RN 583046-97-3 CAPLUS


CN Benzenesulfonamide, 4-(5-chloro-2-thienyl)-N-[2,3,4,5-tetrahydro-8-methoxy-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 28 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:633668 CAPLUS
 DOCUMENT NUMBER: 139:197505
 TITLE: Preparation of aryl- or heteroaryl-containing
 guanidines as melanocortin-4-receptor agonists useful
 against disorders such as obesity or type II diabetes
 INVENTOR(S): Boyce, Rustum; Chu, Daniel
 PATENT ASSIGNEE(S): Chiron Corporation, USA
 SOURCE: PCT Int. Appl., 102 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003066597	A2	20030814	WO 2003-US1078	20030203
WO 2003066597	A3	20040401		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG			
US 20030195187	A1	20031016	US 2003-351574	20030127
AU 2003216053	A1	20030902	AU 2003-216053	20030203
EP 1478626	A2	20041124	EP 2003-737536	20030203
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006503799	T	20060202	JP 2003-565971	20030203
US 20050124652	A1	20050609	US 2005-503392	20050126
PRIORITY APPLN. INFO.:			US 2002-353188P	P 20020204
			US 2003-351574	A 20030127
			WO 2003-US1078	W 20030203
OTHER SOURCE(S):	MARPAT 139:197505			
GI				



AB A variety of small, guanidino group-containing mols. (I; A1-A2-A3-A4; variables defined below; e.g. (3S)-N'-[4-(3,4-dihydroquinolin-1(2H)-ylcarbonyl)phenyl]-3-methyl-N-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide (shown as I)) capable of acting as MC4-R agonists are provided. The compds. are useful in treating MC4-R mediated diseases and may be formulated into pharmaceutical formulations and compns. Although the methods of preparation are not claimed, several example preps. of I and a number of example preps. of intermediates are included; 131 addnl. examples of I are tabulated with mass spectral characterization data. Some of the I have -log EC50 values above .apprx.3. Compds. I showed beneficial effects in in vivo studies on energy intake, body weight, hyperinsulinemia, and glucose levels in male 9-10 wk old ob/ob mice that display early onset of obesity, insulin resistance and diabetes due to leptin deficiency. For I: A1 = R1'R2'NC(NR3')NR4'-, R1'R2'NC(NR3'R4')N-; R1' = H, and (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl; R2' = (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl; or R1' and R2', together with the N to which they are bound, form a (un)substituted heterocyclyl or heteroaryl; R3' = (un)substituted aryl, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl; R4' = H, and (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclylalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, and heteroarylalkyl. A2 = (un)substituted aryl and heteroaryl; A3 is a covalent bond such that A2 is directly bonded to A4, or A3 is a linking group O, S, -NRa-, -C(O)-, -C(O)O-, -NRaC(O)-, -SO2NRa-, -C(S)-, -C(O)S-, -P(O)Rb-, -SO2-, and -S(O)-, wherein if A3 is a linking group, then it is bonded to A2 and A4 in a configuration A2-O-A4, A2-S-A4, A2-NRa-A4, A2-C(O)-A4, A2-C(O)O-A4, A4-C(O)O-A2, A2-NRaC(O)-A4, A4-NRaC(O)-A2, A2-SO2NRa-A4, A4-SO2NRa-A2, A2-C(S)-A4, A2-(C(O)S)-A4, A4-(C(O)S)-A2, A2-(P(O)Rb)-A4, A2-SO2-A4, and A2-S(O)-A4 provided that if A3 is a linking group with the configuration A4-NRaC(O)-A2, then A2 is not a (un)substituted Ph and is not a (un)substituted 6-membered N-containing heteroaryl. A4 = (un)substituted arylalkyl, heteroarylalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, heterocyclylalkyl, cycloalkylalkyl, alkenyl, alkynyl, and alkyl; Ra = H, and (un)substituted arylalkyl, heteroarylalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, heterocyclylalkyl, cycloalkylalkyl, alkenyl,

alkynyl, and alkyl; Rb = (un)substituted arylalkyl, heteroarylalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, heterocyclylalkyl, cycloalkylalkyl, alkenyl, alkynyl, and alkyl.


IT 581101-67-9P, (3S)-3-Methyl-N-[4-[[7-(methoxy)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]carbonyl]phenyl]-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of aryl- or heteroaryl-containing guanidines as melanocortin-4-receptor agonists useful against disorders such as obesity or type II diabetes)

RN 581101-67-9 CAPLUS

CN 1-Piperazinecarboximidamide, 3-methyl-N-[4-[(1,2,4,5-tetrahydro-7-methoxy-3H-3-benzazepin-3-yl)carbonyl]phenyl]-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 402832-78-4P, (4-Azidophenyl) (7-methoxy-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl)methanone

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aryl- or heteroaryl-containing guanidines as melanocortin-4-receptor agonists useful against disorders such as obesity or type II diabetes)


RN 402832-78-4 CAPLUS

CN Methanone, (4-azidophenyl) (1,2,4,5-tetrahydro-7-methoxy-3H-3-benzazepin-3-yl)- (CA INDEX NAME)



L20 ANSWER 29 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:356199 CAPLUS
 DOCUMENT NUMBER: 138:368921
 TITLE: Preparation of compounds as C-C chemokine receptor 8 antagonists, pharmaceutical compositions and use against inflammatory or viral disorders
 INVENTOR(S): Ghosh, Shomir; Patane, Michael A.; Carson, Kenneth G.; Chi, I-Cheng Shannon; Ye, Qing; Elder, Amy M.; Jenkins, Tracy J.
 PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 204 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2003037271	A2	20030508	WO 2002-US34845	20021030
WO 2003037271	A3	20031016		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002363236	A1	20030512	AU 2002-363236	20021030
US 20050143372	A1	20050630	US 2004-490223	20040825
PRIORITY APPLN. INFO.:			US 2001-340663P	P 20011030
			WO 2002-US34845	W 20021030
OTHER SOURCE(S):		MARPAT 138:368921		
GI				



AB The invention relates to (shown as I; variables defined below; e.g. 1-[1-(2',6'-dichlorobiphenyl-3-ylmethyl)piperidin-4-yl]-1,3-dihydrobenzimidazol-2-one and 3-(3-phenoxybenzyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine). Preferred compds. are antagonists of C-C chemokine receptor 8 (no data). The invention also relates to a method for treating a subject having an inflammatory disorder or viral disorder comprising

administering to a subject in need thereof an effective amount of a compound of the invention. Although the methods of preparation are not claimed, hundreds of example preps. are included. For I: L = O, S, NRa, a bond, SO2, C(O), and (CR'R'')m; Ra = H, (un)substituted alkyl, alkylaryl, and cycloalkyl; a is 0 to 3; b is 0 to 3; m is 1 to 8; R' and R'' = H, (un)substituted alkyl, cyano and (un)substituted alkenyl. R6, R7, R8, R9 and R10 = H, hydroxy, halogen, (un)substituted C1-C10 alkyl, (un)substituted C2-C10 alkenyl, (un)substituted C2-C10 alkynyl, (un)substituted C3-C10 cycloalkyl, (un)substituted C3-C10 cycloalkenyl, (un)substituted C3-C10 cycloalkynyl, (un)substituted C3-C10 cycloalkoxy, cyano, C1-C10 alkoxy, C2-C10 alkenyloxy, C2-C10 alkynyloxy, benzyloxy, (un)substituted amino, (un)substituted amido, O(CF3), C(O)O(R1), C(O)(R1), -SO2NR1R2, trifluoromethyl, aryl, aralkyl, heteroaryl and heteroaralkyl. R1 and R2 = H and (un)substituted alkyl; Q3 is (un)substituted alkyl; R11-R19 = H, hydroxy, halogen, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkyl, (un)substituted cycloalkenyl, (un)substituted cycloalkynyl, cyano, alkoxy, alkenyloxy, alkynyloxy, benzyloxy, (un)substituted amino, (un)substituted amido, O(CF3), C(O)O(R41), -C(O)(R41), -SO2NR41R42, trifluoromethyl, aryl, aralkyl, heteroaryl and heteroaralkyl; R41 and R42 = H, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkyl, (un)substituted cycloalkenyl, (un)substituted cycloalkynyl, (un)substituted amino, trifluoromethyl, aryl, aralkyl, heteroaryl and heteroaralkyl; or R41 and R42 may be linked via a C2-C8 (un)substituted alkyl or alkenyl bridge where 21 carbons may be replaced by O, S or NR46. Q5 = -N(R20)C(O)(CR41R42)1-3-, 1-N(R20)C(O)cycloalkyl (ring size = 3-9), N(R20)C(O)-substituted azacycloalkyl; R20 and R46 = H, hydroxy, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkyl, optionally cycloalkenyl, (un)substituted cycloalkynyl, (un)substituted amino, (un)substituted amido, -C(O)O(R41), -C(O)(R41), -SO2NR41R42, trifluoromethyl, aryl, aralkyl, heteroaryl or heteroaralkyl; and Q6 = (un)substituted aromatic ring, (un)substituted nonarom. heterocycle, and (un)substituted heteroarom. ring; or R18 or R19 together with Q5Q6 and the atoms to which they are bonded form an (un)substituted nonarom. carbocyclic group, (un)substituted nonarom. heterocyclic group, (un)substituted aryl ring or (un)substituted heteroaryl ring. Addnl. details are given in the claims.


IT 521977-21-9P, 3-(3-Phenoxybenzyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of compds. as C-C chemokine receptor 8 antagonists, pharmaceutical compns. and use against inflammatory or viral disorders)
 RN 521977-21-9 CAPLUS
 CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-[(3-phenoxyphenyl)methyl]- (CA INDEX NAME)



10/598,888

L20 ANSWER 30 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:319721 CAPLUS
 DOCUMENT NUMBER: 138:321292
 TITLE: Preparation of 2,4,5-trisubstituted pyrimidines as
 cyclin dependent kinase inhibitors
 INVENTOR(S): Dahmann, Georg; Himmelsbach, Frank; Wittneben, Helmut;
 Pautsch, Alexander; Prokopowicz, Anthony S.; Krist,
 Bernd; Schnapp, Gisela; Steegmaier, Martin; Lenter,
 Martin; Schoop, Andreas; Steurer, Steffen; Spevak,
 Walter
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany; Boehringer
 Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim
 International G.m.b.H.
 SOURCE: PCT Int. Appl., 278 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003032997	A1	20030424	WO 2002-EP11453	20021014
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2463989	A1	20030424	CA 2002-2463989	20021014
AU 2002340560	A1	20030428	AU 2002-340560	20021014
EP 1438053	A1	20040721	EP 2002-774710	20021014
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005509624	T	20050414	JP 2003-535800	20021014
US 20030171359	A1	20030911	US 2002-271763	20021016
US 7173028	B2	20070206		
US 20060100211	A1	20060511	US 2005-313380	20051221
PRIORITY APPLN. INFO.:			US 2001-330145P	P 20011017
			WO 2002-EP11453	W 20021014
			US 2002-271763	A3 20021016
OTHER SOURCE(S):	MARPAT	138:321292		
GI				



AB Title compds. I [R1 = H, alkyl; R2 = (un)substituted alkyl; R3 = H, alkyl; R4 = (un)substituted alkyl; R5 = halo] and their pharmaceutically acceptable salts were prepared. For example, condensation of thiocyanatopyrimidine II, e.g., prepared from 3,4-dichloroaniline and 2-chloro-4-thiocyanato-5-nitropyrimidine in one step, and acetylaminostethylamine provided trisubstituted pyrimidine III in 88% yield. In CDK1/CyclinB1 kinase inhibition studies, 88-examples of compds. I exhibited IC50 values more than 100 nM. Compds. I are claimed useful for the treatment of diseases characterized by abnormal cell proliferation.


IT 514837-02-6P 514837-04-8P 514837-05-9P
514837-07-1P 514837-09-3P 514837-10-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of trisubstituted pyrimidines as cyclin dependent kinase inhibitors)

RN 514837-02-6 CAPLUS


CN 2-Pyrimidinamine, 4-(4-morpholinyl)-N-[4-[(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]phenyl]-5-(trifluoromethyl)- (CA INDEX NAME)



RN 514837-04-8 CAPLUS


CN 2-Pyrimidinamine, 4-(4-methyl-1-piperazinyl)-N-[4-[(1,2,4,5-tetrahydro-3H-

3-benzazepin-3-yl)methyl]phenyl]-5-(trifluoromethyl)- (CA INDEX NAME)




RN 514837-05-9 CAPLUS

CN 2-Pyrimidinamine, N-[4-[(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]phenyl]-4-(3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(trifluoromethyl)- (CA INDEX NAME)



RN 514837-07-1 CAPLUS


CN β -Alanine, N-[2-[[4-[(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 514837-09-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[trans-4-(dimethylamino)cyclohexyl]-N2-[4-[(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]phenyl]-5-(trifluoromethyl)-, hydrochloride (1:2) (CA INDEX NAME)


Relative stereochemistry.



● 2 HCl

RN 514837-10-6 CAPLUS

CN Acetamide, N-[2-[[2-[[4-[(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]ethyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 31 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:975649 CAPLUS

DOCUMENT NUMBER: 138:55742

TITLE: Preparation of diamines and their use as chemokine receptor CXCR4 antagonists, anti-HIV, anti-AIDS, and antitumor agents

INVENTOR(S): Kamiyama, Keiji; Kanzaki, Naoyuki; Hasuoka, Atsushi; Mochizuki, Manabu; Kawamoto, Tetsuji

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 84 pp.

CODEN: JKXXAF


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002371042	A	20021226	JP 2001-177827	20010612
PRIORITY APPLN. INFO.:			JP 2001-177827	20010612
OTHER SOURCE(S):	MARPAT 138:55742			
GI				



AB Diamines I [R¹, R² = H, alkyl; A = (un)substituted cyclyl; X = bond, alkylene or alkenylene (linked to A via hetero atom); Y = S, O, CONR¹⁵, SO₂NR¹⁶; CO₂, SO, SO₂, NR¹⁷; R¹⁵-R¹⁷ = H, (un)substituted alkyl; AX¹ may form (un)substituted heterocyclyl; l = 2-6; m = 2-4; n = 0-8; when Y = NR¹⁷, then A = (un)substituted aromatic heterocyclyl], their salts, or their prodrugs are prepared by condensation using AXR³ [A, X = same as above; R³ = CO₂H, SO₃H, their reactive derivative, (un)substituted amino, etc.], AX¹(CH₂)₁NHR⁷ (A, X, Y, l = same as above; R⁷ = H, alkyl, protecting group, CHO, leaving group), or AXNH₂ (A, X = same as above). Thus, amidation of tert-Bu 4-aminobutyl[2-[(tert-butoxycarbonyl)(cyclohexyl)amino]ethyl]carbamate with benzenesulfonyl chloride and deprotection gave I (AX¹ = PhSO₂NH, R¹ = R² = H, l = 4, m = 2, n = 3), which at 1 μM inhibited binding of SDF-1α to CXCR4 receptor by 81%.


IT 479027-69-5P 479027-70-8P 479027-71-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diamines as chemokine receptor CXCR4 antagonists for treatment of AIDS and tumor)

RN 479027-69-5 CAPLUS


CN 1H-3-Benzazepine-7-sulfonamide, 3-benzoyl-N-[4-[[2-(cyclohexylamino)ethyl]amino]butyl]-2,3,4,5-tetrahydro-N-methyl-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 479027-70-8 CAPLUS


CN 1H-3-Benzazepine-7-sulfonamide, 3-benzoyl-N-[4-[[2-(cycloheptylamino)ethyl]amino]butyl]-2,3,4,5-tetrahydro-N-methyl-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 479027-71-9 CAPLUS

CN 1H-3-Benzazepine-7-sulfonamide, 3-benzoyl-N-[4-[[2-(cycloheptylmethylamino)ethyl]amino]butyl]-2,3,4,5-tetrahydro-N-methyl-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


IT 479028-42-7P 479028-60-9P, 3-Benzoyl-N-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulfonamide 479028-61-0P, 3-Benzoyl-N-[4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)butyl]-N-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulfonamide 479028-77-8P 479028-78-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of diamines as chemokine receptor CXCR4 antagonists for treatment of AIDS and tumor)

RN 479028-42-7 CAPLUS


CN 1H-3-Benzazepine-7-sulfonamide, N-(4-aminobutyl)-3-benzoyl-2,3,4,5-tetrahydro-N-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 479028-60-9 CAPLUS

CN 1H-3-Benzazepine-7-sulfonamide, 3-benzoyl-2,3,4,5-tetrahydro-N-methyl- (CA INDEX NAME)




RN 479028-61-0 CAPLUS

CN 1H-3-Benzazepine-7-sulfonamide, 3-benzoyl-N-[4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)butyl]-2,3,4,5-tetrahydro-N-methyl- (CA INDEX NAME)




RN 479028-77-8 CAPLUS

CN Carbamic acid, [2-[[[4-[[3-benzoyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)sulfonyl]methylamino]butyl]amino]ethyl]cyclohexyl-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 479028-78-9 CAPLUS

CN 1H-3-Benzazepine-7-sulfonamide, 3-benzoyl-N-(4-chlorobutyl)-2,3,4,5-tetrahydro-N-methyl- (CA INDEX NAME)



L20 ANSWER 32 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:772126 CAPLUS
 DOCUMENT NUMBER: 137:279089
 TITLE: Preparation of indolinone-6-carboxylic acids as
 inhibitors of endothelial cell proliferation
 INVENTOR(S): Roth, Gerald Juerger; Heckel, Armin; Lehmann-Lintz,
 Thorsten; Kley, Joerg; Hilberg, Frank; Van Meel,
 Jacobus
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma KG, Germany
 SOURCE: Ger. Offen., 26 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10117204	A1	20021010	DE 2001-10117204	20010406
CA 2442695	A1	20021017	CA 2002-2442695	20020330
WO 2002081445	A1	20021017	WO 2002-EP3583	20020330
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG			
AU 2002310905	A1	20021021	AU 2002-310905	20020330
EP 1379501	A1	20040114	EP 2002-735201	20020330
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
EE 200300491	A	20040216	EE 2003-491	20020330
HU 2003003737	A2	20040301	HU 2003-3737	20020330
HU 2003003737	A3	20040928		
BR 2002008900	A	20040420	BR 2002-8900	20020330
CN 1509270	A	20040630	CN 2002-809918	20020330
JP 2004525173	T	20040819	JP 2002-579433	20020330
US 20030092756	A1	20030515	US 2002-116365	20020404
US 6858641	B2	20050222		
IN 2003MN00886	A	20050429	IN 2003-MN886	20030917
ZA 2003007306	A	20040831	ZA 2003-7306	20030918
MX 2003PA08896	A	20031208	MX 2003-PA8896	20030930
BG 108220	A	20040930	BG 2003-108220	20031001
NO 2003004434	A	20031003	NO 2003-4434	20031003
PRIORITY APPLN. INFO.:			DE 2001-10117204	A 20010406
			WO 2002-EP3583	W 20020330
OTHER SOURCE(S):	MARPAT 137:279089			
GI				



AB Title compds. [I; X = O, S; R1 = H, prodrug residue; R2 = CO2H, C1-6 alkoxy, carbonyl, C4-7 cycloalkoxy, carbonyl, aryloxy, carbonyl; R3 = H, alkyl, cycloalkyl, CF3, heteroaryl, (substituted) Ph, naphthyl; R4 = (substituted) Ph, furanyl; R5 = H, alkyl], were prepared. Thus, a mixture of 1-acetyl-3-(1-ethoxy-1-phenylmethylene)-6-methoxycarbonyl-2-indolinone (preparation given) and 4-amino-N-(2-dimethylaminoethyl)-N-methylbenzamide (analog preparation given) in DMF was stirred for 4 h at 70° followed by addition of concentrated NH3 and stirring for 30 min at room temperature to

give 24%

3-(Z)-[1-(4-[(2-dimethylaminoethyl)-N-methylcarbamoyl]phenylamino)-1-phenylmethylidene]-2-indolinone-6-carboxylic acid Me ester. The latter inhibited proliferation of human umbilical cord endothelial cells (HUVEC) with IC50 = 0.04 μM. The title compds. were said to inhibit tyrosine kinases and cyclin/CDK complexes as well as the proliferation of different tumor cells.


IT 466694-71-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indolinone-6-carboxylic acids as inhibitors of endothelial cell proliferation)

RN 466694-71-3 CAPLUS

CN 1H-Indole-6-carboxylic acid, 2,3-dihydro-2-oxo-3-[phenyl[[4-[(1,2,4,5-tetrahydro-3H-benzazepin-3-yl)carbonyl]phenylamino]methylene]-, methyl ester, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.




IT 466694-72-4

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of indolinone-6-carboxylic acids as inhibitors of endothelial cell proliferation)

10/598,888

RN 466694-72-4 CAPLUS


CN Methanone, (4-aminophenyl) (1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)- (CA
INDEX NAME)



L20 ANSWER 33 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:575073 CAPLUS
 DOCUMENT NUMBER: 137:140512
 TITLE: Preparation of benzoheterocyclyloxazolidinones as antibacterial agents.
 INVENTOR(S): Johnson, Paul D.; Aristoff, Paul A.; Poel, Toni-Jo; Thomasco, Lisa M.
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
 SOURCE: PCT Int. Appl., 95 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002059115	A1	20020801	WO 2001-US42944	20011114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2421583	A1	20020801	CA 2001-2421583	20011114
AU 2002248133	A1	20020806	AU 2002-248133	20011114
US 20020133021	A1	20020919	US 2001-992660	20011114
US 6972286	B2	20051206		
EP 1337530	A1	20030827	EP 2001-997007	20011114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004517929	T	20040617	JP 2002-559417	20011114
NZ 525918	A	20051125	NZ 2001-525918	20011114
MX 2003PA04380	A	20040126	MX 2003-PA4380	20030516
US 20040176609	A1	20040909	US 2004-804389	20040319
US 20040186293	A1	20040923	US 2004-804380	20040319
PRIORITY APPLN. INFO.:			US 2000-249550P	P 20001117
			US 2001-992660	A3 20011114
			WO 2001-US42944	W 20011114

OTHER SOURCE(S): MARPAT 137:140512
 GI




AB Title compds. [I; Y = NHC(:W)R1, OZ, SZ, NHZ; X = O, NR3, S, SO, SO2, S(O)(NR4); W = O, S; R1 = H, alkyl, cycloalkyl, alkoxy, alkylthio, amino; R2 = H, halo, alkyl; R3 = H, alkyl, aryl, Z, etc.; R4 = H, alkyl; Z = (substituted) (aromatic) heterocyclyl; with provisos], were prepared Thus, N-[(5S)-3-(1,2,3,4-tetrahydro-6-isoquinolinyl)-2-oxo-5-oxazolidinyl]methyl]acetamide (preparation given) and NaHCO3 in THF were treated with MeO2CCl with vigorous stirring. H2O was added and the mixture was stirred 1 h to give Me (-)-6-[(5S)-5-[(acetyl amino)methyl]-2-oxo-3-oxazolidinyl]-3,4-dihydro-2(1H)-isoquinolinecarboxylate. The latter showed a min. inhibitory concentration of 1 µg/mL against Streptococcus pneumoniae SPNE9912.

IT 444587-62-6P 444587-68-2P 444587-71-7P 444587-72-8P 444587-74-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of benzoheterocyclyloxazolidinones as antibacterial agents)

RN 444587-62-6 CAPLUS

CN Acetamide, N-[[(5S)-3-(3-benzoyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 444587-68-2 CAPLUS

CN Acetamide, N-[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-3-(2-phenylacetyl)-1H-3-benzazepin-7-yl]-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 444587-71-7 CAPLUS

CN Acetamide, N-[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-3-[2-(4-iodophenyl)acetyl]-

1H-3-benzazepin-7-yl]-5-oxazolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 444587-72-8 CAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-3-[2-[3-(trifluoromethyl)phenyl]acetyl]-1H-3-benzazepin-7-yl]-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 444587-74-0 CAPLUS

CN Acetamide, N-[[[(5S)-2-oxo-3-[2,3,4,5-tetrahydro-3-[2-[4-(trifluoromethyl)phenyl]acetyl]-1H-3-benzazepin-7-yl]-5-oxazolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

10/598,888



REFERENCE COUNT:

14

THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L20 ANSWER 34 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:171845 CAPLUS
 DOCUMENT NUMBER: 136:232121
 TITLE: Preparation of guanidinobenzamides as melanocortin-4
 receptor agonists useful for treating diseases such
 obesity and type II diabetes
 INVENTOR(S): Renhowe, Paul A.; Chu, Daniel; Boyce, Rustum; Ni,
 Zhi-jie; Duhl, David; Tozzo, Effie; Johnson, Kirk;
 Myles, David
 PATENT ASSIGNEE(S): Chiron Corporation, USA
 SOURCE: PCT Int. Appl., 145 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018327	A2	20020307	WO 2001-US27206	20010831
WO 2002018327	A3	20020808		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2420694	A1	20020307	CA 2001-2420694	20010831
AU 2001088604	A	20020313	AU 2001-88604	20010831
AU 2001288604	A2	20020313	AU 2001-288604	20010831
AU 2001288604	B2	20050224		
US 20020137939	A1	20020926	US 2001-945384	20010831
US 6638927	B2	20031028		
HU 2003002067	A2	20030929	HU 2003-2067	20010831
SI 21267	A	20040229	SI 2001-20058	20010831
BR 2001013643	A	20040302	BR 2001-13643	20010831
JP 2004508304	T	20040318	JP 2002-523445	20010831
EP 1409468	A2	20040421	EP 2001-968352	20010831
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 524897	A	20040827	NZ 2001-524897	20010831
CN 1659156	A	20050824	CN 2001-817718	20010831
ZA 2003001544	A	20040622	ZA 2003-1544	20030225
NO 2003000929	A	20030430	NO 2003-929	20030227
MX 2003PA01813	A	20041101	MX 2003-PA1813	20030228
US 20030199499	A1	20031023	US 2003-379397	20030304
US 6955269	B2	20060207		
BG 107639	A	20031128	BG 2003-107639	20030318
IN 2003KN00343	A	20050311	IN 2003-KN343	20030324
IN 2003KO00215	A	20060929	IN 2003-KO215	20030410
PRIORITY APPLN. INFO.:			US 2000-230565P	P 20000831
			US 2000-245579P	P 20001106
			US 2001-945384	A3 20010831
			WO 2001-US27206	W 20010831


OTHER SOURCE(S):

MARPAT 136:232121

GI



I




II

AB Compds. I and II, e.g. [4-[(1Z)-2-aza-2-cyclopentyl-1-piperazinylvinyl]amino]phenyl]-N-[2-(2,4-dichlorophenyl)ethyl]carboxamide, are new where the variables R1 through R10 have the values set forth below. Such compds. and prodrugs thereof, pharmaceutically acceptable salts thereof, stereoisomers thereof, tautomers thereof, hydrates thereof, hydrides thereof, or solvates thereof, have use in treating diseases such as obesity and type II diabetes, and may be provided as pharmaceutical formulations in conjunction with a pharmaceutically acceptable carrier. In I and II, R1 is H, and substituted and unsubstituted arylalkyl, heteroarylalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, heterocyclalkyl, cycloalkylalkyl, alkenyl, alkynyl, and alkyl groups; R2 is substituted and unsubstituted arylalkyl, heteroarylalkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, heterocyclalkyl, cycloalkylalkyl, alkenyl, alkynyl, and alkyl groups; R3 is substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclalkyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups. R4 is H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups; R5 is substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, and cycloalkylalkyl groups; or R4 and R5, together with the N to which they are bound, form a substituted or unsubstituted heterocyclyl or heteroaryl group; R6, R7, R8, and R9 may be the same or different, and are each independently H, Cl, I, F, Br, OH, NH2, CN, NO2, and substituted and unsubstituted alkoxy, amino, alkyl, alkenyl, alkynyl, alkylamino, dialkylamino, cycloalkyl, heterocyclalkylamino, heteroarylalkylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, cycloalkylaminocarbonyl, arylaminocarbonyl, heterocyclalkylaminocarbonyl, and heteroarylaminocarbonyl groups; R10 is H, and substituted and unsubstituted alkyl, alkenyl, alkynyl, cycloalkylalkyl, aryl, and

arylalkyl groups. Although the methods of preparation are not claimed, .apprx.60 example preps., involving resin- and non-resin-based methods, are included. EC50 values of test compds. were determined by treating cells expressing MC4-R with test compound and lyzing the cells and measuring intercellular cAMP concentration with Amersham-Pharmacia RPA-559 cAMP Scintillation Proximity Assay (SPA) kit. Compds. listed displayed -log EC50 values .gtorsim.3. In vivo studies were conducted using mice to observe the effect of MC4-R agonists on energy intake, body weight, hyperinsulinemia, and glucose levels; results are given for 4-[(N-cyclohexyl-3,5-dimethylpiperazine-1-carboximidoyl)amino]-N-[2-(2,4-dichlorophenyl)ethyl]benzamide.


- IT 402832-78-4P, (4-Azidophenyl) (7-methoxy-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl)methanone
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of guanidinobenzamides as melanocortin-4 receptor agonists useful for treating diseases such obesity and type II diabetes)
- RN 402832-78-4 CAPLUS
- CN Methanone, (4-azidophenyl) (1,2,4,5-tetrahydro-7-methoxy-3H-3-benzazepin-3-yl)- (CA INDEX NAME)



L20 ANSWER 35 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:31420 CAPLUS
 DOCUMENT NUMBER: 136:85815
 TITLE: Preparation of 2,3,4,5-tetrahydro-1H-3-benzazepine derivatives as GPR14 antagonists
 INVENTOR(S): Tarui, Naoki; Santo, Takashi; Watanabe, Hiroyuki; Aso, Kazuyoshi; Ishihara, Yuji
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: PCT Int. Appl., 217 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002530	A1	20020110	WO 2001-JP5784	20010704
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2414976	A1	20020110	CA 2001-2414976	20010704
AU 2001071018	A	20020114	AU 2001-71018	20010704
JP 2002097142	A	20020402	JP 2001-203519	20010704
EP 1310490	A1	20030514	EP 2001-949909	20010704
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20040063699	A1	20040401	US 2003-332023	20030102
PRIORITY APPLN. INFO.:			JP 2000-206865	A 20000704
			WO 2001-JP5784	W 20010704

OTHER SOURCE(S): MARPAT 136:85815
 GI



AB A G-protein-coupled receptor (GPR14) antagonist comprises compds. represented by the formula (I) or a salt thereof (wherein Ar represents optionally substituted aryl; X represents a spacer consisting of 1-4 atoms in the straight chain moiety; n is an integer of 1 to 10; R represents hydrogen or an optionally substituted hydrocarbon group, provided that R may be bonded to the substituent of Ar to form a ring; and Y represents optionally substituted amino or N-containing heterocyclyl). These compds. are antagonists of orphan receptor GPR14 protein (urotensin II receptor) and are useful as inhibitors of vasoconstriction for the prevention or treatment of hypertension, arteriosclerosis, cardiac hypertrophy,

myocardial infarction, or heart failure. Thus, a mixture of 4-bromo-1-[3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-1-butanone, 1-phenylpiperazine, K₂CO₃, and DMF was stirred at 80° for 2 h, followed by treatment of the product with a mixture of 1 M aqueous KOH and methanol and then with 1 N HCl/EtOAc to give 4-(4-phenyl-1-piperazinyl)-1-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-butanone trihydrochloride (II). N-(2-{4-[bis(4-fluorophenyl)methyl]piperazin-1-yl}ethyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7-carboxamide trihydrochloride in vitro showed IC₅₀ of 1.7 nM for inhibiting the binding of [125I]urotensin to human GPR14. A capsule and a tablet formulation containing II were prepared

IT 387875-88-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tetrahydrobenzazepine derivs. as GPR14 antagonists and vasoconstriction inhibitors for treatment and prevention of hypertension, arteriosclerosis, cardiac hypertrophy, myocardial infarction, or heart failure)


RN 387875-88-9 CAPLUS

CN 1-Butanone, 4-[4-(diphenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 387875-87-8

CMF C38 H43 N3 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2





REFERENCE COUNT:

10

THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 36 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:851111 CAPLUS
 DOCUMENT NUMBER: 136:5926
 TITLE: Preparation of benzoaromatic derivatives as melanin
 concentrating hormone antagonists
 INVENTOR(S): Ishihara, Yuji; Terauchi, Jun; Suzuki, Nobuhiro;
 Takekawa, Shiro; Aso, Kazuyoshi
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: PCT Int. Appl., 285 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001087834	A1	20011122	WO 2001-JP4015	20010515
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2408913	A1	20011122	CA 2001-2408913	20010515
JP 2002371059	A	20021226	JP 2001-145691	20010515
EP 1283199	A1	20030212	EP 2001-930132	20010515
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20030158177	A1	20030821	US 2002-276288	20021112
US 7229986	B2	20070612		
PRIORITY APPLN. INFO.:			JP 2000-148647	A 20000516
			JP 2001-116219	A 20010413
			WO 2001-JP4015	W 20010515
OTHER SOURCE(S):	MARPAT	136:5926		
GI				




AB Title compds. [I; R = H, halo, cyclic; X = bond, spacer containing a chain with one to six atoms; Y = spacer with one to six atoms; A = benzene; B = 5-9 membered nitrogen containing nonarom. heterocycle; R1 = H, hydrocarbon, heterocycle; R2 = H, hydrocarbon, heterocycle; R1R2 = nitrogen containing heterocycle; YR2 = nitrogenous heterocycle], melanin-concentrating hormone antagonist, which contains a compound represented by the formula or a salt thereof are prepared useful as prevention or remedy for adiposity, diabetes, or high blood pressure. Thus, the title compound II was prepared and biol. tested.

IT 374809-83-3P 374809-84-4P 374809-85-5P
374809-89-9P 374809-90-2P 374809-91-3P
374812-84-7P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzoarom. derivs. as melanin concentrating hormone antagonists)


RN 374809-83-3 CAPLUS

CN 1,4-Butanedione, 1-(4-(4-chlorophenyl)-1-piperidiny)-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 374809-84-4 CAPLUS


CN 1,4-Butanedione, 1-(3-benzoyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-[4-(4-chlorophenyl)-1-piperidiny]- (CA INDEX NAME)




RN 374809-85-5 CAPLUS
 CN 1,4-Butanedione, 1-[4-(4-chlorophenyl)-1-piperidinyl]-4-[2,3,4,5-tetrahydro-3-(2-oxo-2-phenylethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 374809-89-9 CAPLUS
 CN 1,4-Butanedione, 1-[4-(4-chlorophenyl)-1-piperidinyl]-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 374809-90-2 CAPLUS
 CN 1,4-Butanedione, 1-[4-(4-chlorophenyl)-1-piperidinyl]-4-[2,3,4,5-tetrahydro-3-[(3-methylphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 374809-91-3 CAPLUS
 CN 1,4-Butanedione, 1-[4-(4-chlorophenyl)-1-piperidinyl]-4-[2,3,4,5-

tetrahydro-3-[(4-methylphenyl)methyl]-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 374812-84-7 CAPLUS

CN 1H-3-Benzazepine, 7-[3-[4-(4-chlorophenyl)-1-piperidinyl]propoxy]-2,3,4,5-tetrahydro-3-(phenylmethyl)- (CA INDEX NAME)



REFERENCE COUNT:

531

THERE ARE 531 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 37 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:603494 CAPLUS

DOCUMENT NUMBER: 135:190842

TITLE: Melanin-concentrating hormone antagonists

INVENTOR(S): Ishihara, Yuji; Suzuki, Nobuhiro; Takekawa, Shiro

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: Jpn. Kokai Tokyo Koho, 88 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001226269	A	20010821	JP 2000-46827	20000218
PRIORITY APPLN. INFO.:			JP 2000-46827	20000218

OTHER SOURCE(S): MARPAT 135:190842

AB Provided are melanin-concentrating hormone antagonists for preventing and treating obesity, diabetes, diabetic complications, atherosclerosis, or rheumatoid arthritis; and for use as appetite inhibitor. The melanin-concentrating hormone antagonists are novel piperidine derivs. The MCH antagonists comprise formula I [i.e. Ar-X1-X4-C5H9N-X2-C6H4-X3-R2], where Ar is a substituted group-containing aromatic ring, X1 is a substituted group-containing divalent main chain of 1-5 atoms, X2, X3 and X4 are linking arms, and R2 is a basic substituting group, and its salts.

IT 122844-73-9P 215045-14-0P 215045-20-8P
 265101-77-7P 265101-78-8P 265101-79-9P
 265101-83-5P 265101-86-8P 265101-88-0P
 265101-95-9P 265101-97-1P 265102-00-9P
 265102-03-2P 265102-16-7P 265102-21-4P
 265102-24-7P 265102-26-9P 265102-29-2P
 265102-57-6P 265102-58-7P 265102-59-8P
 265102-60-1P 355396-28-0P 355396-48-4P


RL: ANT (Analyte); SPN (Synthetic preparation); THU (Therapeutic use);

ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(melanin-concentrating hormone antagonists preventing and treating obesity, diabetes, diabetic complications, atherosclerosis, or rheumatoid arthritis; and for use as appetite inhibitor)


RN 122844-73-9 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-(phenylmethyl)- (CA INDEX NAME)




RN 215045-14-0 CAPLUS

CN Benzenecarboximidamide, 3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]- (CA INDEX NAME)




RN 215045-20-8 CAPLUS
 CN 1-Butanone, 4-[1-[[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl


RN 265101-77-7 CAPLUS
 CN 1H-3-Benzazepin-7-ol, 2,3,4,5-tetrahydro-3-(phenylmethyl)- (CA INDEX NAME)



RN 265101-78-8 CAPLUS
 CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-[(2-methylphenyl)methyl]- (CA INDEX NAME)




RN 265101-79-9 CAPLUS
 CN 1H-3-Benzazepin-7-ol, 2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]- (CA INDEX NAME)




RN 265101-83-5 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-7-[2-(4-piperidinyl)ethoxy]- (CA INDEX NAME)




RN 265101-86-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-[[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]oxy]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 265101-88-0 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[3-(4-piperidinyl)propoxy]- (CA INDEX NAME)




RN 265101-95-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-[[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]oxy]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 265101-97-1 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-7-[3-(4-piperidinyl)propoxy]- (CA INDEX NAME)




RN 265102-00-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]oxy]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 265102-03-2 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[2-(4-piperidinyl)ethoxy]- (CA INDEX NAME)




RN 265102-16-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]thio]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 265102-21-4 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[[2-(4-piperidinyl)ethyl]thio]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 265102-24-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]sulfinyl]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 265102-26-9 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[[2-(4-piperidinyl)ethyl]sulfinyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 265102-29-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]sulfonyl]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 265102-57-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-[[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]sulfonyl]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 265102-58-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-[[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]sulfonyl]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 265102-59-8 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[[3-(4-piperidinyl)propylsulfonyl]- (CA INDEX NAME)




RN 265102-60-1 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-7-[[3-(4-piperidinyl)propylsulfonyl]- (CA INDEX NAME)



RN 355396-28-0 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]oxy]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 355396-48-4 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[[2-(4-piperidinyl)ethylsulfonyl]- (CA INDEX NAME)

10/598,888



L20 ANSWER 38 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:283924 CAPLUS
 DOCUMENT NUMBER: 134:295737
 TITLE: Preparation of 3-aminomethylene-2-indolinones as
 kinase and cyclin/CDK complex inhibitors
 INVENTOR(S): Roth, Gerald Juergen; Heckel, Armin; Walter, Rainer;
 Meel Van, Jacobus; Redemann, Norbert; Schnapp, Gisela;
 Tontsch-Grunt, Ulrike; Spevak, Walter
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
 SOURCE: PCT Int. Appl., 102 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001027080	A2	20010419	WO 2000-EP9847	20001007
WO 2001027080	A3	20011122		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
DE 19949209	A1	20010419	DE 1999-19949209	19991013
EP 1224169	A2	20020724	EP 2000-966136	20001007
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
PRIORITY APPLN. INFO.:			DE 1999-19949209	A 19991013
			WO 2000-EP9847	W 20001007
OTHER SOURCE(S):	MARPAT 134:295737			
GI				



I

AB Title compds. [I; R1 = H or prodrug residue (sic); R2 = OH, (phenyl)alkoxy, (un)esterified P(O)(OH)2, -SO3H, (un)substituted SO2NH2, etc.; R3 = H, (cyclo) alkyl, (un)substituted Ph, etc.; R4 = (un)substituted Ph, alkoxy, (oxo)cycloalkyleneimino, etc.; R5 = H or alkyl; X = O or S] were prepared. Thus, 5-methoxy-2-indolinone was treated with with PhC(OEt)3/Ac2O and the product aminated by 4-(piperidinomethyl)aniline to give I [R1 = Ac, R2 = OMe, R3 = Ph, R4 =


4-(piperidinomethyl)anilino, X = O]. Data for biol. activity of I were given.

IT 334953-63-8P 334953-81-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 3-aminomethylene-2-indolinones as kinase and cyclin/CDK complex inhibitors)

RN 334953-63-8 CAPLUS

CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-N-phenyl-3-[phenyl[[4-[(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]phenyl]amino]methylene]-, (3Z)-(CA INDEX NAME)


Double bond geometry as shown.



RN 334953-81-0 CAPLUS

CN 1H-Indole-5-carbonitrile, 2,3-dihydro-2-oxo-3-[phenyl[[4-[(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]phenyl]amino]methylene]-, (3Z)-(CA INDEX NAME)

Double bond geometry as shown.




IT 251552-47-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of 3-aminomethylene-2-indolinones as kinase and cyclin/CDK complex inhibitors)

RN 251552-47-3 CAPLUS

CN Benzenamine, 4-[(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]- (CA INDEX NAME)

10/598,888



L20 ANSWER 39 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:844935 CAPLUS

DOCUMENT NUMBER: 134:100755

TITLE: Novel 2,3,4,5-tetrahydro-1H-3-benzazepines with high affinity and selectivity for the dopamine D3 receptor

AUTHOR(S): Austin, Nigel E.; Avenell, Kim Y.; Boyfield, Izzy; Branch, Clive L.; Hadley, Michael S.; Jeffrey, Phillip; Johnson, Christopher N.; Macdonald, Gregor J.; Nash, David J.; Riley, Graham J.; Smith, Alexander B.; Stemp, Geoffrey; Thewlis, Kevin M.; Vong, Antonio K. K.; Wood, Martyn

CORPORATE SOURCE: SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Essex, CM19 5AW, UK

SOURCE: Bioorganic & Medicinal Chemistry Letters (2000), 10(22), 2553-2555

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 134:100755

AB Starting from the dopamine D3 receptor antagonist SB-277011, a series of 2,3,4,5-tetrahydro-1H-3-benzazepines was identified with high affinity for the dopamine D3 receptor and selectivity over the D2 receptor. A 3-acetamido-2-fluorocinnamide derivative gave high D3 receptor affinity (pKi 8.4) with 130-fold selectivity over the D2 receptor.

IT 264262-59-1P 264262-62-6P 264262-63-7P

264262-64-8P 264262-84-2P 264262-86-4P

264262-88-6P 264262-90-0P 264262-97-7P

320349-84-6P 320349-85-7P 320349-86-8P

320349-87-9P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and dopamine D3 antagonistic activity of tetrahydrobenzazepines)

RN 264262-59-1 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(4-fluorophenyl)-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 264262-62-6 CAPLUS

CN 5-Quinolincarboxamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-

benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 264262-63-7 CAPLUS

CN 2-Propenamide, 3-[3-(acetylamino)phenyl]-N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 264262-64-8 CAPLUS

CN 2H-1,4-Benzoxazine-6-carboxamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3,4-dihydro-3-oxo- (CA INDEX NAME)

Relative stereochemistry.




RN 264262-84-2 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-

yl)ethyl]cyclohexyl]-3-(3-fluorophenyl)-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 264262-86-4 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(2-fluorophenyl)-, (2E)- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 264262-88-6 CAPLUS

CN 2-Naphthalenecarboxamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 264262-90-0 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(3-methoxyphenyl)-, (2E)- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 264262-97-7 CAPLUS

CN 7-Quinolinecarboxamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-1,2-dihydro-2-oxo- (CA INDEX NAME)


Relative stereochemistry.



RN 320349-84-6 CAPLUS

CN 4-Quinolinecarboxamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 320349-85-7 CAPLUS

CN 1-Naphthalenecarboxamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-

10/598,888

benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 320349-86-8 CAPLUS

CN 1H-Indole-2-carboxamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 320349-87-9 CAPLUS

CN 2-Propenamide, 3-(3-acetylphenyl)-N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



IT 264264-27-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and dopamine D3 antagonistic activity of

10/598,888


tetrahydrobenzazepines)
RN 264264-27-9 CAPLUS
CN 1H-3-Benzazepine-7-carbonitrile, 3-[2-(trans-4-aminocyclohexyl)ethyl]-
2,3,4,5-tetrahydro- (CA INDEX NAME)

Relative stereochemistry.



IT 320349-88-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of tetrahydrobenzazepines as D3-selective dopamine antagonists)
RN 320349-88-0 CAPLUS
CN 2-Propenamide, 3-[3-(acetylamino)-2-fluorophenyl]-N-[trans-4-[2-(7'-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 40 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2000:841864 CAPLUS
 DOCUMENT NUMBER: 134:17397
 TITLE: Preparation of 3-aminomethylene-2-indolinonecarboxylates as cell proliferation inhibitors
 INVENTOR(S): Heckel, Armin; Walter, Rainer; Roth, Gerald; Vann Meel, Jacobus; Redemann, Norbert; Tontsch-Grunt, Ulrike; Spevak, Walter
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
 SOURCE: Ger. Offen., 28 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19924401	A1	20001130	DE 1999-19924401	19990527
WO 2000073297	A1	20001207	WO 2000-EP4685	20000523

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: DE 1999-19924401 A 19990527
 OTHER SOURCE(S): CASREACT 134:17397; MARPAT 134:17397
 GI




- AB Title compds. [I; R1 = H, alkanoyl, alkoxy carbonyl; R2 = (un)substituted (di)alkylaminocarbonyl; X1 = CR3NR4R5; R3 = H, alkyl, (un)substituted Ph, etc.; R4 = alkyl, (un)substituted Ph, etc.; R5 = H or (un)substituted alkyl; X2 = O or S], inhibitors of cyclin-dependant kinases, were prepared. Thus, Me 1-acetyl-2-indolinone-5-carboxylate was condensed with BuC(OEt)3 to give I (R2 = 5-COR, X2 = O) (II; R = OMe, R1 = Ac, X1 = CBuOEt). Similarly prepared II (X1 = CPhOEt) was aminated by 4-(H2N)C6H4CH2NMeCH2Ph and the saponified product amidated by PhCH2NHMe to give II [R = PhCH2NMe, R1 = H, X1 = CPhNHC6H4(CH2NMeCH2Ph)-4]. Data for biol. activity of I were given.
- II 251552-79-1P 251552-85-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 3-aminomethylene-2-indolinonecarboxylates as cell proliferation inhibitors)

RN 251552-79-1 CAPLUS

CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-2-oxo-3-[1-[[4-[(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]phenyl]amino]ethyldene]-, methyl ester, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 251552-85-9 CAPLUS


CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-2-oxo-3-[1-[[4-[(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]phenyl]amino]ethyldene]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



L20 ANSWER 41 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2000:277975 CAPLUS
 DOCUMENT NUMBER: 132:308254
 TITLE: Preparation of heterocyclic compounds as thermogenesis accelerators
 INVENTOR(S): Ishihara, Yuji; Fujisawa, Yukio; Furuyama, Naoki; Ishichi, Yuji; Sasaki, Mitsuru
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: PCT Int. Appl., 260 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000023437	A1	20000427	WO 1999-JP5705	19991015
W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2347095	A1	20000427	CA 1999-2347095	19991015
AU 9961236	A1	20000508	AU 1999-61236	19991015
JP 2000186088	A	20000704	JP 1999-293493	19991015
JP 2000186091	A	20000704	JP 1999-293649	19991015
EP 1122252	A1	20010808	EP 1999-947923	19991015
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRIORITY APPLN. INFO.:			JP 1998-295213	A 19981016
			JP 1998-295488	A 19981016
			WO 1999-JP5705	W 19991015
OTHER SOURCE(S):		MARPAT 132:308254		
GI				



AB The title compds. I [T1 = (CH₂)_k; T2 = (CH₂)_m; T3 = (CHR)_n; A is a benzene ring which may be further substituted; L is O, S or the like; n is an integer of 0 to 6; R is hydrogen, optionally substituted hydrocarbyl, or the like; R1 is optionally substituted hydrocarbyl, etc.; R2 is hydrogen, acyl or the like; X is O, S, etc.; and k and m are each independently a number of 0 to 5 and satisfy the relationship: 1 < k + m < 5] are prepared I are useful in the treatment of obesity. The concentration of cAMP in fat cells


in the presence of 7-[2-[1-(phenylmethyl)-4-piperidiny]ethoxy]-3-(phenylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepine dihydrochloride (10-6 M) was 46.7 pmol/mL, vs. 2.7 pmol/mL in control fat cells. (Thermogenesis is increased when the concentration of cAMP in fat cells is increased). Formulations are given.

IT 265099-52-3P 265099-53-4P 265099-54-5P
 265099-55-6P 265099-58-9P 265099-59-0P
 265099-60-3P 265099-61-4P 265099-66-9P
 265099-67-0P 265099-68-1P 265099-69-2P
 265099-70-5P 265099-77-2P 265099-78-3P
 265099-79-4P 265099-80-7P 265099-83-0P
 265099-84-1P 265100-11-6P 265100-12-7P
 265100-13-8P 265100-16-1P 265100-19-4P
 265100-22-9P 265100-24-1P 265100-26-3P
 265100-28-5P 265100-29-6P 265100-30-9P
 265100-31-0P 265100-33-2P 265100-35-4P
 265100-37-6P 265100-39-8P 265100-40-1P
 265100-41-2P 265100-42-3P 265100-43-4P
 265100-44-5P 265100-47-8P 265100-48-9P
 265100-51-4P 265100-52-5P 265100-53-6P
 265100-54-7P 265100-55-8P 265100-56-9P
 265100-69-4P 265100-70-7P 265100-71-8P
 265100-72-9P 265100-73-0P 265100-74-1P
 265100-75-2P 265100-77-4P 265100-79-6P
 265100-81-0P 265100-82-1P 265100-84-3P
 265100-86-5P 265100-87-6P 265101-38-0P
 265101-39-1P 265101-40-4P 265101-41-5P
 265101-42-6P 265101-43-7P 265101-44-8P
 265101-45-9P 265101-46-0P 265101-47-1P
 265101-48-2P 265101-49-3P 265101-50-6P
 265101-51-7P 265101-52-8P 265101-53-9P
 265101-68-6P 265101-71-1P 265101-72-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of heterocyclic compds. as thermogenesis accelerators)


RN 265099-52-3 CAPLUS

CN 1H-3-Benzazepine, 7-[2-[1-[(2-chlorophenyl)methyl]-4-piperidiny]ethoxy]-2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]- (CA INDEX NAME)



RN 265099-53-4 CAPLUS


CN 1H-3-Benzazepine, 7-[2-[1-[(2-chlorophenyl)methyl]-4-piperidiny]ethoxy]-2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 265099-54-5 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[3-[1-(phenylmethyl)-4-piperidinyl]propoxy]- (CA INDEX NAME)



RN 265099-55-6 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[3-[1-(phenylmethyl)-4-piperidinyl]propoxy]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 265099-58-9 CAPLUS

CN 1H-3-Benzazepine, 7-[3-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]propoxy]-2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]- (CA INDEX NAME)



RN 265099-59-0 CAPLUS


CN 1H-3-Benzazepine, 7-[3-[1-[(2-chlorophenyl)methyl]-4-piperidiny]propoxy]-2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 265099-60-3 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[2-[1-(phenylmethyl)-4-piperidiny]ethoxy]- (CA INDEX NAME)



RN 265099-61-4 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[2-[1-(phenylmethyl)-4-piperidiny]ethoxy]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 265099-66-9 CAPLUS


CN 1H-3-Benzazepine-7-methanol, α-[2-[1-[(3-chlorophenyl)methyl]-4-piperidiny]ethyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)- (CA INDEX NAME)



RN 265099-67-0 CAPLUS
 CN 1H-3-Benzazepine-7-methanol, 2,3,4,5-tetrahydro-3-(phenylmethyl)- α -[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)




RN 265099-68-1 CAPLUS
 CN 1H-3-Benzazepine-7-methanol, 2,3,4,5-tetrahydro-3-(phenylmethyl)- α -[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 265099-69-2 CAPLUS
 CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[3-[1-(phenylmethyl)-4-piperidinyl]propyl]- (CA INDEX NAME)



RN 265099-70-5 CAPLUS
 CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[3-[1-(phenylmethyl)-4-piperidinyl]propyl]-, hydrochloride (1:2) (CA INDEX NAME)

10/598,888

NAME)




● 2 HCl

RN 265099-77-2 CAPLUS

CN 1H-3-Benzazepine-7-methanol, 3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-
 α -[2-[1-[(4-methoxyphenyl)methyl]-4-piperidinyl]ethyl]- (CA INDEX
 NAME)

PAGE 1-A




PAGE 1-B

— OMe

RN 265099-78-3 CAPLUS

CN 1H-3-Benzazepine-7-methanol, 3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-
 α -[2-[1-[(4-methoxyphenyl)methyl]-4-piperidinyl]ethyl]-,
 hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A




● 2 HCl

PAGE 1-B

— OMe

RN 265099-79-4 CAPLUS
 CN 1H-3-Benzazepine-7-methanol, α -[2-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]ethyl]-3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— Cl

RN 265099-80-7 CAPLUS
 CN 1H-3-Benzazepine-7-methanol, α -[2-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]ethyl]-3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A




● 2 HCl

PAGE 1-B

C1


RN 265099-83-0 CAPLUS

CN 1H-3-Benzazepine, 7-[3-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]propyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)- (CA INDEX NAME)



RN 265099-84-1 CAPLUS


CN 1H-3-Benzazepine, 7-[3-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]propyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 265100-11-6 CAPLUS


CN 1H-3-Benzazepine-7-methanol, α-[2-(1-ethyl-4-piperidinyl)ethyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)- (CA INDEX NAME)




RN 265100-12-7 CAPLUS

CN 1H-3-Benzazepine-7-methanol, 2,3,4,5-tetrahydro-3-(phenylmethyl)- α -[2-(1-propyl-4-piperidinyl)ethyl]- (CA INDEX NAME)

RN 265100-13-8 CAPLUS


CN 1H-3-Benzazepine-7-methanol, 2,3,4,5-tetrahydro- α -[2-[1-(1-methylethyl)-4-piperidinyl]ethyl]-3-(phenylmethyl)- (CA INDEX NAME)

RN 265100-16-1 CAPLUS

CN 1H-3-Benzazepine-7-methanol, α -[2-(1-butyl-4-piperidinyl)ethyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)- (CA INDEX NAME)

RN 265100-19-4 CAPLUS


CN 1H-3-Benzazepine-7-methanol, α -[2-(1-butyl-4-piperidinyl)ethyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 265100-22-9 CAPLUS


CN Ethanone, 1-[4-[3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-1-piperidinyll]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 265100-24-1 CAPLUS

CN Ethanone, 1-[4-[3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-1-piperidinyll]- (CA INDEX NAME)




RN 265100-26-3 CAPLUS

CN 1-Piperidineacetic acid, 4-[3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-, ethyl ester (CA INDEX NAME)



RN 265100-28-5 CAPLUS


CN 1-Piperidineacetic acid, 4-[3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-, ethyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 265100-29-6 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[[2-[1-(phenylmethyl)-4-piperidiny]ethyl]thio]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 265100-30-9 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[[2-[1-(phenylmethyl)-4-piperidiny]ethyl]thio]- (CA INDEX NAME)




RN 265100-31-0 CAPLUS

CN 1H-3-Benzazepine, 7-[[2-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]ethyl]thio]-2,3,4,5-tetrahydro-3-(phenylmethyl)- (CA INDEX NAME)



RN 265100-33-2 CAPLUS


CN 1H-3-Benzazepine, 7-[[2-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]ethyl]thio]-2,3,4,5-tetrahydro-3-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 265100-35-4 CAPLUS


CN 1H-3-Benzazepine, 7-[[2-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]ethyl]sulfinyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 265100-37-6 CAPLUS

CN 1H-3-Benzazepine, 7-[[2-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]ethyl]sulfinyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)- (CA INDEX NAME)




RN 265100-39-8 CAPLUS

CN 1H-3-Benzazepine, 7-[[2-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]ethyl]sulfinyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)- (CA INDEX NAME)



RN 265100-40-1 CAPLUS


CN 1H-3-Benzazepine, 7-[[2-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]ethyl]sulfinyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 265100-41-2 CAPLUS


CN 1H-3-Benzazepine, 7-[[2-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]ethyl]sulfonyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 265100-42-3 CAPLUS

CN 1H-3-Benzazepine, 7-[[2-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]ethyl]sulfonyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)- (CA INDEX NAME)




RN 265100-43-4 CAPLUS

CN 1H-3-Benzazepine, 7-[[2-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]ethyl]sulfonyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)- (CA INDEX NAME)



RN 265100-44-5 CAPLUS


CN 1H-3-Benzazepine, 7-[[2-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]ethyl]sulfonyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 265100-47-8 CAPLUS

CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-3-(phenylmethyl)-N-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 265100-48-9 CAPLUS


CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-3-(phenylmethyl)-N-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 265100-51-4 CAPLUS


CN 1H-3-Benzazepine-7-methanol, 2,3,4,5-tetrahydro- α -methyl-3-(phenylmethyl)- α -[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 265100-52-5 CAPLUS

CN 1H-3-Benzazepine-7-methanol, 2,3,4,5-tetrahydro- α -methyl-3-(phenylmethyl)- α -[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)




RN 265100-53-6 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, oxime (CA INDEX NAME)




RN 265100-54-7 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrazone (CA INDEX NAME)




RN 265100-55-8 CAPLUS

CN Propanedinitrile, 2-[3-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propylidene]- (CA INDEX NAME)



RN 265100-56-9 CAPLUS


CN Propanedinitrile, 2-[3-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propylidene]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 265100-69-4 CAPLUS


CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrazone, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 265100-70-7 CAPLUS


CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-3-[(3-methylphenyl)methyl]-N-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 265100-71-8 CAPLUS

CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-3-[(3-methylphenyl)methyl]-N-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (CA INDEX NAME)




RN 265100-72-9 CAPLUS

CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-3-[(4-methylphenyl)methyl]-N-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 265100-73-0 CAPLUS


CN 1H-3-Benzazepine, 7-[[2-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]ethyl]thio]-2,3,4,5-tetrahydro-3-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 265100-74-1 CAPLUS

CN 1H-3-Benzazepine, 7-[[2-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]ethyl]thio]-2,3,4,5-tetrahydro-3-(phenylmethyl)- (CA INDEX NAME)




RN 265100-75-2 CAPLUS

CN 1H-3-Benzazepine, 7-[[2-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]ethyl]thio]-2,3,4,5-tetrahydro-3-(phenylmethyl)- (CA INDEX NAME)



RN 265100-77-4 CAPLUS


CN 1H-3-Benzazepine, 7-[[2-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]ethyl]thio]-2,3,4,5-tetrahydro-3-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 265100-79-6 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]sulfinyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 265100-81-0 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]sulfinyl]- (CA INDEX NAME)




RN 265100-82-1 CAPLUS

CN 1H-3-Benzazepine, 7-[[2-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]ethyl]sulfinyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)- (CA INDEX NAME)



RN 265100-84-3 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]sulfonyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 265100-86-5 CAPLUS


CN 1H-3-Benzazepine, 7-[[2-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]ethyl]sulfonyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 265100-87-6 CAPLUS

CN 1H-3-Benzazepine, 7-[[2-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]ethyl]sulfonyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)- (CA INDEX NAME)




RN 265101-38-0 CAPLUS
 CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[[3-[1-(phenylmethyl)-4-piperidiny]propylsulfonyl]-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 265101-39-1 CAPLUS
 CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[[3-[1-(phenylmethyl)-4-piperidiny]propylsulfonyl]- (CA INDEX NAME)




RN 265101-40-4 CAPLUS
 CN 1H-3-Benzazepine, 7-[[3-[1-[(2-chlorophenyl)methyl]-4-piperidiny]propylsulfonyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)- (CA INDEX NAME)



RN 265101-41-5 CAPLUS
 CN 1H-3-Benzazepine, 7-[[3-[1-[(2-chlorophenyl)methyl]-4-


piperidinyl]propyl]sulfonyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)-,
hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 265101-42-6 CAPLUS


CN 1H-3-Benzazepine, 7-[[3-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]propyl]sulfonyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)-,
hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 265101-43-7 CAPLUS

CN 1H-3-Benzazepine, 7-[[3-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]propyl]sulfonyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)- (CA
INDEX NAME)




RN 265101-44-8 CAPLUS

CN 1H-3-Benzazepine, 7-[[3-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]propyl]sulfonyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)- (CA
INDEX NAME)



RN 265101-45-9 CAPLUS


CN 1H-3-Benzazepine, 7-[[3-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]propyl]sulfonyl]-2,3,4,5-tetrahydro-3-(phenylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 265101-46-0 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-7-[[3-[1-(phenylmethyl)-4-piperidinyl]propyl]sulfonyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 265101-47-1 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-7-[[3-[1-(phenylmethyl)-4-piperidinyl]propyl]sulfonyl]- (CA INDEX NAME)




RN 265101-48-2 CAPLUS

CN 1H-3-Benzazepine, 7-[[3-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]propyl]sulfonyl]-2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-
(CA INDEX NAME)



RN 265101-49-3 CAPLUS


CN 1H-3-Benzazepine, 7-[[3-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]propyl]sulfonyl]-2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-
, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 265101-50-6 CAPLUS


CN 1H-3-Benzazepine, 7-[[3-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]propyl]sulfonyl]-2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-
, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 265101-51-7 CAPLUS

CN 1H-3-Benzazepine, 7-[[3-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]propyl]sulfonyl]-2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]- (CA INDEX NAME)




RN 265101-52-8 CAPLUS

CN Methanone, phenyl[4-[2-[[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]oxy]ethyl]-1-piperidinyl]- (CA INDEX NAME)



RN 265101-53-9 CAPLUS


CN Methanone, phenyl[4-[2-[[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]oxy]ethyl]-1-piperidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 265101-68-6 CAPLUS

CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-3-(phenylmethyl)-N-[[1-(phenylmethyl)-4-piperidiny]amino]carbonyl]- (CA INDEX NAME)




RN 265101-71-1 CAPLUS

CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N-[imino[[1-(phenylmethyl)-4-piperidiny]amino]methyl]-3-(phenylmethyl)- (CA INDEX NAME)



RN 265101-72-2 CAPLUS

CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N-[imino[[1-(phenylmethyl)-4-piperidiny]amino]methyl]-3-[(2-methylphenyl)methyl]- (CA INDEX NAME)



IT 215039-82-0 215039-92-2 215040-17-8

215040-21-4 215041-68-2 215047-91-9

265102-81-6 265102-82-7 265102-83-8


265102-84-9 265102-85-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of heterocyclic compds. as thermogenesis accelerators)


RN 215039-82-0 CAPLUS

CN 1-Propanone, 3-(4-piperidiny1)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 215039-92-2 CAPLUS

CN 1-Propanone, 3-[1-[(3-chlorophenyl)methyl]-4-piperidiny1]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215040-17-8 CAPLUS

CN 1-Propanone, 1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-[1-[(4-methoxyphenyl)methyl]-4-piperidiny1]- (CA INDEX NAME)




PAGE 1-B

—OMe


RN 215040-21-4 CAPLUS

CN 1-Propanone, 3-[1-[(4-chlorophenyl)methyl]-4-piperidiny1]-1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 215041-68-2 CAPLUS

CN 1-Butanone, 4-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 215047-91-9 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 265102-81-6 CAPLUS

CN 1-Propanone, 3-(1-ethyl-4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 265102-82-7 CAPLUS

CN 1-Propanone, 3-(1-propyl-4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 265102-83-8 CAPLUS

CN 1-Propanone, 3-[1-(1-methylethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 265102-84-9 CAPLUS

CN 1-Propanone, 3-(1-butyl-4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 265102-85-0 CAPLUS

CN 1-Propanone, 1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-[1-[(2-methylphenyl)methyl]-4-piperidinyl]- (CA INDEX NAME)



IT 122844-73-9P 265101-77-7P 265101-78-8P

265101-79-9P 265101-83-5P 265101-86-8P

265101-88-0P 265101-95-9P 265101-97-1P

265102-00-9P 265102-03-2P 265102-16-7P

265102-19-0P 265102-21-4P 265102-22-5P

265102-24-7P 265102-25-8P 265102-26-9P

265102-29-2P 265102-57-6P 265102-58-7P


265102-59-8P 265102-60-1P 265102-77-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of heterocyclic compds. as thermogenesis accelerators)


RN 122844-73-9 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-(phenylmethyl)- (CA INDEX NAME)




RN 265101-77-7 CAPLUS

CN 1H-3-Benzazepine-7-ol, 2,3,4,5-tetrahydro-3-(phenylmethyl)- (CA INDEX NAME)




RN 265101-78-8 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-[(2-methylphenyl)methyl]- (CA INDEX NAME)




RN 265101-79-9 CAPLUS

CN 1H-3-Benzazepine-7-ol, 2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]- (CA INDEX NAME)




RN 265101-83-5 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-7-[2-(4-piperidinyl)ethoxy]- (CA INDEX NAME)




RN 265101-86-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-[[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]oxy]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 265101-88-0 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[3-(4-piperidinyl)propoxy]- (CA INDEX NAME)




RN 265101-95-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-[[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]oxy]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 265101-97-1 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-7-[3-(4-piperidinyl)propoxy]- (CA INDEX NAME)




RN 265102-00-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]oxy]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 265102-03-2 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[2-(4-piperidinyl)ethoxy]- (CA INDEX NAME)




RN 265102-16-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]thio]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 265102-19-0 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[[2-(4-piperidinyl)ethyl]thio]- (CA INDEX NAME)



RN 265102-21-4 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[[2-(4-piperidinyl)ethyl]thio]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 265102-22-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[(3-benzoyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)sulfinyl]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 265102-24-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]sulfinyl]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 265102-25-8 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[[2-(4-piperidinyl)ethyl]sulfinyl]- (CA INDEX NAME)



RN 265102-26-9 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[[2-(4-piperidinyl)ethyl]sulfinyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 265102-29-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]sulfonyl]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 265102-57-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-[[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]sulfonyl]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 265102-58-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-[[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]sulfonyl]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 265102-59-8 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[[3-(4-piperidinyl)propyl]sulfonyl]- (CA INDEX NAME)



RN 265102-60-1 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-7-[[3-(4-piperidinyl)propyl]sulfonyl]- (CA INDEX NAME)



RN 265102-77-0 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-7-[[3-(4-piperidinyl)propyl]-, hydrochloride (1:2) (CA INDEX NAME)

10/598,888



● 2 HCl

REFERENCE COUNT:


78

THERE ARE 78 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 42 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2000:260270 CAPLUS
 DOCUMENT NUMBER: 132:293680
 TITLE: Preparation of tetrahydrobenzazepine derivatives as
 modulators of dopamine D3 receptors (antipsychotic
 agents)
 INVENTOR(S): Hadley, Michael Stewart; Johnson, Christopher Norbert;
 MacDonald, Gregor James; Stemp, Geoffrey; Vong,
 Antonio Kuok Keong
 PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK
 SOURCE: PCT Int. Appl., 102 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000021951	A1	20000420	WO 1999-EP7763	19991006
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TG, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2346689	A1	20000420	CA 1999-2346689	19991006
EP 1119563	A1	20010801	EP 1999-953833	19991006
EP 1119563	B1	20060201		
R: AE, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
TR 200101025	T2	20010921	TR 2001-1025	19991006
BR 9914370	A	20011127	BR 1999-14370	19991006
HU 2001004280	A2	20020328	HU 2001-4280	19991006
HU 2001004280	A3	20020729		
JP 2002527433	T	20020827	JP 2000-575857	19991006
AU 761018	B2	20030529	AU 2000-10381	19991006
NZ 511018	A	20030926	NZ 1999-511018	19991006
AT 316969	T	20060215	AT 1999-953833	19991006
ES 2255311	T3	20060616	ES 1999-953833	19991006
IN 2001MN00358	A	20050304	IN 2001-MN358	20010403
ZA 2001002758	A	20020604	ZA 2001-2758	20010404
NO 2001001745	A	20010606	NO 2001-1745	20010406
MX 2001PA03645	A	20020311	MX 2001-PA3645	20010409
BG 105467	A	20011130	BG 2001-105467	20010424
US 6605607	B1	20030812	US 2001-806902	20010716
PRIORITY APPLN. INFO.:			GB 1998-21976	A 19981008
			GB 1998-24340	A 19981106
			GB 1999-10711	A 19990507
			GB 1999-18032	A 19990730
			WO 1999-EP7763	W 19991006

OTHER SOURCE(S): MARPAT 132:293680
 GI



AB The title compds. I [R1 represents a hydrogen or halogen atom, hydroxy,, etc.; R2 represents a hydrogen atom or a C1-4alkyl group; m is 1 or 2; A represents Ar, etc.; (Ar represents an optionally substituted Ph ring or an optionally substituted 5- or 6-membered aromatic heterocyclic ring; or an optionally substituted bicyclic ring system)] are prepared. In binding expts. on cloned dopamine receptors, compds. of this invention had pKi values in the range 7 - 9. Formulations are given.

IT 264262-48-8P 264262-49-9P 264262-50-2P
 264262-51-3P 264262-52-4P 264262-53-5P
 264262-54-6P 264262-55-7P 264262-56-8P
 264262-57-9P 264262-58-0P 264262-59-1P
 264262-60-4P 264262-61-5P 264262-62-6P
 264262-63-7P 264262-64-8P 264262-65-9P
 264262-66-0P 264262-67-1P 264262-68-2P
 264262-69-3P 264262-70-6P 264262-71-7P
 264262-72-8P 264262-73-9P 264262-74-0P
 264262-75-1P 264262-76-2P 264262-77-3P
 264262-78-4P 264262-79-5P 264262-80-8P
 264262-81-9P 264262-82-0P 264262-83-1P
 264262-84-2P 264262-85-3P 264262-86-4P
 264262-87-5P 264262-88-6P 264262-89-7P
 264262-90-0P 264262-91-1P 264262-92-2P
 264262-93-3P 264262-94-4P 264262-95-5P
 264262-96-6P 264262-97-7P 264262-98-8P
 264262-99-9P 264263-00-5P 264263-01-6P
 264263-02-7P 264263-03-8P 264263-04-9P
 264263-05-0P 264263-06-1P 264263-07-2P
 264263-08-3P 264263-09-4P 264263-10-7P
 264263-11-8P 264263-12-9P 264263-13-0P
 264263-14-1P 264263-15-2P 264263-16-3P
 264263-17-4P 264263-18-5P 264263-19-6P
 264263-20-9P 264263-21-0P 264263-23-2P
 264263-24-3P 264263-25-4P 264263-26-5P
 264263-27-6P 264263-28-7P 264263-29-8P
 264263-30-1P 264263-31-2P 264263-32-3P
 264263-33-4P 264263-34-5P 264263-35-6P
 264263-36-7P 264263-37-8P 264263-38-9P
 264263-39-0P 264263-40-3P 264263-41-4P
 264263-42-5P 264263-43-6P 264263-44-7P
 264263-45-8P 264263-46-9P 264263-47-0P
 264263-48-1P 264263-49-2P 264263-50-5P
 264263-51-6P 264263-52-7P 264263-53-8P
 264263-55-0P 264263-59-4P 264263-60-7P
 264263-61-8P 264263-62-9P 264263-63-0P
 264263-64-1P 264263-65-2P 264263-66-3P


264263-67-4P 264263-68-5P 264263-69-6P
 264263-70-9P 264263-71-0P 264263-72-1P
 264263-73-2P 264263-74-3P 264263-75-4P
 264263-76-5P 264263-77-6P 264263-78-7P
 264263-79-8P 264263-80-1P 264263-81-2P
 264263-84-5P 264263-85-6P 264263-86-7P
 264263-87-8P 264263-88-9P 264263-89-0P
 264263-90-3P 264263-91-4P 264263-92-5P
 264263-93-6P 264263-94-7P 264263-95-8P
 264263-96-9P 264263-97-0P 264263-99-2P
 264264-01-9P 264264-03-1P 264264-05-3P
 264264-07-5P 264264-09-7P 264264-10-0P
 264264-11-1P 264264-12-2P 264264-13-3P
 264264-14-4P 264264-15-5P 264264-16-6P
 264264-17-7P 264264-18-8P 264264-19-9P
 264264-20-2P 264264-21-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of tetrahydrobenzazepine derivs. as modulators of dopamine D3 receptors (antipsychotic agents))

RN 264262-48-8 CAPLUS

CN 4-Quinolincarboxamide, N-[trans-4-[2-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 264262-49-9 CAPLUS

CN 2-Propenamide, 3-[3-(methylsulfonyl)phenyl]-N-[trans-4-[2-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




10/598,888

RN 264262-50-2 CAPLUS

CN 2-Propenamide, 3-(4-fluorophenyl)-N-[trans-4-[2-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 264262-51-3 CAPLUS

CN 1H-Indole-2-carboxamide, N-[trans-4-[2-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 264262-52-4 CAPLUS

CN Benzamide, 3-(3-pyridinyl)-N-[trans-4-[2-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 264262-53-5 CAPLUS

CN Benzeneacetamide, N-[trans-4-[2-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 264262-54-6 CAPLUS

CN 1H-Indole-3-acetamide, N-[trans-4-[2-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 264262-55-7 CAPLUS

CN 4-Quinoloneacetamide, N-[trans-4-[2-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 264262-56-8 CAPLUS

CN 2-Propenamide, 3-(4-fluorophenyl)-N-[trans-4-[2-(1,2,4,5-tetrahydro-6-methoxy-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)


10/598,888

Relative stereochemistry.
Double bond geometry as shown.




RN 264262-57-9 CAPLUS
CN 4-Quinolinecarboxamide, N-[trans-4-[2-(1,2,4,5-tetrahydro-6-methoxy-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 264262-58-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[trans-4-[2-(1,2,4,5-tetrahydro-6-methoxy-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 264262-59-1 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(4-fluorophenyl)-, (2E)- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 264262-60-4 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(4-fluorophenyl)- (CA INDEX NAME)

Relative stereochemistry.




10/598,888

RN 264262-61-5 CAPLUS

CN Benamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(5-methyl-1,2,4-oxadiazol-3-yl)- (CA INDEX NAME)


Relative stereochemistry.



RN 264262-62-6 CAPLUS

CN 5-Quinolincarboxamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 264262-63-7 CAPLUS

CN 2-Propenamide, 3-[3-(acetylamino)phenyl]-N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 264262-64-8 CAPLUS

10/598,888

CN 2H-1,4-Benzoxazine-6-carboxamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3,4-dihydro-3-oxo- (CA INDEX NAME)

Relative stereochemistry.




RN 264262-65-9 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(1,2-dihydro-2-oxo-6-quinolinyl)-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 264262-66-0 CAPLUS

CN 2-Propenamide, 3-[4-(acetylamino)-2-fluorophenyl]-N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 264262-67-1 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(1,2-dihydro-2-oxo-8-quinoliny)-, (2E)- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 264262-68-2 CAPLUS

CN 5-Quinolinecarboxamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-8-fluoro- (CA INDEX NAME)


Relative stereochemistry.



RN 264262-69-3 CAPLUS

CN 5-Quinolinescarboxamide, N-[trans-4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 264262-70-6 CAPLUS

CN 5-Quinolinescarboxamide, 2-methyl-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 264262-71-7 CAPLUS

CN Benzamide, 3-(5-methyl-1,2,4-oxadiazol-3-yl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 264262-72-8 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[trans-4-[2-[1,2,4,5-tetrahydro-

10/598,888

7-(3-methyl-1,2,4-oxadiazol-5-yl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-,
hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 264262-73-9 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(3-methyl-1,2,4-oxadiazol-5-yl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-
(CA INDEX NAME)

Relative stereochemistry.




RN 264262-74-0 CAPLUS

CN 2-Propenamide, 3-(4-fluorophenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(5-methyl-1,2,4-oxadiazol-3-yl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-,
(2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

— Me

RN 264262-75-1 CAPLUS
 CN 2-Propenamide, 3-(4-fluorophenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(5-methyl-1,2,4-oxadiazol-3-yl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, hydrochloride (1:1), (2E)- (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



● HCl


PAGE 1-B

— Me

RN 264262-76-2 CAPLUS

CN 2-Propenamide, 3-(4-fluorophenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(3-methyl-1,2,4-oxadiazol-5-yl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



PAGE 1-B


— Me

RN 264262-77-3 CAPLUS

CN 2-Propenamide, 3-(4-fluorophenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(3-methyl-5-isoxazolyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

Me


RN 264262-78-4 CAPLUS
 CN Benzeneacetamide, 4-fluoro-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(3-methyl-1,2,4-oxadiazol-5-yl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 264262-79-5 CAPLUS
 CN 5-Quinolinecarboxamide, 2-methyl-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-[(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 264262-80-8 CAPLUS

CN Benzenesacetamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-2,5-difluoro- (CA INDEX NAME)


Relative stereochemistry.



RN 264262-81-9 CAPLUS

CN 2-Naphthaleneacetamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 264262-82-0 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(2,4-difluorophenyl)-, (2E)- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 264262-83-1 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(2,5-difluorophenyl)-, (2E)- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 264262-84-2 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(3-fluorophenyl)-, (2E)- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 264262-85-3 CAPLUS

CN Benzenepropanamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 264262-86-4 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(2-fluorophenyl)-, (2E)- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 264262-87-5 CAPLUS

CN 8-Quinolincarboxamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-1,4-dihydro-4-oxo- (CA INDEX NAME)

Relative stereochemistry.




RN 264262-88-6 CAPLUS

CN 2-Naphthalenecarboxamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)

10/598,888

Relative stereochemistry.




RN 264262-89-7 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(2-methoxyphenyl)-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 264262-90-0 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(3-methoxyphenyl)-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 264262-91-1 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(4-methoxyphenyl)-, (2E)- (CA INDEX NAME)


10/598,888

Relative stereochemistry.
Double bond geometry as shown.




RN 264262-92-2 CAPLUS
CN 2-Propenamide, 3-(2-(4-methoxyphenyl)-N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 264262-93-3 CAPLUS
CN 2-Propenamide, 3-(4-(4-acetylphenyl)-N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 264262-94-4 CAPLUS

10/598,888

CN 2-Propenamide, 3-(2-cyanophenyl)-N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 264262-95-5 CAPLUS

CN 2-Propenamide, 3-(3-cyanophenyl)-N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 264262-96-6 CAPLUS

CN Benzamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(3-methyl-5-isoxazolyl)- (CA INDEX NAME)

Relative stereochemistry.




10/598,888

RN 264262-97-7 CAPLUS

CN 7-Quinolinecarboxamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-1,2-dihydro-2-oxo- (CA INDEX NAME)

Relative stereochemistry.




RN 264262-98-8 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-phenyl-, (2Z)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 264262-99-9 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(2-pyridinyl)-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 264263-00-5 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-

yl)ethyl)cyclohexyl]-3-(4-fluoro-1-naphthalenyl)-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 264263-01-6 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl)cyclohexyl]-3-(2,3-dihydro-1,4-benzodioxin-6-yl)-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 264263-02-7 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl)cyclohexyl]-3-(5-fluoro-1H-indol-3-yl)-, (2E)- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 264263-03-8 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(1-methyl-1H-benzimidazol-6-yl)-, (2E)- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 264263-04-9 CAPLUS

CN 2-Propenamide, 3-(7-benzofuranyl)-N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 264263-05-0 CAPLUS

10/598,888

CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(3-methyl-1H-indol-5-yl)-, (2E)- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 264263-06-1 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(2,3-dihydro-2-oxo-1H-indol-6-yl)-, (2E)- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 264263-07-2 CAPLUS

CN 2-Benzofuranacetamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




10/598,888

RN 264263-08-3 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(2-methyl-1H-indol-4-yl)-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 264263-09-4 CAPLUS

CN 2-Propenamide, 3-(1H-benzimidazol-6-yl)-N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 264263-10-7 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-phenyl-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




10/598,888

RN 264263-11-8 CAPLUS

CN 2-Propenamide, 3-(1,3-benzodioxol-4-yl)-N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 264263-12-9 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-[3-(2-oxo-1-pyrrolidinyl)phenyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 264263-13-0 CAPLUS

CN 1H-Indole-2-acetamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 264263-14-1 CAPLUS

CN Benzo[b]thiophene-2-acetamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 264263-15-2 CAPLUS

CN 2-Propenamide, 3-(3-bromo-2-thienyl)-N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 264263-16-3 CAPLUS

CN Benzamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(2-pyridinyl)- (CA INDEX NAME)

Relative stereochemistry.




RN 264263-17-4 CAPLUS

10/598,888

CN Benzamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(5-pyrimidinyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 264263-18-5 CAPLUS

CN [1,1'-Biphenyl]-3-carboxamide, 4'-cyano-N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 264263-19-6 CAPLUS

CN Benzamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(5-ethyl-1,2,4-oxadiazol-3-yl)- (CA INDEX NAME)


Relative stereochemistry.



RN 264263-20-9 CAPLUS


CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(2-thienyl)-, (2E)- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 264263-21-0 CAPLUS
CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(2-furanyl)-, (2E)- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 264263-23-2 CAPLUS
CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(3-thienyl)-, (2E)- (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 264263-24-3 CAPLUS
CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(3-furanyl)-, (2E)- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 264263-25-4 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(4-quinoliny)-, (2E)- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 264263-26-5 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(5-pyrimidinyl)-, (2E)- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 264263-27-6 CAPLUS

CN Benzeneacetamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-2,4-difluoro- (CA INDEX NAME)


Relative stereochemistry.



RN 264263-28-7 CAPLUS

CN 1-Naphthaleneacetamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 264263-29-8 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[trans-4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 264263-30-1 CAPLUS

CN Benzeneacetamide, N-[trans-4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-2-fluoro- (CA INDEX NAME)


Relative stereochemistry.



RN 264263-31-2 CAPLUS

CN Benzamide, N-[trans-4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(5-methyl-1,2,4-oxadiazol-3-yl)- (CA INDEX NAME)

Relative stereochemistry.




RN 264263-32-3 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(4-fluorophenyl)-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 264263-33-4 CAPLUS

CN 6-Benzothiazoleacetamide, 2-amino-N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)

10/598,888


Relative stereochemistry.



RN 264263-34-5 CAPLUS

CN 6-Benzothiazoleacetamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-2-methyl- (CA INDEX NAME)


Relative stereochemistry.



RN 264263-35-6 CAPLUS

CN 1H-Indole-6-acetamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-2,3-dihydro-2-oxo- (CA INDEX NAME)


Relative stereochemistry.



RN 264263-36-7 CAPLUS

CN 1H-Indole-5-acetamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-2,3-dihydro-2-oxo- (CA INDEX NAME)


Relative stereochemistry.



RN 264263-37-8 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-[4-(methylamino)phenyl]- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 264263-38-9 CAPLUS

CN 5-Benzoxazoleacetamide, 2-amino-N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 264263-39-0 CAPLUS

CN 6-Quinolineacetamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-1,2-dihydro-2-oxo- (CA INDEX NAME)


Relative stereochemistry.



RN 264263-40-3 CAPLUS

CN 7-Quinoloneacetamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-1,2-dihydro-2-oxo- (CA INDEX NAME)

Relative stereochemistry.




RN 264263-41-4 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(3-methoxyphenyl)-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 264263-42-5 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(2-cyanophenyl)-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 264263-43-6 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(3-thienyl)-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 264263-44-7 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(1,2-dihydro-2-oxo-8-quinoliny)-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 264263-45-8 CAPLUS

CN Benzamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-

yl)ethyl]cyclohexyl]-3-(1H-pyrazol-1-yl)- (CA INDEX NAME)


Relative stereochemistry.



RN 264263-46-9 CAPLUS

CN 2-Thiopheneacetamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 264263-47-0 CAPLUS

CN Benzo[b]thiophene-3-acetamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 264263-48-1 CAPLUS

CN Benzamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(5-methyl-1,3,4-oxadiazol-2-yl)- (CA INDEX NAME)

Relative stereochemistry.




RN 264263-49-2 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(2-naphthalenyl)-, (2E)- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 264263-50-5 CAPLUS

CN Benzo[b]thiophene-3-acetamide, N-[trans-4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 264263-51-6 CAPLUS

CN 2-Propenamide, 3-[4-(acetylamino)phenyl]-N-[trans-4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 264263-52-7 CAPLUS

CN 6-Benzothiazoleacetamide, N-[trans-4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-2-amino- (CA INDEX NAME)


Relative stereochemistry.



RN 264263-53-8 CAPLUS

CN 8-Quinolincarboxamide, N-[trans-4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-1,4-dihydro-4-oxo- (CA INDEX NAME)

Relative stereochemistry.




RN 264263-55-0 CAPLUS

CN 2-Propenamide, 3-(2-acetylphenyl)-N-[trans-4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 264263-59-4 CAPLUS

CN Benzo[b]thiophene-2-acetamide, N-[trans-4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 264263-60-7 CAPLUS

CN 2-Propenamide, 3-(3-acetyl-1H-indol-5-yl)-N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 264263-61-8 CAPLUS

CN Benzo[b]thiophene-2-acetamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3-(3-methyl-1,2,4-oxadiazol-5-yl)- (CA INDEX NAME)


Relative stereochemistry.



RN 264263-62-9 CAPLUS

CN 1H-Benzimidazole-6-acetamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-2-methyl- (CA INDEX NAME)


Relative stereochemistry.



RN 264263-63-0 CAPLUS

CN 6-Quinoxalineacetamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 264263-64-1 CAPLUS

CN 2-Propenamide, 3-(2-acetyl-3-furanyl)-N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 264263-65-2 CAPLUS

CN 6-Benzoxazoleacetamide, 2-amino-N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 264263-66-3 CAPLUS

CN 2H-1,4-Benzoxazine-6-acetamide, N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-3,4-dihydro-2-oxo- (CA INDEX NAME)

Relative stereochemistry.




RN 264263-67-4 CAPLUS

CN 2-Propenamide, 3-[5-(acetylaminophenyl)-N-[trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 264263-68-5 CAPLUS

CN Benzo[b]thiophene-2-acetamide, N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(3-methyl-1,2,4-oxadiazol-5-yl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B


— Me

RN 264263-69-6 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(3-methyl-1,2,4-oxadiazol-5-yl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-3-(3-thienyl)-, (2E)- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 264263-72-1 CAPLUS

CN 8-Quinolinecarboxamide, 1,4-dihydro-4-oxo-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(3-methyl-1,2,4-oxadiazol-5-yl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 264263-73-2 CAPLUS

CN 2-Propenamide, 3-(3-fluorophenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(3-methyl-1,2,4-oxadiazol-5-yl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.



PAGE 1-B

— Me


RN 264263-74-3 CAPLUS

CN 2-Propenamide, 3-[3-(acetylamino)-2-fluorophenyl]-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(3-methyl-1,2,4-oxadiazol-5-yl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

— Me


RN 264263-75-4 CAPLUS

CN 2-Propenamide, 3-(3-acetylphenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(3-methyl-1,2,4-oxadiazol-5-yl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

Me

RN 264263-76-5 CAPLUS

CN Benzeneacetamide, 3-fluoro-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(3-methyl-1,2,4-oxadiazol-5-yl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 264263-77-6 CAPLUS

CN Benzeneacetamide, 2,4-difluoro-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(3-methyl-1,2,4-oxadiazol-5-yl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 264263-78-7 CAPLUS

CN 2-Naphthalenecarboxamide, N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(3-methyl-1,2,4-oxadiazol-5-yl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 264263-79-8 CAPLUS

CN 2H-1,4-Benzoxazine-7-carboxamide, 3,4-dihydro-3-oxo-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(3-methyl-1,2,4-oxadiazol-5-yl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 1-B

=O

RN 264263-80-1 CAPLUS

CN 5-Quinolinecarboxamide, 2-methyl-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(3-methyl-1,2,4-oxadiazol-5-yl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 264263-81-2 CAPLUS

CN Benzeneacetamide, 2-fluoro-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(3-methyl-1,2,4-oxadiazol-5-yl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 264263-84-5 CAPLUS

CN Benzeneacetamide, 2,5-difluoro-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(3-methyl-1,2,4-oxadiazol-5-yl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 264263-85-6 CAPLUS

CN 1H-Indole-2-carboxamide, N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(3-methyl-1,2,4-oxadiazol-5-yl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 264263-86-7 CAPLUS

CN Benzo[b]thiophene-2-acetamide, N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(3-methyl-1,2,4-oxadiazol-5-yl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

methyl-1,2,4-oxadiazol-3-yl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B


— Me

RN 264263-87-8 CAPLUS

CN 2-Propenamide, N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(5-methyl-1,2,4-oxadiazol-3-yl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-3-(3-thienyl)-, (2E)- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 264263-88-9 CAPLUS

CN 5-Quinolincarboxamide, N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(5-methyl-1,2,4-oxadiazol-3-yl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-3-(3-thienyl)-, (2E)- (CA INDEX NAME)


Relative stereochemistry.



RN 264263-89-0 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(5-methyl-1,2,4-oxadiazol-3-yl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 264263-90-3 CAPLUS

CN 8-Quinolinecarboxamide, 1,4-dihydro-4-oxo-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(5-methyl-1,2,4-oxadiazol-3-yl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 264263-91-4 CAPLUS


CN Benamide, 3-(5-methyl-1,2,4-oxadiazol-3-yl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(5-methyl-1,2,4-oxadiazol-3-yl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B




RN 264263-92-5 CAPLUS

CN 2-Propenamide, 3-(3-fluorophenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(5-methyl-1,2,4-oxadiazol-3-yl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.

PAGE 1-A




— Me

RN 264263-93-6 CAPLUS

CN 2-Propenamide, 3-(2-fluorophenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(5-methyl-1,2,4-oxadiazol-3-yl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 264263-94-7 CAPLUS

CN 2-Propenamide, 3-(2-fluorophenyl)-N-[trans-4-[2-(1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 264263-95-8 CAPLUS

CN Benzamide, 3-(4-methyl-2-oxazolyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 264263-96-9 CAPLUS

CN Benzamide, N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-3- (trifluoromethyl)- (CA INDEX NAME)


Relative stereochemistry.



RN 264263-97-0 CAPLUS

CN 5-Quinolincarboxamide, 8-chloro-2-methyl-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 264263-99-2 CAPLUS

CN 5-Quinolincarboxamide, 8-fluoro-2-methyl-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

10/598,888

INDEX NAME)


Relative stereochemistry.



RN 264264-01-9 CAPLUS

CN Benzamide, 2-fluoro-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(3-methyl-5-isoxazolyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 264264-03-1 CAPLUS

CN 2-Propenamide, 3-(4-fluorophenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(5-methyl-2-oxazolyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 264264-05-3 CAPLUS

CN 2-Propenamide, 3-(4-fluorophenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(5-methyl-3-isoxazolyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 264264-07-5 CAPLUS

CN Benzeneacetamide, 2-fluoro-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(5-methyl-3-isoxazolyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 264264-09-7 CAPLUS

CN 2-Propenamide, 3-(4-fluorophenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-pyridinyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 264264-10-0 CAPLUS

CN 2-Propenamide, 3-(4-fluorophenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(2-pyrimidinyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 264264-11-1 CAPLUS

CN 2-Propenamide, 3-(4-fluorophenyl)-N-[trans-4-[2-(1,2,4,5-tetrahydro-7-(1-pyrrolidinylcarbonyl)-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 264264-12-2 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[trans-4-[2-(1,2,4,5-tetrahydro-7-(1-pyrrolidinylcarbonyl)-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 264264-13-3 CAPLUS

CN Benzamide, 3-(5-methyl-1,2,4-oxadiazol-3-yl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(5-pyrimidinyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 1-B



RN 264264-14-4 CAPLUS

CN 5-Quinolinecarboxamide, 2-methyl-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(5-pyrimidinyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 264264-15-5 CAPLUS

CN 2-Propenamide, 3-(4-fluorophenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(5-pyrimidinyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 264264-16-6 CAPLUS

CN 5-Quinolinecarboxamide, 2-methyl-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(5-methyl-3-isoxazolyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 264264-17-7 CAPLUS

CN 2-Propenamide, 3-(2-cyanophenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(5-methyl-3-isoxazolyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 264264-18-8 CAPLUS

CN 2-Propenamide, 3-(3-cyanophenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(5-methyl-3-isoxazolyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry as shown.




RN 264264-19-9 CAPLUS

CN 2-Propenamide, 3-(4-cyanophenyl)-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-(5-methyl-3-isoxazolyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, (2E)- (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 264264-20-2 CAPLUS

CN 5-Quinolinecarboxamide, 8-fluoro-2-methyl-N-[trans-4-[2-[1,2,4,5-tetrahydro-7-[(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]- (CA INDEX NAME)


Relative stereochemistry.



RN 264264-21-3 CAPLUS

CN Benzamide, 3-(5-methyl-2-oxazolyl)-N-[trans-4-[2-(1,2,4,5-tetrahydro-7-
[(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]- (CA INDEX
NAME)

Relative stereochemistry.



IT 264264-22-4P 264264-23-5P 264264-24-6P

264264-25-7P 264264-26-8P 264264-27-9P

264264-29-1P 264264-30-4P 264264-38-2P

264264-39-3P 264264-40-6P 264264-42-8P

264264-44-0P 264264-45-1P 264264-48-4P

264264-49-5P 264264-52-0P 264264-53-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of tetrahydrobenzazepine derivs. as modulators of dopamine D3
receptors (antipsychotic agents))

RN 264264-22-4 CAPLUS

CN Carbamic acid, [trans-4-[2-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-
yl)ethyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 264264-23-5 CAPLUS

CN Carbamic acid, [trans-4-[2-(1,2,4,5-tetrahydro-6-methoxy-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 264264-24-6 CAPLUS

CN Carbamic acid, [trans-4-[2-(7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 264264-25-7 CAPLUS


CN Cyclohexanamine, 4-[2-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 264264-26-8 CAPLUS
 CN Cyclohexanamine, 4-[2-(1,2,4,5-tetrahydro-6-methoxy-3H-3-benzazepin-3-yl)ethyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 264264-27-9 CAPLUS
 CN 1H-3-Benzazepine-7-carbonitrile, 3-[2-(trans-4-aminocyclohexyl)ethyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)

Relative stereochemistry.



RN 264264-29-1 CAPLUS
 CN Carbamic acid, [trans-4-[2-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)ethyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 264264-30-4 CAPLUS

CN Ethanone, 1-[3-[2-(trans-4-aminocyclohexyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]- (CA INDEX NAME)


Relative stereochemistry.



RN 264264-38-2 CAPLUS

CN Carbamic acid, [trans-4-[2-[1,2,4,5-tetrahydro-7-(5-methyl-1,2,4-oxadiazol-3-yl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 264264-39-3 CAPLUS

CN Carbamic acid, [trans-4-[2-[1,2,4,5-tetrahydro-7-(3-methyl-1,2,4-oxadiazol-5-yl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 264264-40-6 CAPLUS

CN Cyclohexanamine, 4-[2-[1,2,4,5-tetrahydro-7-(5-methyl-1,2,4-oxadiazol-3-yl)-3H-3-benzazepin-3-yl]ethyl]-, trans- (CA INDEX NAME)


Relative stereochemistry.



RN 264264-42-8 CAPLUS

CN Cyclohexanamine, 4-[2-[1,2,4,5-tetrahydro-7-(3-methyl-1,2,4-oxadiazol-5-yl)-3H-3-benzazepin-3-yl]ethyl]-, trans- (CA INDEX NAME)


Relative stereochemistry.



RN 264264-44-0 CAPLUS

CN Carbamic acid, [trans-4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 264264-45-1 CAPLUS

CN Cyclohexanamine, 4-[2-[1,2,4,5-tetrahydro-7-(methylsulfonyl)-3H-3-benzazepin-3-yl]ethyl]-, trans- (CA INDEX NAME)


Relative stereochemistry.



RN 264264-48-4 CAPLUS

CN Carbamic acid, [trans-4-[2-[1,2,4,5-tetrahydro-7-(3-methyl-5-isoxazolyl)-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 264264-49-5 CAPLUS

CN Cyclohexanamine, 4-[2-[1,2,4,5-tetrahydro-7-(3-methyl-5-isoxazolyl)-3H-3-benzazepin-3-yl]ethyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.


10/598,888



RN 264264-52-0 CAPLUS

CN Carbamic acid, [trans-4-[2-[1,2,4,5-tetrahydro-7-[(methylsulfonyl)oxy]-3H-3-benzazepin-3-yl]ethyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 264264-53-1 CAPLUS

CN 1H-3-Benzazepin-7-ol, 3-[2-(trans-4-aminocyclohexyl)ethyl]-2,3,4,5-tetrahydro-, 7-methanesulfonate (CA INDEX NAME)

Relative stereochemistry.




REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 43 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1999:784079 CAPLUS
 DOCUMENT NUMBER: 132:12258
 TITLE: Aminomethyleneindolinones with antitumor activity
 INVENTOR(S): Heckel, Armin; Walter, Rainer; Grell, Wolfgang; Van
 Meel, Jacobus C. A.; Redemann, Norbert
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
 SOURCE: PCT Int. Appl., 112 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9962882	A1	19991209	WO 1999-EP3692	19990528
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19824922	A1	19991209	DE 1998-19824922	19980604
CA 2328291	A1	19991209	CA 1999-2328291	19990528
AU 9943707	A	19991220	AU 1999-43707	19990528
AU 764782	B2	20030828		
BR 9910898	A	20010213	BR 1999-10898	19990528
EP 1100779	A1	20010523	EP 1999-926454	19990528
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200003515	T2	20010621	TR 2000-3515	19990528
HU 2001002210	A2	20011128	HU 2001-2210	19990528
HU 2001002210	A3	20021228		
EE 200000723	A	20020415	EE 2000-723	19990528
JP 2002516906	T	20020611	JP 2000-552094	19990528
US 6319918	B1	20011120	US 1999-323499	19990601
ZA 2000005435	A	20020107	ZA 2000-5435	20001005
IN 2000MN00488	A	20050304	IN 2000-MN488	20001011
MX 2000PA10095	A	20010507	MX 2000-PA10095	20001016
BG 104938	A	20010629	BG 2000-104938	20001113
NO 2000006138	A	20010201	NO 2000-6138	20001201
HR 2000000831	A1	20011231	HR 2000-831	20001201
US 6545035	B1	20030408	US 2001-969912	20011003
PRIORITY APPLN. INFO.:			DE 1998-19824922	A 19980604
			US 1998-92014P	P 19980708
			WO 1999-EP3692	W 19990528
			US 1999-323499	A3 19990601
OTHER SOURCE(S):	MARPAT 132:12258			
GI				



AB Title compds. I [X = O, S; R1 = H, alkoxycarbonyl, alkanoyl; R2 = CO2H, alkoxycarbonyl, (un)substituted CONH2; R3 = H, (un)substituted alkyl; R4 = H, (un)substituted alkyl, Ph, naphthyl, heteroaryl; R5 = H, alkyl] were prepared. Thus, 2-oxo-5-indolinecarboxylic acid was attached to Rink resin and treated with tri-Me orthovalerate to give polymer-bound 3-Z-(1-methoxy-1-butylmethylene)-2-oxo-5-indolinecarboxamide which was treated with 4-piperidinomethylaniline to give I [X = O, R1 = 5-CONH2, R2, R4 = h, R3 = Bu, R5 = 4-piperidinomethylanilino]. This compound had an IC50 for inhibition of SKUT-1B cell proliferation of 0.036 μ M.


IT 251551-90-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of aminomethyleneindolinones with antitumor activity)
 RN 251551-90-3 CAPLUS
 CN 1H-Indole-5-carboxamide, 2,3-dihydro-2-oxo-3-[1-[[4-[(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]phenyl]amino]ethylidene]-, (3Z)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 251551-89-0

CMF C28 H28 N4 O2

Double bond geometry as shown.




CM 2

CRN 76-05-1

CMF C2 H F3 O2




IT 251552-47-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of aminomethyleneindolinones with antitumor activity)
 RN 251552-47-3 CAPLUS
 CN Benzenamine, 4-[(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]- (CA INDEX NAME)




IT 251552-79-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of aminomethyleneindolinones with antitumor activity)
 RN 251552-79-1 CAPLUS
 CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-2-oxo-3-[1-[[4-[(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]phenyl]amino]ethylidene]-, methyl ester, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



IT 251552-85-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of aminomethyleneindolinones with antitumor activity)
 RN 251552-85-9 CAPLUS
 CN 1H-Indole-5-carboxylic acid, 2,3-dihydro-2-oxo-3-[1-[[4-[(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]phenyl]amino]ethylidene]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.




IT 251551-89-0P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminomethyleneindolinones with antitumor activity)

RN 251551-89-0 CAPLUS

CN 1H-Indole-5-carboxamide, 2,3-dihydro-2-oxo-3-[1-[[4-[(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]phenyl]amino]ethylidene]-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 44 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:708810 CAPLUS

DOCUMENT NUMBER: 129:330744

ORIGINAL REFERENCE NO.: 129:67462h,67463a

TITLE: Preparation of benzazepine thermogenics

INVENTOR(S): Ishihara, Yuji; Fujisawa, Yukio; Furuyama, Naoki

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 399 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9846590	A1	19981022	WO 1998-JP1753	19980416
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2282390	A1	19981022	CA 1998-2282390	19980416
AU 9868528	A	19981111	AU 1998-68528	19980416
EP 975624	A1	20000202	EP 1998-914055	19980416
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 11310532	A	19991109	JP 1998-107257	19980417
US 6534496	B1	20030318	US 1999-402806	19991007
PRIORITY APPLN. INFO.:			JP 1997-100675	A 19970417
			JP 1998-41495	A 19980224
			WO 1998-JP1753	W 19980416

OTHER SOURCE(S): MARPAT 129:330744

GI



II

AB The title compds. ArC(O)(CHR)_nY [I; Ar = Ph which may be substituted and/or condensed; n = 1-10; R = H, hydrocarbon group which may be substituted, which may not be the same in n occurrences; R may be bound to either Ar or a substituent on Ar; Y = (un)substituted NH₂, (un)substituted nitrogen-containing saturated heterocyclic group] and their salts, useful as thermogenic, antiobesity, and lipolytic agents, or as prophylactic and/or treating drugs for obesity-associated diseases or diabetes with a reduced risk for central side effects and high universality in usage, were prepared

and formulated. Thus, reaction of 3-(1-acetyl-4-piperidinyl)propionyl chloride with 3-formyl-2,3,4,5-tetrahydro-1H-3-benzazepine in the presence of AlCl₃ in CH₂Cl₂ followed by treatment of the resulting 3-(1-acetyl-4-piperidinyl)-1-(3-formyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-propanone in MeOH with concentrate HCl, and reaction of 3-(1-acetyl-4-piperidinyl)-1-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1-propanone with benzyl bromide afforded the title compound II.HCl which showed cAMP concentration of 1369.1 pmol/mL at 10-5 M in murine preadipocyte

line

(3T3-L1).


IT 215039-79-5P 215039-82-0P 215039-84-2P
 215039-86-4P 215039-88-6P 215040-13-4P
 215040-17-8P 215041-21-7P 215041-22-8P
 215041-24-0P 215041-59-1P 215041-62-6P
 215041-92-2P 215041-94-4P 215042-46-9P
 215042-48-1P 215042-54-9P 215042-96-9P
 215042-98-1P 215043-02-0P 215043-08-6P
 215043-10-0P 215044-18-1P 215044-27-2P
 215044-36-3P 215044-73-8P 215044-79-4P
 215044-91-0P 215044-93-2P 215045-08-2P
 215045-28-6P 215045-34-4P 215045-47-9P
 215045-52-6P 215046-35-8P 215046-39-2P
 215046-97-2P 215047-01-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of benzazepine thermogenics)


RN 215039-79-5 CAPLUS

CN 1-Propanone, 3-(1-acetyl-4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 215039-82-0 CAPLUS

CN 1-Propanone, 3-(4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 215039-84-2 CAPLUS

CN 1-Butanone, 4-(1-acetyl-4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 215039-86-4 CAPLUS

CN 1-Butanone, 4-(4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 215039-88-6 CAPLUS

CN 1-Propanone, 3-(1-acetyl-4-piperidinyl)-1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215040-13-4 CAPLUS


CN 1-Propanone, 1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-(4-piperidinyl)- (CA INDEX NAME)



RN 215040-17-8 CAPLUS

CN 1-Propanone, 1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-[1-[(4-methoxyphenyl)methyl]-4-piperidinyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OMe


RN 215041-21-7 CAPLUS

CN 1-Propanone, 3-(1-acetyl-4-piperidiny1)-1-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215041-22-8 CAPLUS


CN 1-Propanone, 3-(4-piperidiny1)-1-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215041-24-0 CAPLUS

CN 1-Propanone, 3-[1-[(4-fluorophenyl)methyl]-4-piperidiny1]-1-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

F

RN 215041-59-1 CAPLUS


CN Ethanone, 2-(1-acetyl-4-piperidinyloxy)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 215041-62-6 CAPLUS

CN Ethanone, 2-(4-piperidinyloxy)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 215041-92-2 CAPLUS

CN 1-Butanone, 4-(1-acetyl-4-piperidinyloxy)-1-[2,3,4,5-tetrahydro-3-(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 215041-94-4 CAPLUS

CN 1-Butanone, 4-(4-(2-methylphenyl)methyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 215042-46-9 CAPLUS

CN Benzoic acid, 3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]-, methyl ester (CA INDEX NAME)




RN 215042-48-1 CAPLUS

CN Benzeneacetic acid, α,α -dimethyl-3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]-, ethyl ester (CA INDEX NAME)

RN 215042-54-9 CAPLUS


CN 1-Butanone, 4-[1-[(3-methoxyphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-

tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 215042-96-9 CAPLUS

CN Acetamide, N-[3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 215042-98-1 CAPLUS

CN 1-Butanone, 4-[1-[4-(3-aminophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215043-02-0 CAPLUS


CN Benzoic acid, 4-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]-, methyl ester (CA INDEX NAME)



RN 215043-08-6 CAPLUS

CN Benzeneacetic acid, 4-[[7-[4-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-α,α-dimethyl-, ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 215043-10-0 CAPLUS
 CN Benzeacetic acid, 3-[[7-[4-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]- α,α -dimethyl-, ethyl ester (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




RN 215044-18-1 CAPLUS
 CN 1-Butanone, 4-(1-acetyl-4-piperidinyl)-1-[3-[(2,4-difluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 215044-27-2 CAPLUS

CN Benzoic acid, 2-[[1,2,4,5-tetrahydro-7-[4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-oxobutyl]-3H-3-benzazepin-3-yl]methyl]-, methyl ester (CA INDEX NAME)




RN 215044-36-3 CAPLUS

CN Acetic acid, 2-[2-[[1,2,4,5-tetrahydro-7-[4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-oxobutyl]-3H-3-benzazepin-3-yl]methyl]phenoxy]-, ethyl ester (CA INDEX NAME)




RN 215044-73-8 CAPLUS

CN Acetamide, N-[2-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)




RN 215044-79-4 CAPLUS

CN 1-Butanone, 4-[1-[(2-aminophenyl)methyl]-4-piperidiny]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 215044-91-0 CAPLUS

CN Benzoic acid, 2-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidiny]methyl]-, methyl ester (CA INDEX NAME)




RN 215044-93-2 CAPLUS

CN Benzoic acid, 2-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidiny]methyl]- (CA INDEX NAME)




RN 215045-08-2 CAPLUS

CN Benzonitrile, 3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]-
(CA INDEX NAME)




RN 215045-28-6 CAPLUS

CN Benzonitrile, 2-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]- (CA INDEX NAME)




RN 215045-34-4 CAPLUS

CN Benzonitrile, 3-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]- (CA INDEX NAME)




RN 215045-47-9 CAPLUS

CN Benzonitrile, 4-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidiny]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]- (CA INDEX NAME)



RN 215045-52-6 CAPLUS

CN Benzeneacetic acid, 4-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidiny]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]- α , α -dimethyl-, ethyl ester (CA INDEX NAME)

PAGE 1-A


Cl

PAGE 1-B




RN 215046-35-8 CAPLUS

CN Acetamide, N-[3-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidiny]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenyl]- (CA INDEX NAME)




RN 215046-39-2 CAPLUS

CN 1-Butanone, 1-[3-[(3-aminophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-chlorophenyl)methyl]-4-piperidiny]- (CA INDEX NAME)




RN 215046-97-2 CAPLUS

CN Acetamide, N-[2-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidiny]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenyl]- (CA INDEX NAME)



RN 215047-01-1 CAPLUS

CN 1-Butanone, 1-[3-[(2-aminophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-chlorophenyl)methyl]-4-piperidiny]- (CA INDEX NAME)



IT 215039-77-3P 215039-81-9P 215039-83-1P
 215039-85-3P 215039-87-5P 215039-89-7P
 215039-90-0P 215039-91-1P 215039-92-2P
 215039-93-3P 215039-94-4P 215039-95-5P
 215039-96-6P 215039-97-7P 215039-98-8P
 215039-99-9P 215040-00-9P 215040-01-0P
 215040-02-1P 215040-03-2P 215040-04-3P
 215040-06-5P 215040-07-6P 215040-08-7P


215040-09-8P 215040-10-1P 215040-11-2P
215040-15-6P 215040-19-0P 215040-21-4P
215040-23-6P 215040-25-8P 215040-26-9P
215040-28-1P 215040-30-5P 215040-32-7P
215040-34-9P 215040-36-1P 215040-37-2P
215040-38-3P 215040-39-4P 215040-40-7P
215040-41-8P 215040-42-9P 215040-43-0P
215040-44-1P 215040-45-2P 215040-46-3P
215041-20-6P 215041-23-9P 215041-25-1P
215041-26-2P 215041-27-3P 215041-28-4P
215041-29-5P 215041-30-8P 215041-31-9P
215041-32-0P 215041-33-1P 215041-34-2P
215041-35-3P 215041-37-5P 215041-38-6P
215041-39-7P 215041-60-4P 215041-61-5P
215041-63-7P 215041-64-8P 215041-65-9P
215041-66-0P 215041-67-1P 215041-68-2P
215041-69-3P 215041-70-6P 215041-71-7P
215041-72-8P 215041-73-9P 215041-74-0P
215041-75-1P 215041-76-2P 215041-77-3P
215041-78-4P 215041-79-5P 215041-80-8P
215041-81-9P 215041-82-0P 215041-83-1P
215041-85-3P 215041-86-4P 215041-87-5P
215041-88-6P 215041-89-7P 215041-90-0P
215041-91-1P 215041-95-5P 215041-96-6P
215041-97-7P 215041-98-8P 215041-99-9P
215042-00-5P 215042-01-6P 215042-02-7P
215042-07-2P 215042-08-3P 215042-09-4P
215042-10-7P 215042-11-8P 215042-12-9P
215042-13-0P 215042-14-1P 215042-15-2P
215042-16-3P 215042-17-4P 215042-18-5P
215042-19-6P 215042-20-9P 215042-21-0P
215042-22-1P 215042-23-2P 215042-25-4P
215042-31-2P 215042-32-3P 215042-33-4P
215042-34-5P 215042-35-6P 215042-36-7P
215042-43-6P 215042-44-7P 215042-45-8P
215042-47-0P 215042-49-2P 215042-50-5P
215042-51-6P 215042-52-7P 215042-53-8P
215042-55-0P 215042-57-2P 215042-58-3P
215042-59-4P 215042-76-5P 215042-77-6P
215042-84-5P 215042-85-6P 215042-86-7P
215042-87-8P 215042-89-0P 215042-90-3P
215042-91-4P 215042-92-5P 215042-93-6P
215042-94-7P 215042-95-8P 215042-97-0P
215042-99-2P 215043-00-8P 215043-01-9P
215043-03-1P 215043-04-2P 215043-05-3P
215043-06-4P 215043-07-5P 215043-09-7P
215043-11-1P 215043-12-2P 215043-13-3P
215043-14-4P 215043-15-5P 215043-16-6P
215043-17-7P 215043-18-8P 215043-20-2P
215043-21-3P 215043-22-4P 215043-23-5P
215043-24-6P 215043-25-7P 215043-26-8P
215043-27-9P 215043-28-0P 215043-29-1P
215043-30-4P 215043-31-5P 215043-32-6P
215043-33-7P 215043-34-8P 215043-35-9P
215043-36-0P 215043-37-1P 215043-38-2P
215043-39-3P 215043-40-6P 215043-41-7P
215043-42-8P 215043-43-9P 215043-44-0P

215043-45-1P 215043-48-4P 215043-49-5P
 215044-21-6P 215044-24-9P 215044-30-7P
 215044-33-0P 215044-39-6P 215044-42-1P
 215044-45-4P 215044-54-5P 215044-56-7P
 215044-59-0P 215044-62-5P 215044-70-5P
 215044-76-1P 215044-81-8P 215044-83-0P
 215044-85-2P 215044-87-4P 215044-89-6P
 215044-95-4P 215044-97-6P 215044-99-8P
 215045-02-6P 215045-04-8P 215045-06-0P
 215045-10-6P 215045-12-8P 215045-14-0P
 215045-16-2P 215045-18-4P 215045-20-8P
 215045-22-0P 215045-30-0P 215045-32-2P
 215045-36-6P 215045-38-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of benzazepine thermogenics)

RN 215039-77-3 CAPLUS


CN 1-Propanone, 3-(1-acetyl-4-piperidiny)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 215039-81-9 CAPLUS


CN 1-Propanone, 3-(1-acetyl-4-piperidiny)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 215039-83-1 CAPLUS


CN 1-Butanone, 4-(1-acetyl-4-piperidiny)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 215039-85-3 CAPLUS


CN 1-Butanone, 4-(4-piperidiny1)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 215039-87-5 CAPLUS


CN 1-Propanone, 3-(1-acetyl-4-piperidiny1)-1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 215039-89-7 CAPLUS

CN 1-Propanone, 3-[1-[(2-methylphenyl)methyl]-4-piperidiny1]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 215039-90-0 CAPLUS
 CN 1-Propanone, 3-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 215039-91-1 CAPLUS
 CN 1-Propanone, 3-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 215039-92-2 CAPLUS
 CN 1-Propanone, 3-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215039-93-3 CAPLUS


CN 1-Propanone, 3-[1-(2-phenylethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215039-94-4 CAPLUS

CN 1-Propanone, 3-[1-(2-phenylethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215039-95-5 CAPLUS


CN 1-Propanone, 3-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215039-96-6 CAPLUS

CN 1-Propanone, 3-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215039-97-7 CAPLUS


CN 1-Propanone, 3-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2)
(CA INDEX NAME)



● 2 HCl


RN 215039-98-8 CAPLUS

CN 1-Propanone, 3-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215039-99-9 CAPLUS


CN 1-Propanone, 3-(1-benzoyl-4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HC1


RN 215040-00-9 CAPLUS

CN 1-Propanone, 3-(1-benzoyl-4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215040-01-0 CAPLUS


CN 1-Propanone, 3-(1-methyl-4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HC1


RN 215040-02-1 CAPLUS

CN 1-Propanone, 3-(1-methyl-4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215040-03-2 CAPLUS


CN 1-Piperidineacetic acid, 4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-, ethyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215040-04-3 CAPLUS

CN 1-Piperidineacetic acid, 4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-, ethyl ester (CA INDEX NAME)



RN 215040-06-5 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 215040-07-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-, ethyl ester (CA INDEX NAME)



RN 215040-08-7 CAPLUS


CN 1-Propanone, 3-[1-(methylsulfonyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215040-09-8 CAPLUS

CN 1-Piperidinecarboxamide, N-methyl-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




● 2 HCl

PAGE 1-B


— OMe

RN 215040-19-0 CAPLUS
 CN 1-Propanone, 3-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]-1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215040-21-4 CAPLUS
 CN 1-Propanone, 3-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]-1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



10/598,888

RN 215040-23-6 CAPLUS


CN 1-Propanone, 1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-(1-methyl-4-piperidinyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 215040-25-8 CAPLUS


CN 1-Propanone, 1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-(1-methyl-4-piperidinyl)- (CA INDEX NAME)



RN 215040-26-9 CAPLUS

CN Benzeneacetic acid, 4-[[4-[3-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-oxopropyl]-1-piperidinyl]methyl]- α,α -dimethyl-, ethyl ester, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A



● 2 HCl


PAGE 1-B



RN 215040-28-1 CAPLUS

CN Benzeneacetic acid, 4-[[4-[3-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-oxopropyl]-1-piperidinyl]methyl]- α,α -dimethyl-, ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 215040-30-5 CAPLUS

CN 1-Propanone, 3-[1-[(3,4-dimethoxyphenyl)methyl]-4-piperidinyl]-1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

PAGE 1-B

— OMe

RN 215040-32-7 CAPLUS
 CN 1-Propanone, 3-[1-[(3,4-dimethoxyphenyl)methyl]-4-piperidinyl]-1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




PAGE 1-B

— OMe


RN 215040-34-9 CAPLUS
 CN Acetic acid, 2-[4-[3-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-oxopropyl]-1-piperidinyl]methyl]phenoxy]-, ethyl ester, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A



● 2 HCl


PAGE 1-B




RN 215040-36-1 CAPLUS

CN Acetic acid, 2-[4-[[3-[[4-(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-oxopropyl]-1-piperidinyl]methyl]phenoxy]-, ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 215040-37-2 CAPLUS


CN 1-Propanone, 1-[3-[[4-(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-[1-(phenylmethyl)-4-piperidinyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 215040-38-3 CAPLUS


CN 1-Propanone, 1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-[1-(phenylmethyl)-4-piperidiny]- (CA INDEX NAME)



RN 215040-39-4 CAPLUS

CN 1-Propanone, 3-[1-[[4-(1,1-dimethylethyl)phenyl]methyl]-4-piperidiny]-1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A



●2 HCl


PAGE 1-B

Bu-t

RN 215040-40-7 CAPLUS

CN 1-Propanone, 3-[1-[[4-(1,1-dimethylethyl)phenyl]methyl]-4-piperidiny]-1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

Bu-t

RN 215040-41-8 CAPLUS

CN Benzoic acid, 4-[[4-[3-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-oxopropyl]-1-piperidinyl)methyl]-, ethyl ester, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A



● 2 HCl

PAGE 1-B




RN 215040-42-9 CAPLUS

CN Benzoic acid, 4-[[4-[3-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-oxopropyl]-1-piperidinyl)methyl]-, ethyl ester (CA INDEX NAME)

RN 215040-45-2 CAPLUS


CN 1-Propanone, 1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-[1-[(4-hydroxyphenyl)methyl]-4-piperidinyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215040-46-3 CAPLUS

CN 1-Propanone, 1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-[1-[(4-hydroxyphenyl)methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 215041-20-6 CAPLUS

CN 1-Propanone, 3-(1-acetyl-4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 215041-23-9 CAPLUS

CN 1-Propanone, 3-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-

tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]-,
hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A




● 2 HCl

PAGE 1-B


F

RN 215041-25-1 CAPLUS
CN 1-Propanone, 3-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(4-hydroxyphenyl)methyl]-1H-3-benzazepin-7-yl]-,
hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215041-26-2 CAPLUS
CN 1-Propanone, 3-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(4-hydroxyphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215041-27-3 CAPLUS

CN 1-Propanone, 3-[1-[[4-(1,1-dimethylethyl)phenyl]methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A



● 2 HCl


PAGE 1-B

Bu-t

RN 215041-28-4 CAPLUS

CN 1-Propanone, 3-[1-[[4-(1,1-dimethylethyl)phenyl]methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

Bu-t

RN 215041-29-5 CAPLUS

CN Benzeneacetic acid, α,α -dimethyl-4-[[4-[3-oxo-3-(2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl)propyl]-1-piperidinyl)methyl]-, ethyl ester, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A



● 2 HCl


PAGE 1-B



RN 215041-30-8 CAPLUS

CN Benzeneacetic acid, α,α -dimethyl-4-[[4-[3-oxo-3-(2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl)propyl]-1-piperidinyl)methyl]-, ethyl ester (CA INDEX NAME)


PAGE 1-A





RN 215041-31-9 CAPLUS


CN 1-Propanone, 3-[1-(4-chlorobenzoyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215041-32-0 CAPLUS

CN 1-Propanone, 3-[1-(4-chlorobenzoyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215041-33-1 CAPLUS

CN 1-Propanone, 3-[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

PAGE 1-B

— Cl

RN 215041-34-2 CAPLUS
 CN 1-Propanone, 3-[1-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




PAGE 1-B

— Cl

RN 215041-35-3 CAPLUS
 CN 1-Propanone, 3-[1-[(1,1'-biphenyl)-4-ylmethyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A




● 2 HCl

PAGE 1-B

Ph

RN 215041-37-5 CAPLUS
 CN 1-Propanone, 3-[1-([1,1'-biphenyl]-4-ylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)


PAGE 1-A



PAGE 1-B

Ph


RN 215041-38-6 CAPLUS
 CN 1-Propanone, 3-[1-([1,1'-biphenyl]-4-ylcarbonyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HC1


RN 215041-39-7 CAPLUS

CN 1-Propanone, 3-[1-([1,1'-biphenyl]-4-ylcarbonyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 215041-60-4 CAPLUS

CN Ethanone, 2-(1-acetyl-4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215041-61-5 CAPLUS


CN Ethanone, 2-(4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 215041-63-7 CAPLUS


CN Ethanone, 2-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215041-64-8 CAPLUS

CN Ethanone, 2-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215041-65-9 CAPLUS


CN Ethanone, 2-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215041-66-0 CAPLUS

CN Ethanone, 2-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215041-67-1 CAPLUS


CN 1-Butanone, 4-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 215041-68-2 CAPLUS

CN 1-Butanone, 4-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 215041-69-3 CAPLUS
 CN 1-Butanone, 4-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2)
 (CA INDEX NAME)




● 2 HCl

RN 215041-70-6 CAPLUS
 CN 1-Butanone, 4-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 215041-71-7 CAPLUS
 CN Ethanone, 2-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2)
 (CA INDEX NAME)




● 2 HCl

RN 215041-72-8 CAPLUS
 CN Ethanone, 2-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215041-73-9 CAPLUS


CN Ethanone, 2-[1-[(3-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2)
(CA INDEX NAME)



● 2 HCl


RN 215041-74-0 CAPLUS

CN Ethanone, 2-[1-[(3-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215041-75-1 CAPLUS


CN Ethanone, 2-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2)
(CA INDEX NAME)



● 2 HCl


RN 215041-76-2 CAPLUS

CN Ethanone, 2-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215041-77-3 CAPLUS


CN 1-Butanone, 4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 215041-78-4 CAPLUS

CN 1-Butanone, 4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 215041-79-5 CAPLUS

CN 1-Butanone, 4-[1-[(3-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2)
(CA INDEX NAME)

●2 HCl

RN 215041-80-8 CAPLUS


CN 1-Butanone, 4-[1-[(3-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




●2 HCl

RN 215041-82-0 CAPLUS


CN 1-Butanone, 4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)





RN 215041-83-1 CAPLUS


CN Benzenesuccinic acid, 4-[[7-[3-(1-acetyl-4-piperidinyl)-1-oxopropyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-α,α-dimethyl-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 215041-85-3 CAPLUS

CN Benzenesuccinic acid, 3-[[7-[3-(1-acetyl-4-piperidinyl)-1-oxopropyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-α,α-dimethyl-, ethyl ester (CA INDEX NAME)



RN 215041-86-4 CAPLUS


CN Benzenesuccinic acid, 3-[[7-[3-(1-acetyl-4-piperidinyl)-1-oxopropyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-α,α-dimethyl-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 215041-87-5 CAPLUS

CN Benzeneacetic acid, 3-[[7-[3-(1-acetyl-4-piperidinyl)-1-oxopropyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]- α,α -dimethyl-, ethyl ester (CA INDEX NAME)



RN 215041-88-6 CAPLUS

CN Acetic acid, 2-[4-[[7-[3-(1-acetyl-4-piperidinyl)-1-oxopropyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenoxy]-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 215041-89-7 CAPLUS


CN Acetic acid, 2-[4-[[7-[3-(1-acetyl-4-piperidinyl)-1-oxopropyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenoxy]-, ethyl ester (CA INDEX NAME)

10/598,888



RN 215041-90-0 CAPLUS


CN 1-Propanone, 3-(1-acetyl-4-piperidinyl)-1-[3-(cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 215041-91-1 CAPLUS

CN 1-Propanone, 3-(1-acetyl-4-piperidinyl)-1-[3-(cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215041-95-5 CAPLUS


CN 1-Butanone, 4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215041-96-6 CAPLUS

CN 1-Butanone, 4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215041-97-7 CAPLUS


CN 1-Butanone, 4-[1-[(3-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215041-98-8 CAPLUS

CN 1-Butanone, 4-[1-[(3-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215041-99-9 CAPLUS


CN 1-Butanone, 4-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215042-00-5 CAPLUS

CN 1-Butanone, 4-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215042-01-6 CAPLUS


CN 1-Butanone, 4-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215042-02-7 CAPLUS

CN 1-Butanone, 4-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215042-07-2 CAPLUS


CN 1-Propanone, 3-(1-acetyl-4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 215042-08-3 CAPLUS

CN 1-Propanone, 3-(1-acetyl-4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215042-09-4 CAPLUS


CN 1-Propanone, 3-(1-acetyl-4-piperidiny1)-1-[2,3,4,5-tetrahydro-3-[(3-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 215042-10-7 CAPLUS

CN 1-Propanone, 3-(1-acetyl-4-piperidiny1)-1-[2,3,4,5-tetrahydro-3-[(3-methylphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215042-11-8 CAPLUS


CN 1-Propanone, 3-(1-acetyl-4-piperidiny1)-1-[2,3,4,5-tetrahydro-3-[(4-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 215042-12-9 CAPLUS

CN 1-Propanone, 3-(1-acetyl-4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-[(4-methylphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215042-13-0 CAPLUS


CN 1-Propanone, 3-(1-acetyl-4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-[(2-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 215042-14-1 CAPLUS

CN 1-Propanone, 3-(1-acetyl-4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-[(2-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215042-15-2 CAPLUS


CN 1-Propanone, 3-[(1-acetyl-4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-[(3-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 215042-16-3 CAPLUS

CN 1-Propanone, 3-[(1-acetyl-4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-[(3-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215042-17-4 CAPLUS


CN 1-Propanone, 3-[(1-acetyl-4-piperidinyl)-1-[3-[(2-chlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 215042-18-5 CAPLUS

CN 1-Propanone, 3-(1-(2-chlorophenyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 215042-19-6 CAPLUS


CN 1-Propanone, 3-(1-(3-chlorophenyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 215042-20-9 CAPLUS

CN 1-Propanone, 3-(1-(3-chlorophenyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 215042-21-0 CAPLUS


CN Acetic acid, 2-[3-[[7-[3-(1-acetyl-4-piperidinyl)-1-oxopropyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenoxy]-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 215042-22-1 CAPLUS

CN Acetic acid, 2-[3-[[7-[3-(1-acetyl-4-piperidinyl)-1-oxopropyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenoxy]-, ethyl ester (CA INDEX NAME)



RN 215042-23-2 CAPLUS


CN Acetic acid, 2-[2-[[7-[3-(1-acetyl-4-piperidinyl)-1-oxopropyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenoxy]-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 215042-25-4 CAPLUS

CN Acetic acid, 2-[2-[[7-[3-(1-acetyl-4-piperidinyl)-1-oxopropyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenoxy]-, ethyl ester (CA INDEX NAME)



RN 215042-31-2 CAPLUS

CN 1-Butanone, 4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 215042-32-3 CAPLUS


CN 1-Butanone, 4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-

tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 215042-33-4 CAPLUS


CN 1-Butanone, 1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-4-[1-[[2-(trifluoromethyl)phenyl]methyl]-4-piperidinyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215042-34-5 CAPLUS

CN 1-Butanone, 1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-4-[1-[[3-(trifluoromethyl)phenyl]methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 215042-35-6 CAPLUS


CN 1-Butanone, 1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-4-[1-[[3-(trifluoromethyl)phenyl]methyl]-4-piperidinyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215042-36-7 CAPLUS

CN 1-Butanone, 1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-4-[1-[3-(trifluoromethyl)phenyl]methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 215042-43-6 CAPLUS


CN 1-Butanone, 4-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215042-44-7 CAPLUS

CN 1-Butanone, 4-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215042-45-8 CAPLUS


CN Benzoic acid, 3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 215042-47-0 CAPLUS


CN Benzeneacetic acid, α,α -dimethyl-3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]-, ethyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 215042-49-2 CAPLUS


CN 1-Butanone, 4-[1-[(3-nitrophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215042-50-5 CAPLUS

CN 1-Butanone, 4-[1-[(3-nitrophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215042-51-6 CAPLUS


CN 1-Butanone, 4-[1-[(3-fluorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 215042-52-7 CAPLUS


CN 1-Butanone, 4-[1-[(3-fluorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



10/598,888

RN 215042-53-8 CAPLUS


CN 1-Butanone, 4-[1-[(3-methoxyphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2)
(CA INDEX NAME)



● 2 HCl

RN 215042-55-0 CAPLUS

CN 1-Butanone, 4-[1-[(3-hydroxyphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2)
(CA INDEX NAME)



● 2 HCl


RN 215042-57-2 CAPLUS

CN Benzoic acid, 3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]-, compd. with
N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 215042-56-1

CMF C34 H40 N2 O3




CM 2

10/598,888

CRN 121-44-8
CMF C6 H15 N




RN 215042-58-3 CAPLUS
CN 1-Butanone, 4-[1-[(4-nitrophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2)
(CA INDEX NAME)




● 2 HCl

RN 215042-59-4 CAPLUS
CN 1-Butanone, 4-[1-[(4-nitrophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215042-76-5 CAPLUS
CN Benzeneacetic acid, α,α -dimethyl-3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]-, ethyl ester, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A



● 2 HCl


PAGE 1-B

— OEt

RN 215042-77-6 CAPLUS

CN Benzeneacetic acid, α,α -dimethyl-3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]-, ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— OEt


RN 215042-84-5 CAPLUS

CN 1-Butanone, 4-[1-[(2-nitrophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 215042-85-6 CAPLUS
 CN 1-Butanone, 4-[1-[(2-nitrophenyl)methyl]-4-piperidinyl]-1-[(2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 215042-86-7 CAPLUS
 CN Benzoic acid, 2-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215042-87-8 CAPLUS
 CN Benzoic acid, 2-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]-, methyl ester (CA INDEX NAME)



10/598,888

RN 215042-89-0 CAPLUS


CN Acetic acid, 2-[2-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]phenoxy]-, ethyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215042-90-3 CAPLUS

CN Acetic acid, 2-[2-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]phenoxy]-, ethyl ester (CA INDEX NAME)



RN 215042-91-4 CAPLUS


CN 1-Butanone, 4-[1-[(2-fluorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215042-92-5 CAPLUS

CN 1-Butanone, 4-[1-[(2-fluorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215042-93-6 CAPLUS


CN 1-Butanone, 4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215042-94-7 CAPLUS

CN 1-Butanone, 4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215042-95-8 CAPLUS


CN Acetamide, N-[3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 215042-97-0 CAPLUS


CN 1-Butanone, 4-[1-[(3-aminophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:3)
(CA INDEX NAME)



●3 HCl

RN 215042-99-2 CAPLUS


CN Urea, N-methyl-N'-[3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]phenyl]-, hydrochloride
(1:2) (CA INDEX NAME)



●2 HCl


RN 215043-00-8 CAPLUS

CN Urea, N-methyl-N'-[3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 215043-01-9 CAPLUS


CN Benzoic acid, 4-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215043-03-1 CAPLUS

CN Benzoic acid, 4-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]- (CA INDEX NAME)




RN 215043-04-2 CAPLUS

CN Benzeneacetic acid, α,α -dimethyl-3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]- (CA INDEX NAME)



RN 215043-05-3 CAPLUS


CN Methanesulfonamide, N-[3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215043-06-4 CAPLUS

CN Methanesulfonamide, N-[3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 215043-07-5 CAPLUS

CN Benzeneacetic acid, 4-[[7-[4-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-α,α-dimethyl-, ethyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

PAGE 1-A


PAGE 1-B



RN 215043-09-7 CAPLUS

CN Benzeneacetic acid, 3-[[7-[4-[1-[(4-fluorophenyl)methyl]-4-piperidiny]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]- α , α -dimethyl-, ethyl ester, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A



● 2 HCl


PAGE 1-B



RN 215043-11-1 CAPLUS

CN Benzeneacetic acid, 4-[[7-[4-[1-[(4-fluorophenyl)methyl]-4-piperidiny]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]- α , α -dimethyl- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 215043-12-2 CAPLUS

CN Benzeneacetic acid, 3-[[7-[4-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]- α,α -dimethyl- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 215043-13-3 CAPLUS


CN 1-Butanone, 4-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 215043-14-4 CAPLUS


CN 1-Butanone, 4-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



● 2 HCl


RN 215043-18-8 CAPLUS

CN 1-Butanone, 4-[1-[(4-fluorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(4-methylphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215043-20-2 CAPLUS


CN 1-Propanone, 3-[1-[(1-oxopropyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 215043-21-3 CAPLUS

CN 1-Propanone, 3-[1-[(1-oxopropyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215043-22-4 CAPLUS


CN 1-Propanone, 2-methyl-1-[4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-1-piperidiny]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 215043-23-5 CAPLUS

CN 1-Propanone, 2-methyl-1-[4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-1-piperidiny]- (CA INDEX NAME)




RN 215043-24-6 CAPLUS

CN 1-Piperidinebutanoic acid, γ-oxo-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 215043-25-7 CAPLUS

CN 1-Piperidinebutanoic acid, γ -oxo-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-, ethyl ester (CA INDEX NAME)


RN 215043-26-8 CAPLUS

CN 1-Piperidinepentanoic acid, δ -oxo-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)

● HCl


RN 215043-27-9 CAPLUS

CN 1-Piperidinepentanoic acid, δ -oxo-4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-, ethyl ester (CA INDEX NAME)



RN 215043-28-0 CAPLUS


CN 1-Butanone, 4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-nitrophenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215043-29-1 CAPLUS

CN 1-Butanone, 4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(3-nitrophenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215043-30-4 CAPLUS


CN 1-Butanone, 4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(3-nitrophenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215043-31-5 CAPLUS

CN 1-Butanone, 4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(3-nitrophenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215043-32-6 CAPLUS


CN 1-Butanone, 4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(4-nitrophenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215043-33-7 CAPLUS

CN 1-Butanone, 4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(4-nitrophenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215043-34-8 CAPLUS


CN 1-Butanone, 1-[3-[(2-chlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215043-35-9 CAPLUS

CN 1-Butanone, 1-[3-[(3-chlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-, hydrochloride (1:2) (CA INDEX NAME)



RN 215043-36-0 CAPLUS


CN 1-Butanone, 1-[3-[(3-chlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215043-37-1 CAPLUS

CN 1-Butanone, 1-[3-[(3-chlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 215043-38-2 CAPLUS


CN 1-Butanone, 1-[3-[(4-chlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215043-39-3 CAPLUS

CN 1-Butanone, 1-[3-[(4-chlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 215043-40-6 CAPLUS


CN Benzonitrile, 2-[[1,2,4,5-tetrahydro-7-[4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-oxobutyl]-3H-3-benzazepin-3-yl)methyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215043-41-7 CAPLUS

CN Benzonitrile, 2-[[1,2,4,5-tetrahydro-7-[4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-oxobutyl]-3H-3-benzazepin-3-yl)methyl]- (CA INDEX NAME)



RN 215043-42-8 CAPLUS


CN Benzonitrile, 3-[[1,2,4,5-tetrahydro-7-[4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-oxobutyl]-3H-3-benzazepin-3-yl)methyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215043-43-9 CAPLUS

CN Benzonitrile, 3-[[1,2,4,5-tetrahydro-7-[4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-oxobutyl]-3H-3-benzazepin-3-yl)methyl]- (CA INDEX NAME)



RN 215043-44-0 CAPLUS


CN Benzonitrile, 4-[[1,2,4,5-tetrahydro-7-[4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-oxobutyl]-3H-3-benzazepin-3-yl)methyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215043-45-1 CAPLUS

CN Benzonitrile, 4-[[1,2,4,5-tetrahydro-7-[4-[1-[(4-methylphenyl)methyl]-4-piperidinyl]-1-oxobutyl]-3H-3-benzazepin-3-yl)methyl]- (CA INDEX NAME)



RN 215043-48-4 CAPLUS


CN 1-Pentanone, 5-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215043-49-5 CAPLUS

CN 1-Pentanone, 5-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215044-21-6 CAPLUS


CN 1-Butanone, 1-[3-[(2,4-difluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(4-piperidinyl)- (CA INDEX NAME)



10/598,888

RN 215044-24-9 CAPLUS


CN Benzoic acid, 2-[[[1,2,4,5-tetrahydro-7-[4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-oxobutyl]-3H-3-benzazepin-3-yl]methyl]-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 215044-30-7 CAPLUS

CN Benzoic acid, 2-[[[1,2,4,5-tetrahydro-7-[4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-oxobutyl]-3H-3-benzazepin-3-yl]methyl]- (CA INDEX NAME)



RN 215044-33-0 CAPLUS


CN Acetic acid, 2-[2-[[[1,2,4,5-tetrahydro-7-[4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-oxobutyl]-3H-3-benzazepin-3-yl]methyl]phenoxy]-, ethyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 215044-39-6 CAPLUS

CN Acetic acid, 2-[2-[[1,2,4,5-tetrahydro-7-[4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-oxobutyl]-3H-3-benzazepin-3-yl]methyl]phenoxy]- (CA INDEX NAME)



RN 215044-42-1 CAPLUS


CN 1-Butanone, 4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[[2-[(4-methyl-1-piperazinyl)carbonyl]phenyl]methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl


RN 215044-45-4 CAPLUS

CN 1-Butanone, 4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[[2-[(4-methyl-1-piperazinyl)carbonyl]phenyl]methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215044-54-5 CAPLUS


CN 1-Butanone, 4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-[3-[(2,4-difluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 215044-56-7 CAPLUS


CN 1-Butanone, 4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-[3-[(2,4-difluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215044-59-0 CAPLUS

CN 1-Butanone, 1-[3-[(2,4-difluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-,


hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215044-62-5 CAPLUS

CN 1-Butanone, 1-[3-[(2,4-difluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 215044-70-5 CAPLUS

CN Acetamide, N-[2-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 215044-76-1 CAPLUS

CN 1-Butanone, 4-[1-[(2-aminophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-


tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-,
hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

RN 215044-81-8 CAPLUS


CN Methanesulfonamide, N-[2-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 215044-83-0 CAPLUS

CN Methanesulfonamide, N-[2-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 215044-85-2 CAPLUS


CN Urea, N-methyl-N'-[2-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 215044-87-4 CAPLUS


CN Urea, N-methyl-N'-[2-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 215044-89-6 CAPLUS

CN Benzoic acid, 2-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)


CN 1-Butanone, 4-(4-piperidiny1)-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 215045-02-6 CAPLUS


CN Benzamide, 4-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidiny1]methyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 215045-04-8 CAPLUS

CN Benzamide, 4-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidiny1]methyl]- (CA INDEX NAME)



RN 215045-06-0 CAPLUS


CN Benzonitrile, 3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidiny1]methyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 215045-10-6 CAPLUS


CN Benamide, 3-[[4-[[4-oxo-4-[[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]-1-phenyl]benzamide, hydrochloride (1:2)
(CA INDEX NAME)



● 2 HCl


RN 215045-12-8 CAPLUS

CN Benamide, 3-[[4-[[4-oxo-4-[[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]-1-phenyl]benzamide, hydrochloride (1:2)
(CA INDEX NAME)




RN 215045-14-0 CAPLUS

CN Benzenecarboximidamide, 3-[[4-[[4-oxo-4-[[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]-1-phenyl]benzamide, hydrochloride (1:2)
(CA INDEX NAME)



RN 215045-16-2 CAPLUS


CN 1-Butanone, 4-[1-[[3-(4,5-dihydro-2-thiazolyl)phenyl]methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215045-18-4 CAPLUS

CN 1-Butanone, 4-[1-[[3-(4,5-dihydro-2-thiazolyl)phenyl]methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215045-20-8 CAPLUS


CN 1-Butanone, 4-[1-[[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl


RN 215045-22-0 CAPLUS

CN 1-Butanone, 4-[1-[[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215045-30-0 CAPLUS


CN Benzamide, 2-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 215045-32-2 CAPLUS

CN Benzamide, 2-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]- (CA INDEX NAME)



RN 215045-36-6 CAPLUS


CN Benamide, 3-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidiny]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 215045-38-8 CAPLUS

CN Benamide, 3-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidiny]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]- (CA INDEX NAME)




IT 215045-40-2P 215045-42-4P 215045-43-5P
 215045-45-7P 215045-48-0P 215045-50-4P
 215045-53-7P 215046-33-6P 215046-37-0P
 215046-41-6P 215046-43-8P 215046-45-0P
 215046-47-2P 215046-49-4P 215046-51-8P
 215046-53-0P 215046-55-2P 215046-57-4P
 215046-59-6P 215046-61-0P 215046-63-2P
 215046-65-4P 215046-67-6P 215046-69-8P

215046-71-2P 215046-73-4P 215046-75-6P
 215046-77-8P 215046-79-0P 215046-81-4P
 215046-83-6P 215046-85-8P 215046-87-0P
 215046-89-2P 215046-91-6P 215046-93-8P
 215046-95-0P 215046-99-4P 215047-03-3P
 215047-05-5P 215047-07-7P 215047-08-8P
 215047-09-9P 215047-11-3P 215047-13-5P
 215047-15-7P 215047-17-9P 215047-19-1P
 215047-21-5P 215047-31-7P 215047-33-9P
 215047-35-1P 215047-37-3P 215047-57-7P
 215047-59-9P 215047-61-3P 215047-63-5P
 215047-64-6P 215047-65-7P 215047-66-8P
 215047-84-0P 215047-91-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of benzazepine thermogenics)

RN 215045-40-2 CAPLUS


CN Benzenecarboximidamide, 3-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl


RN 215045-42-4 CAPLUS

CN Benzenecarboximidamide, 3-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-, (CA INDEX NAME)



RN 215045-43-5 CAPLUS


CN 1-Butanone, 4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-[3-[[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl


RN 215045-45-7 CAPLUS

CN 1-Butanone, 4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-[3-[[3-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215045-48-0 CAPLUS


CN Benzamide, 4-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]- (CA INDEX NAME)



RN 215045-50-4 CAPLUS

CN Benzeneacetic acid, 4-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]- α , α -dimethyl-, ethyl ester, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A




● 2 HCl

PAGE 1-B



RN 215045-53-7 CAPLUS


CN Benzeneacetic acid, 4-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]- α,α -dimethyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 215046-33-6 CAPLUS


CN Acetamide, N-[3-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 215046-37-0 CAPLUS


CN 1-Butanone, 1-[3-[(3-aminophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 215046-41-6 CAPLUS

CN Urea, N-[3-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

PAGE 1-B



RN 215046-43-8 CAPLUS
 CN Urea, N-[3-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




RN 215046-45-0 CAPLUS
 CN 1-Butanone, 4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(3-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 215046-47-2 CAPLUS
 CN 1-Butanone, 4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(3-methylphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215046-49-4 CAPLUS


CN 1-Butanone, 4-[1-[(2-chlorophenyl)methyl]-4-piperidiny]-1-[2,3,4,5-tetrahydro-3-[(4-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215046-51-8 CAPLUS

CN 1-Butanone, 4-[1-[(2-chlorophenyl)methyl]-4-piperidiny]-1-[2,3,4,5-tetrahydro-3-[(4-methylphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215046-53-0 CAPLUS


CN 1-Butanone, 1-[3-[(2-chlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-methylphenyl)methyl]-4-piperidiny]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 215046-55-2 CAPLUS


CN 1-Butanone, 1-[3-[(2,6-dichlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215046-57-4 CAPLUS

CN 1-Butanone, 1-[3-[(2,6-dichlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 215046-59-6 CAPLUS


CN 1-Butanone, 1-[3-[(2,3-dichlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215046-61-0 CAPLUS

CN 1-Butanone, 1-[3-(2,3-dichlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-(2-methylphenyl)methyl]-4-piperidiny]- (CA INDEX NAME)



RN 215046-63-2 CAPLUS

CN 1-Butanone, 4-[1-(2-methylphenyl)methyl]-4-piperidiny]-1-[2,3,4,5-tetrahydro-3-[[2-(trifluoromethyl)phenyl]methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 215046-65-4 CAPLUS


CN 1-Butanone, 4-[1-(2-methylphenyl)methyl]-4-piperidiny]-1-[2,3,4,5-tetrahydro-3-[[2-(trifluoromethyl)phenyl]methyl]-1H-3-benzazepin-7-yl]-

(CA INDEX NAME)



RN 215046-67-6 CAPLUS


CN 1-Butanone, 4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[[3-(trifluoromethyl)phenyl]methyl]-1H-3-benzazepin-7-yl]-hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215046-69-8 CAPLUS

CN 1-Butanone, 4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[[3-(trifluoromethyl)phenyl]methyl]-1H-3-benzazepin-7-yl]-hydrochloride (1:2) (CA INDEX NAME)




RN 215046-71-2 CAPLUS

CN 1-Butanone, 4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[[3-(trifluoromethoxy)phenyl]methyl]-1H-3-benzazepin-7-yl]-hydrochloride (1:2) (CA INDEX NAME)



RN 215046-73-4 CAPLUS


CN 1-Butanone, 4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(3-nitrophenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215046-75-6 CAPLUS

CN 1-Butanone, 4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(3-nitrophenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 215046-77-8 CAPLUS

CN 1-Butanone, 1-[3-[(2-bromophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]- (CA INDEX NAME)




RN 215046-79-0 CAPLUS

CN 1-Butanone, 1-[3-[(2,6-difluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]- (CA INDEX NAME)




RN 215046-81-4 CAPLUS

CN 1-Butanone, 1-[3-[[3,5-bis(trifluoromethyl)phenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 215046-83-6 CAPLUS


CN 1-Butanone, 1-[3-[(1,3-benzodioxol-5-yl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215046-85-8 CAPLUS

CN 1-Butanone, 1-[3-(1,3-benzodioxol-5-ylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 215046-87-0 CAPLUS


CN 1-Butanone, 4-[1-[2-[(4-methyl-1-piperazinyl)carbonyl]phenyl]methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl


RN 215046-89-2 CAPLUS

CN 1-Butanone, 4-[1-[2-[(4-methyl-1-piperazinyl)carbonyl]phenyl]methyl]-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215046-91-6 CAPLUS


CN 1-Butanone, 4-[1-[[2-(4-morpholinylcarbonyl)phenyl)methyl]-4-piperidinyl]-
1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-,
hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215046-93-8 CAPLUS

CN 1-Butanone, 4-[1-[[2-(4-morpholinylcarbonyl)phenyl)methyl]-4-piperidinyl]-
1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-
(CA INDEX NAME)



RN 215046-95-0 CAPLUS


CN Acetamide, N-[2-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 215046-99-4 CAPLUS


CN 1-Butanone, 1-[3-[(2-aminophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

RN 215047-03-3 CAPLUS


CN Urea, N-[2-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenyl]-N'-methyl-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 215047-05-5 CAPLUS

CN Urea, N-[2-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenyl]-N'-methyl-, (CA INDEX NAME)



RN 215047-07-7 CAPLUS

CN Benzenesulfonamide, N-[2-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenyl]-4-methyl-, dihydrochloride (9Cl) (CA INDEX NAME)




●2 HCl

RN 215047-08-8 CAPLUS


CN Benzenesulfonamide, N-[2-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenyl]-4-methyl-, dihydrochloride (9Cl) (CA INDEX NAME)

1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]phenyl]-4-methyl- (CA INDEX NAME)



RN 215047-09-9 CAPLUS


CN Methanesulfonamide, N-[2-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215047-11-3 CAPLUS

CN Methanesulfonamide, N-[2-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]phenyl]- (CA INDEX NAME)



RN 215047-13-5 CAPLUS


CN Benzenesulfonamide, 4-methyl-N-[2-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215047-15-7 CAPLUS

CN Benzenesulfonamide, 4-methyl-N-[2-[[[4-(4-oxo-4-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]butyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 215047-17-9 CAPLUS


CN 1-Propanone, 3-(1-acetyl-4-piperidinyl)-1-[2,3,4,5-tetrahydro-3-(2-naphthalenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● 2 HCl


RN 215047-33-9 CAPLUS

CN 1-Propanone, 3-[1-(1-naphthalenylmethyl)-4-piperidiny]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215047-35-1 CAPLUS


CN 1-Propanone, 3-[1-(2-naphthalenylmethyl)-4-piperidiny]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 215047-37-3 CAPLUS

CN 1-Propanone, 3-[1-(2-naphthalenylmethyl)-4-piperidiny]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 215047-57-7 CAPLUS


CN Benzoic acid, 2-[[7-[3-(1-acetyl-4-piperidiny)-1-oxopropyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 215047-59-9 CAPLUS

CN Benzoic acid, 2-[[7-[3-(1-acetyl-4-piperidiny)-1-oxopropyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-, methyl ester (CA INDEX NAME)



RN 215047-61-3 CAPLUS


CN Benzoic acid, 3-[[7-[3-(1-acetyl-4-piperidiny)-1-oxopropyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 215047-63-5 CAPLUS

CN Benzoic acid, 3-[[7-[3-(1-acetyl-4-piperidinyl)-1-oxopropyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-, methyl ester (CA INDEX NAME)



RN 215047-64-6 CAPLUS


CN Benzoic acid, 4-[[7-[3-(1-acetyl-4-piperidinyl)-1-oxopropyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 215047-65-7 CAPLUS


CN Benzoic acid, 4-[[7-[3-(1-acetyl-4-piperidinyl)-1-oxopropyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-, methyl ester (CA INDEX NAME)




RN 215047-66-8 CAPLUS

CN Carbamic acid, [[3-[[7-[4-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]-1-oxobutyl]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenyl]amino]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 215047-84-0 CAPLUS


CN 1-Butanone, 1-[3-[(2-chlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-[1-[(2-methylphenyl)methyl]-4-piperidinyl]- (CA INDEX NAME)



RN 215047-91-9 CAPLUS

CN 1-Propanone, 3-[1-(phenylmethyl)-4-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)

10/598,888



REFERENCE COUNT:


7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 45 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1998:169454 CAPLUS
 DOCUMENT NUMBER: 128:217191
 ORIGINAL REFERENCE NO.: 128:43027a, 43030a
 TITLE: Preparation of 3,4-dinitrobenzamides as calcitonin gene related peptide receptor ligands.
 INVENTOR(S): Daines, Robert A.
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA; Daines, Robert A.
 SOURCE: PCT Int. Appl., 45 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9809630	A1	19980312	WO 1997-US15931	19970909
W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, GH, HU, ID, IL, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, AZ, BY, KZ, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
IN 1997/DE02510	A	20050311	IN 1997-DE2510	19970904
ZA 9708046	A	19980401	ZA 1997-8046	19970908
CA 2264942	A1	19980312	CA 1997-2264942	19970909
AU 9742616	A	19980326	AU 1997-42616	19970909
EP 934068	A1	19990811	EP 1997-940951	19970909
R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
JP 2002511836	T	20020416	JP 1998-512994	19970909
PRIORITY APPLN. INFO.:			US 1996-25690P	P 19960909
			US 1997-48012P	P 19970529
			WO 1997-US15931	W 19970909

OTHER SOURCE(S): MARPAT 128:217191
 GI



AB Title compds. [I; R1 = H, Me, alkyl, phenylalkyl, heterocyclalkyl, aminoalkyl, carboxyalkyl, alkoxyalkyl, etc.; R2 = (substituted) aryl, heteroaryl, arylalkyl, heteroarylalkyl; R1R2N = (benzo-fused) 5-6 membered heterocyclalkyl], were prepared. Thus, N-methylaniline in CH2Cl2 was treated with Et3N and then with 3,4-dinitrobenzoyl chloride and the mixture was shaken overnight to give N-methyl-N-phenyl-3,4-dinitrobenzamide. I antagonized CGRP receptors with IC50 = 0.001-100 μ M.


IT 204261-51-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

10/598,888

(preparation of 3,4-dinitrobenzamides as calcitonin gene related peptide
receptor ligands)

RN 204261-51-8 CAPLUS

CN Methanone, (3,4-dinitrophenyl) (1,2,4,5-tetrahydro-3H-benzazepin-3-yl)-
(CA INDEX NAME)



REFERENCE COUNT: 1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 46 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:629208 CAPLUS

DOCUMENT NUMBER: 125:316116

ORIGINAL REFERENCE NO.: 125:58835a,58838a

TITLE: Pharmacokinetics of a series of bis(methanesulfonamido-arylakyl)amines in the beagle dog

AUTHOR(S): Walker, D. K.; Beaumont, K. C.; Stopher, D. A.; Smith, D. A.

CORPORATE SOURCE: Department of Drug Metabolism, Pfizer Central Research, Sandwich, CT13 9NJ, UK

SOURCE: Xenobiotica (1996), 26(10), 1101-1111

CODEN: XENOBH; ISSN: 0049-8254

PUBLISHER: Taylor & Francis

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The pharmacokinetics of three closely related analogs of dofetilide have been investigated in the beagle dog. These have been compared with those of dofetilide and related to physicochem. properties and structural features of the mols. Following i.v. administration, the four compds. exhibit elimination half-lives ranging from 4.6 to 19 h. This range is due to changes in both volume of distribution and plasma clearance across the series. In vitro plasma protein binding shows a relationship to lipophilicity within this series. Protein binding increasing from 54% for dofetilide, the least lipophilic compound ($\log D_{7.4} = 0.73$), to 92% for the most lipophilic analog ($\log D_{7.4} = 2.07$). There is a trend for a decrease in the volume of distribution with increased plasma protein binding. Plasma clearance values range from 2.4 to 10.2 mL/min/kg and are comprised of renal and non-renal components. Renal clearance rates from 0.11 to 2.9 mL/min/kg and shows an inverse correlation with the lipophilicity of the compds. Values for the renal clearance of unbound drug suggest that only the most lipophilic derivative has sufficient membrane affinity to undergo tubular reabsorption. Non-renal clearance of either total or free drug shows no relationship with lipophilicity. Highest values are observed for the two compds. with a Me substituent on the tertiary amine and lowest values for the two compds. in which the tertiary amine is incorporated into a 7-membered ring. In vitro metabolism in dog liver microsomes also shows increased lability for the two N-Me compds. The N-desmethyl metabolite is the major product in both cases.

IT 118454-05-0


RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(bis(methanesulfonamido-arylakyl)amine dofetilide analog pharmacokinetics and metabolism)

RN 118454-05-0 CAPLUS

CN Methanesulfonamide, N-[4-[2-[1,2,4,5-tetrahydro-7-[(methylsulfonyl)amino]-3H-3-benzazepin-3-yl]ethyl]phenyl]- (CA INDEX NAME)

10/598,888



L20 ANSWER 47 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:466898 CAPLUS

DOCUMENT NUMBER: 125:114489

ORIGINAL REFERENCE NO.: 125:21482h,21483a

TITLE: Preparation of heterocyclic amine-compound antagonists of gonadotropin-releasing hormone receptors

INVENTOR(S): Kato, Kaneyoshi; Sugiura, Yoshihiro; Kato, Koichi

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: Eur. Pat. Appl., 123 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 712845	A1	19960522	EP 1995-308331	19951121
EP 712845	B1	20011017		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 08253447	A	19961001	JP 1995-300330	19951117
CA 2163325	A1	19960522	CA 1995-2163325	19951120
US 5633248	A	19970527	US 1995-561282	19951121
AT 207058	T	20011115	AT 1995-308331	19951121
			JP 1994-286245	A 19941121

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 125:114489

GI For diagram(s), see printed CA Issue.

AB The title compds. [I; Ar1, Ar2 = (un)substituted aryl; P, Q = divalent aliphatic hydrocarbyl having ≥ 2 carbon atoms and optionally having ether O or S in the chain; R1, R3 = COR, CONHR, hydrocarbyl; R = hydrocarbyl, heterocyclyl; R2, R4 = H, alkyl; group; NR1R2 and/or NR3R4 may form a nitrogen-containing heterocyclic group; j = 0, 1], which demonstrate high gonadotropin-releasing hormone (GnRH) receptor antagonist activity, useful in the treatment of hormone-dependent diseases [e.g., prostate cancer (no data), endometriosis (no data), etc. (no data)], are prepared and I-containing formulations presented. Thus, II was prepared and demonstrated a IC50 of 0.08 μM against the binding of 125I-leuprolerin to human GnRH receptors.


IT 179313-30-5P 179313-31-6P 179313-32-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic amine-compound antagonists of gonadotropin-releasing hormone receptors)

RN 179313-30-5 CAPLUS


CN Benzenepropanamide, N-[4,4-diphenyl-7-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)heptyl]-4-methoxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 179313-31-6 CAPLUS


CN Benzenepropanamide, N-[7-(7-acetyl-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4,4-diphenylheptyl]-4-methoxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 179313-32-7 CAPLUS

CN Benzenepropanamide, N-[4,4-diphenyl-7-(1,2,4,5-tetrahydro-7,8-dimethoxy-3H-3-benzazepin-3-yl)heptyl]-4-methoxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L20 ANSWER 48 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:550906 CAPLUS

DOCUMENT NUMBER: 122:314547

ORIGINAL REFERENCE NO.: 122:57205a,57208a

TITLE: Preparation of urea residue-substituted heterocyclic compounds with antithrombotic, antineoplastic and blood platelet-aggregation inhibition activities
 INVENTOR(S): Himmelsbach, Frank; Pieper, Helmut; Austel, Volkhart; Linz, Guenter; Guth, Brian; Mueller, Thomas; Weisenberger, Johannes

PATENT ASSIGNEE(S): Dr. Karl Thomae GmbH, Germany

SOURCE: Eur. Pat. Appl., 81 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 612741	A1	19940831	EP 1994-102557	19940221
EP 612741	B1	19980610		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
DE 4305388	A1	19940825	DE 1993-4305388	19930222
DE 4332168	A1	19950323	DE 1993-4332168	19930922
EE 3397	B1	20010416	EE 1994-311	19941123
PRIORITY APPLN. INFO.:			DE 1993-4305388	A 19930222
			DE 1993-4332168	A 19930922

OTHER SOURCE(S): MARPAT 122:314547

AB The title compds., which contain urea-like moieties, often in the form of divalent imidazolidinone groups, which demonstrate a combination of antithrombotic, antineoplastic (no data), and blood platelet-aggregation inhibition activities, are prepared and pharmaceutical dosage forms containing them presented. Thus, 1-[4-(2-carboxyethyl)phenyl]-3-(1,2,3,4-tetrahydroisoquinolin-6-yl)imidazolidin-2-one was prepared and demonstrated ED50 for blood platelet aggregation inhibition of 40 nM.

IT 163066-94-2P 163066-97-5P 163067-71-8P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of urea residue-substituted heterocyclic compds. with antithrombotic, antineoplastic and blood platelet aggregation inhibition activities)

RN 163066-94-2 CAPLUS

CN Cyclohexanepropanoic acid, 4-[2-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-1-imidazolidinyl]-, monohydrochloride, trans- (9CI)
 (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 163066-97-5 CAPLUS

CN Cyclohexanepropanoic acid, 4-[3-[3-(cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-2-oxo-1-imidazolidinyl]-, monohydrochloride, trans-(9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 163067-71-8 CAPLUS

CN Cyclohexanepropanoic acid, 4-[2-oxo-3-(2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl)-1-imidazolidinyl]-, methyl ester, monohydrochloride, trans-(9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

10/598,888

L20 ANSWER 49 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:452025 CAPLUS

DOCUMENT NUMBER: 122:213956

ORIGINAL REFERENCE NO.: 122:39111a, 39114a

TITLE: Preparation of N-(3-benzazepinopropyl)benzamides and analogs as antiarrhythmics

INVENTOR(S): Nadler, Guy Marguerite Marie Gerard; Martin, Michel Jean Roger

PATENT ASSIGNEE(S): Smithkline Beecham Laboratoires Pharmaceutiques, Fr.

SOURCE: PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9427971	A1	19941208	WO 1994-EP1705	19940524
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
FR 2705675	A1	19941202	FR 1993-6346	19930527
FR 2705675	B1	19960503		
AU 9469718	A	19941220	AU 1994-69718	19940524
EP 700389	A1	19960313	EP 1994-918377	19940524
R: AT, CH, DE, FR, GB, IT, LI, NL				
JP 09501405	T	19970210	JP 1994-500225	19940524
ZA 9403641	A	19950412	ZA 1994-3641	19940525
PRIORITY APPLN. INFO.:			FR 1993-6346	A 19930527
			FR 1993-9327	A 19930729
			WO 1994-EP1705	W 19940524

OTHER SOURCE(S): MARPAT 122:213956

GI




- AB Title compds. [I; A = CH₂,CH₂CH₂, CH:CH, CO, COCH₂; B = CH₂, CO; R = EN(ZR₃)DQ; D = CO, SO₂, NHCO, CH:CH, P(O)OR₆; E = (alkyl-substituted) alkylene; Q = aryl[alk(en)yl], heteroaryl, etc.; R₁,R₂ = H, OH, alkyl, alkoxy, etc.; R₃ = (un)substituted Ph; R₆ = alkyl; Z = bond, CH₂, OCH₂CH₂, etc.] were prepared. Thus, 2,3,4,5-tetrahydro-7,8-dimethoxy-1H-3-benzazepine was N-alkylated by 3,4-(MeO)C₆H₃NHCOCH₂CH₂Cl and the reduced product N-acylated by 4-(O₂N)C₆H₄COCl to give title compound II. Data for effect of II on action potential duration of isolated guinea pig papillary muscle were given in graphic form.
- IT 161884-99-7P 161885-21-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of N-(3-benzazepinopropyl)benzamides and analogs as antiarrhythmics)
- RN 161884-99-7 CAPLUS
- CN 2-Propenamide, N-(3,4-dimethoxyphenyl)-N-[3-(1,2,4,5-tetrahydro-7,8-dimethoxy-3H-3-benzazepin-3-yl)propyl]-3-(2-thienyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

- RN 161885-21-8 CAPLUS
- CN 2-Propenamide, N-(3,4-dimethoxyphenyl)-N-[3-(1,2,4,5-tetrahydro-7,8-dimethoxy-3H-3-benzazepin-3-yl)propyl]-3-(2-thienyl)- (CA INDEX NAME)

10/598,888



L20 ANSWER 50 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:270451 CAPLUS

DOCUMENT NUMBER: 120:270451

ORIGINAL REFERENCE NO.: 120:47919a, 47922a

TITLE: Condensed heterocyclic ketone cholinesterase inhibitors, their production and use

INVENTOR(S): Goto, Giichi; Miyamoto, Masaomi; Ishihara, Yuji

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: Eur. Pat. Appl., 95 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 560235	A1	19930915	EP 1993-103614	19930306
EP 560235	B1	19970604		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AU 9333803	A	19930916	AU 1993-33803	19930225
AU 658481	B2	19950413		
NO 9300783	A	19930910	NO 1993-783	19930303
ZA 9301510	A	19940903	ZA 1993-1510	19930303
US 5462934	A	19951031	US 1993-26041	19930304
AT 154020	T	19970615	AT 1993-103614	19930306
CA 2091216	A1	19930910	CA 1993-2091216	19930308
JP 06166676	A	19940614	JP 1993-46747	19930308
JP 3523887	B2	20040426		
CN 1078969	A	19931201	CN 1993-102438	19930309
CN 1039119	C	19980715		
HU 67283	A2	19950328	HU 1993-659	19930309
PRIORITY APPLN. INFO.:			JP 1992-50960	A 19920309
			JP 1992-97948	A 19920417
			JP 1992-145852	A 19920605
			JP 1992-210225	A 19920806
			JP 1992-259606	A 19920929

OTHER SOURCE(S): MARPAT 120:270451

GI



II

AB The title compds. I [R1 = H, (un)substituted hydrocarbon or acyl group;

R2-R4 = H, (un)substituted hydrocarbon group; k = 0-3; m = 1-8; n = 1-10; R3R4N = (un)substituted heterocyclic group; when k = 0 and n = 2 then n = ≥ 2], which are effective cholinesterase inhibitors and useful in the treatment of senile dementia (no data) and/or Alzheimer's disease (no data), are prepared and I-containing formulations presented. Thus, dihydroindole derivative II, m.p. 194-196°, was prepared and demonstrated 50% acetylcholinesterase inhibitory activity (rat cerebral cortex as the cholinesterase source) of 0.0152 μ M vs. 0.220 μ M for physostigmine.

IT 153030-50-3 153032-00-9 153032-11-2


153032-13-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(cholinesterase inhibitory activity of)


RN 153030-50-3 CAPLUS

CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153032-00-9 CAPLUS

CN 1-Propanone, 3-[4-[(2-methyl-4-thiazolyl)methyl]-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153032-11-2 CAPLUS

CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 153032-13-4 CAPLUS

CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(2-phenylethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




IT 153030-32-1P 153030-33-2P 153030-44-5P
 153030-45-6P 153030-46-7P 153030-47-8P
 153030-48-9P 153030-49-0P 153030-50-3P
 153030-51-4P 153030-52-5P 153030-53-6P
 153030-59-2P 153030-60-5P 153030-64-9P
 153030-65-0P 153030-66-1P 153030-67-2P
 153030-68-3P 153030-69-4P 153030-70-7P
 153030-71-8P 153030-72-9P 153030-73-0P
 153030-74-1P 153030-75-2P 153030-76-3P
 153030-77-4P 153030-82-1P 153030-85-4P
 153030-86-5P 153030-89-8P 153030-97-8P
 153030-98-9P 153030-99-0P 153031-00-6P
 153031-01-7P 153031-02-8P 153031-03-9P
 153031-04-0P 153031-05-1P 153031-06-2P
 153031-07-3P 153031-08-4P 153031-10-8P
 153031-12-0P 153031-13-1P 153031-15-3P
 153031-28-8P 153031-36-8P 153031-37-9P
 153031-39-1P 153031-40-4P 153031-41-5P
 153031-43-7P 153031-44-8P 153031-45-9P
 153031-46-0P 153031-47-1P 153031-48-2P
 153031-49-3P 153031-50-6P 153031-51-7P
 153031-52-8P 153031-53-9P 153031-54-0P
 153031-55-1P 153031-56-2P 153031-57-3P
 153031-58-4P 153031-59-5P 153031-60-8P
 153031-61-9P 153031-62-0P 153031-63-1P
 153031-64-2P 153031-65-3P 153031-67-5P
 153031-68-6P 153031-69-7P 153031-73-3P
 153031-74-4P 153031-76-6P 153031-79-9P
 153031-80-2P 153031-87-9P 153031-88-0P
 153031-90-4P 153031-91-5P 153031-92-6P
 153031-94-8P 153031-95-9P 153031-96-0P
 153031-97-1P 153031-98-2P 153031-99-3P
 153032-00-9P 153032-01-0P 153032-02-1P
 153032-03-2P 153032-04-3P 153032-05-4P
 153032-06-5P 153032-07-6P 153032-08-7P
 153032-09-8P 153032-10-1P 153032-11-2P
 153032-12-3P 153032-13-4P 153032-14-5P
 153032-16-7P 153032-17-8P 153032-18-9P
 153032-22-5P 153032-23-6P 153032-25-8P
 153032-26-9P 153032-31-6P 153032-37-2P
 153032-42-9P 153032-43-0P 153032-44-1P
 153032-46-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and cholinesterase inhibitory activity of)

RN 153030-32-1 CAPLUS


CN 1-Butanone, 4-(1-piperidinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 153030-33-2 CAPLUS

CN 1-Butanone, 4-(1-piperidinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 153030-44-5 CAPLUS


CN 1-Propanone, 3-(1-piperidinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 153030-45-6 CAPLUS


CN 1-Propanone, 3-(1-piperidinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 153030-46-7 CAPLUS


CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-

(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:3) (CA INDEX NAME)




●3 HCl

RN 153030-47-8 CAPLUS
CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 153030-48-9 CAPLUS
CN 1-Propanone, 3-[4-(2-pyridinyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl


RN 153030-49-0 CAPLUS
CN 1-Propanone, 3-[4-(4-fluorobenzoyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 153030-50-3 CAPLUS

CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153030-51-4 CAPLUS

CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 153030-52-5 CAPLUS


CN 1-Propanone, 3-[4-(2-pyridinyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 153030-53-6 CAPLUS


CN 1-Propanone, 3-[4-(4-fluorobenzoyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-

(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 153030-59-2 CAPLUS


CN Ethanone, 2-(1-piperidinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 153030-60-5 CAPLUS

CN Ethanone, 2-(1-piperidinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153030-64-9 CAPLUS

CN 1-Propanone, 3-(4-methyl-1-piperazinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 153030-65-0 CAPLUS
CN 1-Propanone, 3-[4-(2-hydroxyethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 153030-66-1 CAPLUS
CN 1-Propanone, 3-(4-morpholinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 153030-67-2 CAPLUS
CN 4-Piperidinone, 1-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 153030-68-3 CAPLUS

CN 1,3,8-Triazaspiro[4.5]decan-4-one, 8-[3-oxo-3-(2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-1-phenyl- (CA INDEX NAME)



RN 153030-69-4 CAPLUS


CN 1-Propanone, 3-(3,4-dihydro-2(1H)-isoquinolinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 153030-70-7 CAPLUS

CN 1-Propanone, 3-(4-acetyl-1-piperazinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 153030-71-8 CAPLUS
 CN 1-Propanone, 3-(4-phenyl-1-piperazinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 153030-72-9 CAPLUS
 CN 1-Propanone, 3-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl


RN 153030-73-0 CAPLUS
 CN 1-Propanone, 3-[[[(2-chlorophenyl)methyl](2-hydroxyethyl)amino]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 153030-74-1 CAPLUS

CN 1H-3-Benzazepine, 7,7'-[1,4-piperazinediyl]bis(1-oxo-3,1-propanediyl)]bis[2,3,4,5-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 153030-75-2 CAPLUS

CN 1-Propanone, 3-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 153030-76-3 CAPLUS
CN Ethanone, 2-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:3) (CA INDEX NAME)




●3 HCl

RN 153030-77-4 CAPLUS
CN 1-Hexanone, 6-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:3) (CA INDEX NAME)




●3 HCl

RN 153030-82-1 CAPLUS
CN 1-Propanone, 3-[4-(4-pyridinylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:4) (CA INDEX NAME)




● 4 HCl

RN 153030-85-4 CAPLUS
CN 1-Piperazinecarboxaldehyde, 4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 153030-86-5 CAPLUS
CN 1-Propanone, 3-[bis(phenylmethyl)amino]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 153030-89-8 CAPLUS
CN 1-Propanone, 3-[hexahydro-4-(phenylmethyl)-1H-1,4-diazepin-1-yl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl


RN 153030-97-8 CAPLUS

CN 1-Propanone, 3-(4-methyl-1-piperazinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153030-98-9 CAPLUS

CN 1-Propanone, 3-[4-(2-hydroxyethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153030-99-0 CAPLUS

CN 1-Propanone, 3-(4-morpholinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153031-00-6 CAPLUS

CN 4-Piperidinone, 1-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]- (CA INDEX NAME)




RN 153031-01-7 CAPLUS

CN 1-Propanone, 3-[(3,4-dihydro-2(1H)-isoquinolinyl)-1-(2,3,4,5-tetrahydro-3-phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153031-02-8 CAPLUS

CN 1-Propanone, 3-[(4-acetyl-1-piperazinyl)-1-[2,3,4,5-tetrahydro-3-phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153031-03-9 CAPLUS

CN 1-Propanone, 3-[(4-phenyl-1-piperazinyl)-1-[2,3,4,5-tetrahydro-3-phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153031-04-0 CAPLUS

CN 1-Propanone, 3-[(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl)-1-[2,3,4,5-tetrahydro-3-phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153031-05-1 CAPLUS

CN 1-Propanone, 3-[(2-chlorophenyl)methyl] (2-hydroxyethyl)amino]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153031-06-2 CAPLUS

CN 1-Propanone, 3-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153031-07-3 CAPLUS

CN Ethanone, 2-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153031-08-4 CAPLUS

CN 1-Hexanone, 6-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153031-10-8 CAPLUS

CN 1-Propanone, 3-[4-(4-pyridinylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153031-12-0 CAPLUS

CN 1-Piperazinecarboxaldehyde, 4-[3-oxo-3-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]propyl]- (CA INDEX NAME)




RN 153031-13-1 CAPLUS

CN 1-Propanone, 3-[bis(phenylmethyl)amino]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153031-15-3 CAPLUS

CN 1-Propanone, 3-[hexahydro-4-(phenylmethyl)-1H-1,4-diazepin-1-yl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 153031-28-8 CAPLUS


CN 1-Propanone, 3-[(1-piperazinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 153031-36-8 CAPLUS


CN 1-Pentanone, 5-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl


RN 153031-37-9 CAPLUS

CN 1-Propanone, 1-[3-[(3-chlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-[4-(phenylmethyl)-1-piperazinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 153031-39-1 CAPLUS
 CN 1-Propanone, 3-[4-[(2-chlorophenyl)methyl]-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:3)
 (CA INDEX NAME)




● 3 HCl

RN 153031-40-4 CAPLUS
 CN 1-Propanone, 3-[4-[(3-chlorophenyl)methyl]-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:3)
 (CA INDEX NAME)



● 3 HCl


RN 153031-41-5 CAPLUS
 CN 1-Propanone, 3-[4-[(4-chlorophenyl)methyl]-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:3)
 (CA INDEX NAME)



● 3 HCl


RN 153031-43-7 CAPLUS

CN 1-Propanone, 1-[3-[(4-chlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-[4-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)



RN 153031-44-8 CAPLUS


CN 1-Propanone, 1-[3-[(2-chlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-[4-(phenylmethyl)-1-piperazinyl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl


RN 153031-45-9 CAPLUS

CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-[(4-nitrophenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 153031-46-0 CAPLUS
 CN Benzonitrile, 2-[[1,2,4,5-tetrahydro-7-[1-oxo-3-[4-(phenylmethyl)-1-piperazinyl]propyl]-3H-3-benzazepin-3-yl]methyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 153031-47-1 CAPLUS
 CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 153031-48-2 CAPLUS
 CN 1-Propanone, 3-[4-[(3-methoxyphenyl)methyl]-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 153031-49-3 CAPLUS
CN 1-Propanone, 3-[4-(1-phenylethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 153031-50-6 CAPLUS
CN 1-Propanone, 3-[4-(2-furanylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153031-51-7 CAPLUS
CN 1-Propanone, 3-[4-[(2-methyl-4-thiazolyl)methyl]-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 153031-52-8 CAPLUS
CN Benzonitrile, 4-[[1,2,4,5-tetrahydro-7-[1-oxo-3-[4-(phenylmethyl)-1-piperazinyl]propyl]-3H-3-benzazepin-3-yl]methyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 153031-53-9 CAPLUS
CN 1-Propanone, 1-[3-[(3-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-[4-(phenylmethyl)-1-piperazinyl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 153031-54-0 CAPLUS
CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 153031-55-1 CAPLUS
 CN 1-Propanone, 1-[3-[(4-dimethoxyphenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-[4-(phenylmethyl)-1-piperazinyl]-, hydrochloride (1:3)
 (CA INDEX NAME)




● 3 HCl

RN 153031-56-2 CAPLUS
 CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl


RN 153031-57-3 CAPLUS
 CN 1-Propanone, 1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-[4-(phenylmethyl)-1-piperazinyl]-, hydrochloride (1:3)
 (CA INDEX NAME)



● 3 HCl

RN 153031-58-4 CAPLUS


CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-[(3-methylphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 153031-59-5 CAPLUS


CN 1-Propanone, 1-[3-[(2-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-[4-(phenylmethyl)-1-piperazinyl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl


RN 153031-60-8 CAPLUS

CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-[(3-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 153031-61-9 CAPLUS
 CN Benzonitrile, 3-[[1,2,4,5-tetrahydro-7-[1-oxo-3-[4-(phenylmethyl)-1-piperazinyl]propyl]-3H-3-benzazepin-3-yl]methyl]-, hydrochloride (1:3)
 (CA INDEX NAME)




● 3 HCl

RN 153031-62-0 CAPLUS
 CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl


RN 153031-63-1 CAPLUS
 CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-[(4-hydroxyphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

RN 153031-64-2 CAPLUS


CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(2-phenylethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

RN 153031-65-3 CAPLUS


CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-[(3-(phenylmethoxy)phenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

RN 153031-67-5 CAPLUS


CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-[(3-nitrophenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 153031-68-6 CAPLUS


CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-[(3,4,5-trimethoxyphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 153031-69-7 CAPLUS


CN 1-Propanone, 1-[3-[2-(3,4-dimethoxyphenyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-[4-(phenylmethyl)-1-piperazinyl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 153031-73-3 CAPLUS


CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-[(3-hydroxyphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 153031-74-4 CAPLUS


CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-[(2-hydroxyphenyl)methyl]-1H-3-benzazepin-7-yl]-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 153031-76-6 CAPLUS

CN 1-Propanone, 3-[4-[(2-methyl-4-thiazolyl)methyl]-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:4) (CA INDEX NAME)




● 4 HCl

RN 153031-79-9 CAPLUS


CN 1-Pentanone, 5-(1-piperazinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-

benzazepin-7-yl]- (CA INDEX NAME)




RN 153031-80-2 CAPLUS

CN 1-Propanone, 3-(1-piperazinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153031-87-9 CAPLUS

CN 1-Pentanone, 5-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153031-88-0 CAPLUS

CN 1-Propanone, 1-[3-[(3-chlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-[4-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 153031-90-4 CAPLUS

CN 1-Propanone, 3-[4-[(2-chlorophenyl)methyl]-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153031-91-5 CAPLUS

CN 1-Propanone, 3-[4-[(3-chlorophenyl)methyl]-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153031-92-6 CAPLUS

CN 1-Propanone, 3-[4-[(4-chlorophenyl)methyl]-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153031-94-8 CAPLUS

CN 1-Propanone, 1-[3-[(2-chlorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-[4-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 153031-95-9 CAPLUS

CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-[(4-nitrophenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153031-96-0 CAPLUS

CN Benzonitrile, 2-[[1,2,4,5-tetrahydro-7-[1-oxo-3-[4-(phenylmethyl)-1-piperazinyl]propyl]-3H-3-benzazepin-3-yl]methyl]- (CA INDEX NAME)




RN 153031-97-1 CAPLUS

CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methylphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153031-98-2 CAPLUS

CN 1-Propanone, 3-[4-[(3-methoxyphenyl)methyl]-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153031-99-3 CAPLUS

CN 1-Propanone, 3-[4-(1-phenylethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153032-00-9 CAPLUS

CN 1-Propanone, 3-[4-[(2-methyl-4-thiazolyl)methyl]-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153032-01-0 CAPLUS

CN Benzonitrile, 4-[[1,2,4,5-tetrahydro-7-[1-oxo-3-[4-(phenylmethyl)-1-piperazinyl]propyl]-3H-3-benzazepin-3-yl]methyl]- (CA INDEX NAME)




RN 153032-02-1 CAPLUS

CN 1-Propanone, 1-[3-[(3-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-[4-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 153032-03-2 CAPLUS

CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-[(2-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153032-04-3 CAPLUS

CN 1-Propanone, 1-[3-[(3,4-dimethoxyphenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-[4-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 153032-05-4 CAPLUS

CN 1-Propanone, 1-[3-[(4-methoxyphenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-[4-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 153032-06-5 CAPLUS

CN 1-Propanone, 1-[3-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-[4-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 153032-07-6 CAPLUS

CN 1-Propanone, 1-[3-[(3-methylphenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-[4-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 153032-08-7 CAPLUS

CN 1-Propanone, 1-[3-[(2-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-[4-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 153032-09-8 CAPLUS

CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-[(3-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153032-10-1 CAPLUS

CN Benzonitrile, 3-[[1,2,4,5-tetrahydro-7-[1-oxo-3-[4-(phenylmethyl)-1-piperazinyl]propyl]-3H-3-benzazepin-3-yl]methyl]- (CA INDEX NAME)




RN 153032-11-2 CAPLUS

CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-[(4-methoxyphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153032-12-3 CAPLUS

CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-[(4-hydroxyphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153032-13-4 CAPLUS

CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(2-phenylethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153032-14-5 CAPLUS

CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-[[3-(phenylmethoxy)phenyl]methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153032-16-7 CAPLUS

CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-[(3-nitrophenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153032-17-8 CAPLUS

CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-[(3,4,5-trimethoxyphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153032-18-9 CAPLUS

CN 1-Propanone, 1-[3-[2-(3,4-dimethoxyphenyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-3-[4-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 153032-22-5 CAPLUS

CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-[(3-hydroxyphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 153032-23-6 CAPLUS

CN 1-Propanone, 3-[4-(phenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-[(2-hydroxyphenyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 153032-25-8 CAPLUS


CN 1-Propanone, 3-(diphenylamino)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 153032-26-9 CAPLUS

CN 1-Propanone, 3-(diphenylamino)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 153032-31-6 CAPLUS


CN 1-Propanone, 1-(3-benzoyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-[4-(phenylmethyl)-1-piperazinyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 153032-37-2 CAPLUS

CN 1-Propanone, 1-(3-benzoyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-[4-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)



RN 153032-42-9 CAPLUS


CN 1-Butanone, 2-phenyl-4-(1-piperidinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 153032-43-0 CAPLUS

CN 1-Butanone, 2-phenyl-4-(1-piperidinyl)-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 153032-44-1 CAPLUS


CN 1-Butanone, 4-(dimethylamino)-2-phenyl-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 153032-46-3 CAPLUS

CN 1-Butanone, 4-(dimethylamino)-2-phenyl-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



IT 153030-09-2P 153030-10-5P 153030-15-0P

153030-16-1P 153030-17-2P 153030-29-6P

153030-31-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of cholinesterase inhibitors)

RN 153030-09-2 CAPLUS


CN Ethanone, 1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)

10/598,888



RN 153030-10-5 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 153030-15-0 CAPLUS

CN Ethanone, 2-chloro-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 153030-16-1 CAPLUS

CN 1-Propanone, 3-chloro-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 153030-17-2 CAPLUS


CN 1-Hexanone, 6-bromo-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-

7-yl]- (CA INDEX NAME)




RN 153030-29-6 CAPLUS

CN Ethanone, 2-phenyl-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 153030-31-0 CAPLUS


CN 1-Butanone, 4-bromo-2-phenyl-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



L20 ANSWER 51 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1991:206799 CAPLUS
 DOCUMENT NUMBER: 114:206799
 ORIGINAL REFERENCE NO.: 114:34863a,34866a
 TITLE: Preparation of 4-phenylbutenamides and
 4-phenylpropenamides for treatment of heart ischemia
 INVENTOR(S): Minami, Norio; Ozaki, Fumihiro; Ishibashi, Keiji;
 Kabasawa, Yasuhiro; Ikemori, Megumi; Ogawa, Toshiaki;
 Kawamura, Takanori
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 40 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02306951	A	19901220	JP 1989-126175	19890519
JP 2747013	B2	19980506		
PRIORITY APPLN. INFO.:			JP 1989-126175	19890519
OTHER SOURCE(S):	MARPAT	114:206799		

GI



AB GR1C:CR2(CH2)mC(:X)NR3ANR4(CH2)nJ [I; G = (substituted) Ph, naphthyl; X = S, O; A = C1-6 (alkyl)alkylene; J = (substituted) Ph; m = 0, 1; n = 1-6; R1,R2 = H, cyano, alkyl, halo; or R1R2 together with the C atoms of the Ph ring can form a ring optionally containing O; R3, R4 = H, (cyclo)alkyl, alkenyl, alkoxy, CF3; R3NANR4, R3NA, ANR4 can form a 5- or 7-membered saturated heterocyclic ring; or R3R2, R4N(CH2)n form a ring], which reduce heart beat and are useful for the treatment of heart ischemia, e.g., coronary arteriosclerosis, angina pectoris, and cardiac infarction, were prepared. Thus, treatment of (E)-4-(4-fluorophenyl)-3-butenic acid with SOC12 in refluxing benzene followed by amidation with N-methyl-N-[2-(3,4-dimethoxyphenyl)ethyl]-1,3-propanediamine (preparation given) in the presence of K2CO3 in CH2Cl2, gave the title amide [(E)-II]. Approx. 120 I were prepared and some I at 0.3 mg/kg in dogs reduced the heart beat $\leq 30\%$.


IT 127406-00-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, for treatment of heart ischemia)

RN 127406-00-2 CAPLUS

CN 2-Propenamide, 3-(4-fluorophenyl)-N-[3-(1,2,4,5-tetrahydro-7,8-dimethoxy-3H-3-benzazepin-3-yl)propyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

10/598,888



L20 ANSWER 52 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1990:423909 CAPLUS

DOCUMENT NUMBER: 113:23909

ORIGINAL REFERENCE NO.: 113:4151a,4154a

TITLE: Preparation of butenoic or propenoic acid derivatives containing aryl and heterocyclyl groups having coronary vasodilating and heart rate lowering effect
 Minami, Norio; Ozaki, Fumihiko; Ishibashi, Keiji; Kabasawa, Yasuhiro; Ikemori, Megumi; Ogawa, Toshiaki; Kawamura, Takanori

INVENTOR(S): Eisai Co., Ltd., Japan

SOURCE: Eur. Pat. Appl., 152 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
EP 344577	A2	19891206	EP 1989-109228	19890523
EP 344577	A3	19920325		
EP 344577	B1	19961009		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
FI 8902362	A	19891202	FI 1989-2362	19890517
US 5047417	A	19910910	US 1989-354306	19890519
AT 143949	T	19961015	AT 1989-109228	19890523
NO 8902170	A	19891204	NO 1989-2170	19890530
AU 8935822	A	19891207	AU 1989-35822	19890530
AU 616014	B2	19911017		
HU 50319	A2	19900129	HU 1989-2734	19890530
HU 210932	B	19950928		
ZA 8904102	A	19900328	ZA 1989-4102	19890530
DD 287496	A5	19910228	DD 1989-329059	19890530
DK 8902649	A	19891202	DK 1989-2649	19890531
CN 1040366	A	19900314	CN 1989-103717	19890531
CA 1318667	C	19930601	CA 1989-601297	19890531
SU 1833371	A3	19930807	SU 1989-4614354	19890601
US 5177089	A	19930105	US 1990-557713	19900725
RU 2041871	C1	19950820	RU 1992-5010978	19920302
US 5382595	A	19950117	US 1992-959654	19921013
US 5607953	A	19970304	US 1994-347099	19941123
PRIORITY APPLN. INFO.:			JP 1988-134892	A 19880601
			US 1989-354306	A3 19890519
			US 1990-557713	A3 19900725
			US 1992-959654	A3 19921013

OTHER SOURCE(S): MARPAT 113:23909

GI




AB Title compds. GCH:CHCH2CONR2ANR3(CH2)nJ (G = substituted Ph, naphthyl, (heteroaryl)phenyl, (heteroaryl)heterocyclyl; R2, R3 = H, alkyl, allyl, cycloalkyl; R2R3N = 5-7-membered saturated heterocyclyl; R3N = 5-7-membered heterocyclyl having N or N and O together with A; A = substituted C1-3-, -C1-6 alkylene; J = (un)substituted Ph, -pyridyl; n = 1-6) and a pharmacol. acceptable salt thereof, are prepared (E)-4-[4-(1-Imidazol-1-yl)phenyl]-3-butenic acid in aqueous MeCN was treated with DCC/N-hydroxybenzotriazole, the mixture was stirred 4 h, 3,5-(MeO)2C6H3CH2CH2NMe(CH2)3NH2 in MeCN was added, and the mixture was stirred 3 d to give butenamide I. I in dogs at 0.3 mg/kg i.v. lowered heart rate by 11-20% and increased coronary blood flow 201-300%.

IT 127406-00-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, for lowering heart rate and as coronary vasodilator)


RN 127406-00-2 CAPLUS

CN 2-Propenamide, 3-(4-fluorophenyl)-N-[3-(1,2,4,5-tetrahydro-7,8-dimethoxy-3H-3-benzazepin-3-yl)propyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L20 ANSWER 53 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1989:573966 CAPLUS
 DOCUMENT NUMBER: 111:173966
 ORIGINAL REFERENCE NO.: 111:28979a,28982a
 TITLE: A new entry into C⁷-oxygenated tetrahydro-1H-3-benzazepines; efficient labeling with carbon-14 in the benzo ring
 AUTHOR(S): Heys, J. Richard; Senderoff, Stephen G.
 CORPORATE SOURCE: Synth. Chem. Dep., Smith Kline and French Lab., King of Prussia, PA, 19406, USA
 SOURCE: Journal of Organic Chemistry (1989), 54(19), 4702-6
 CODEN: JOCEAH; ISSN: 0022-3263
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 111:173966
 GI




AB Addition of $^{14}\text{CH}_3\text{MgI}$ to hexahydropyranoazepinone I provided diketone II in 64% yield (based on $^{14}\text{CH}_3\text{I}$). Base-catalyzed intramol. aldol condensation provided the corresponding cyclic enone in 93% yield, and aromatization-methylation of the latter gave [^{14}C]benzazepine III in 47% yield. In optimized reactions with unlabeled materials, yields for the 3 steps were 80, 100, and 70%, resp. I was prepared in 44% overall yield through a diazo insertion reaction initiated by base-induced decomposition of $\text{MeO}_2\text{CN}(\text{NO})(\text{CN}_2)_3\text{CO}_2\text{Et}$ in the presence of N-benzyl-4-piperidone, followed by acid hydrolysis of the ester group of the insertion product and cyclization in $\text{Ac}_2\text{O}-\text{AcCl}$.

IT 122844-73-9P 124182-59-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 122844-73-9 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-(phenylmethyl)- (CA INDEX NAME)



10/598,888


RN 124182-59-8 CAPLUS

CN 1H-3-Benzazepine-6-¹⁴C, 2,3,4,5-tetrahydro-7-methoxy-3-(phenylmethyl)-
(9CI) (CA INDEX NAME)



L20 ANSWER 54 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1989:57537 CAPLUS
 DOCUMENT NUMBER: 110:57537
 ORIGINAL REFERENCE NO.: 110:9521a,9524a
 TITLE: Preparation of [(alkylsulfonyl)amino]tetrahydro-1H-3-benzazepines as antiarrhythmic agents
 INVENTOR(S): Cross, Peter Edward; Arrowsmith, John Edmund
 PATENT ASSIGNEE(S): Pfizer Ltd., UK
 SOURCE: Eur. Pat. Appl., 30 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 284384	A1	19880928	EP 1988-302597	19880324
EP 284384	B1	19901128		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 4891372	A	19900102	US 1988-170499	19880321
FI 8801392	A	19880926	FI 1988-1392	19880323
FI 85468	B	19920115		
FI 85468	C	19920427		
PL 153455	B1	19910430	PL 1988-271379	19880323
CA 1294273	C	19920114	CA 1988-562151	19880323
IL 85822	A	19920329	IL 1988-85822	19880323
NO 8801314	A	19880926	NO 1988-1314	19880324
NO 168421	B	19911111		
NO 168421	C	19920219		
AU 8813571	A	19880929	AU 1988-13571	19880324
AU 583763	B2	19890504		
DK 8801604	A	19881230	DK 1988-1604	19880324
DK 170890	B1	19960304		
ZA 8802103	A	19891129	ZA 1988-2103	19880324
SU 1579456	A3	19900715	SU 1988-4355570	19880324
DD 280965	A5	19900725	DD 1988-313961	19880324
AT 58726	T	19901215	AT 1988-302597	19880324
JP 63255267	A	19881021	JP 1988-71710	19880325
CN 88101782	A	19881102	CN 1988-101782	19880325
CN 1023644	C	19940202		
HU 47544	A2	19890328	HU 1988-1530	19880325
HU 199124	B	19900129		
PRIORITY APPLN. INFO.:			GB 1987-7120	A 19870325
OTHER SOURCE(S):			EP 1988-302597	A 19880324
GI				
MARPAT 110:57537				




I

AB The title compds. (I; R1 = H, C1-4 alkyl, C1-4 alkoxy; R2, R3 = C1-4 alkyl; X = O, NHCO, bond; when X = NHCO, R2 = R3) and their pharmaceutically acceptable salts were prepared as antiarrhythmics (no data). 2,3,4,5-Tetrahydro-1H-3-benzazepine was successively nitrated, alkylated with 4-O2NC6H4OCH2CH2Cl (preparation given), and hydrogenated over Pd/C to give 7-amino-3-[2-(4-aminophenoxy)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepine. The latter was treated with MeSO2Cl to give I (R1 = H, R2 = R3 = Me, X = O) (II), converted to II.HCl.

IT 118454-15-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and hydrogenation of, in preparation of antiarrhythmics)
 RN 118454-15-2 CAPLUS
 CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-nitro-3-[2-(4-nitrophenyl)ethyl]-
 (CA INDEX NAME)




IT 118454-09-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and mesylation of, in preparation of antiarrhythmics)
 RN 118454-09-4 CAPLUS
 CN 1H-3-Benzazepin-7-amine, 3-[2-(4-aminophenyl)ethyl]-2,3,4,5-tetrahydro-
 (CA INDEX NAME)



IT 118454-05-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of, as antiarrhythmic)
 RN 118454-05-0 CAPLUS
 CN Methanesulfonamide, N-[4-[2-[1,2,4,5-tetrahydro-7-[(methylsulfonyl)amino]-3H-3-benzazepin-3-yl]ethyl]phenyl]- (CA INDEX NAME)


10/598,888



L20 ANSWER 55 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1982:406183 CAPLUS
 DOCUMENT NUMBER: 97:6183
 ORIGINAL REFERENCE NO.: 97:1195a, 1198a
 TITLE: Substituted 1,2,4,5-tetrahydro-3H,3-benzazepines
 PATENT ASSIGNEE(S): Pennwalt Corp., USA
 SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 57045162	A	19820313	JP 1981-100724	19810630
JP 58027790	B	19830611		

PRIORITY APPLN. INFO.: JP 1972-11056 19720201
 GI




AB The title compds. (I; R = alkylamidophenyl, alkylamidophenylalkyl; R1 = H, alkyl; R2, R3 = H, OH, alkoxy), useful as analgesics (data given), were prepared. Thus, acylation of 10.3 g II with 11.7 g 4-O₂NC₆H₄CH₂CO₂H followed by hydrogenation and reduction gave 11.1 g I (R = 4-H₂NC₆H₄CH₂, R1 = R3 = H, R2 = 7-MeO)·2HCl, acetylation of which gave I (R = 4-AcNHC₆H₄CH₂, R1 = R3 = H, R2 = 7-MeO)·HCl.

IT 36134-21-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and acetylation of)


RN 36134-21-1 CAPLUS

CN Benzenamine, 4-[2-(1,2,4,5-tetrahydro-7-methoxy-3H-3-benzazepin-3-yl)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

IT 36134-34-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and analgesic activity of)
 RN 36134-34-6 CAPLUS
 CN Acetamide, N-[4-[2-(1,2,4,5-tetrahydro-7-methoxy-3H-3-benzazepin-3-yl)ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 82103-74-0P 82103-75-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reduction of)
 RN 82103-74-0 CAPLUS
 CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-[(4-nitrophenyl)acetyl]- (9CI) (CA INDEX NAME)




RN 82103-75-1 CAPLUS
 CN 1H-3-Benzazepine, 3-[(4-aminophenyl)acetyl]-2,3,4,5-tetrahydro-7-methoxy- (9CI) (CA INDEX NAME)



IT 47229-66-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and salt formation of)
 RN 47229-66-3 CAPLUS

10/598,888

CN Benzenamine, 4-[2-(1,2,4,5-tetrahydro-7-methoxy-3H-3-benzazepin-3-yl)ethyl]- (CA INDEX NAME)




IT 36134-22-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 36134-22-2 CAPLUS

CN 1H-3-Benzazepin-7-ol, 3-[2-(4-aminophenyl)ethyl]-2,3,4,5-tetrahydro-,
dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

L20 ANSWER 56 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1981:480764 CAPLUS
 DOCUMENT NUMBER: 95:80764
 ORIGINAL REFERENCE NO.: 95:13655a,13658a
 TITLE: 6-Phenylthio- and 6-cyclohexylthio-2,3,4,5-tetrahydro-1H-3-benzazepines
 INVENTOR(S): Holden, Kenneth G.; Kaiser, Carl
 PATENT ASSIGNEE(S): Smithkline Corp., USA
 SOURCE: U.S., 12 pp. Cont.-in-part of U.S. Ser. No. 922,613, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4265890	A	19810505	US 1979-39713	19790517
ZA 7902785	A	19800827	ZA 1979-2785	19790605
IL 57532	A	19820831	IL 1979-57532	19790611
JP 55011584	A	19800126	JP 1979-82527	19790628
JP 01053271	B	19891113		
DK 7902783	A	19800108	DK 1979-2783	19790702
DK 156001	B	19890612		
DK 156001	C	19891106		
CS 213381	B2	19820409	CS 1979-4635	19790702
AU 7948613	A	19800207	AU 1979-48613	19790703
AU 525789	B2	19821202		
CA 1115271	A1	19811229	CA 1979-331022	19790703
EP 80012	A1	19830601	EP 1982-105188	19790704
EP 80012	B1	19860409		
R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
AT 19069	T	19860415	AT 1982-105188	19790704
FI 7902125	A	19800108	FI 1979-2125	19790705
FI 67215	B	19841031		
FI 67215	C	19850211		
HU 21669	A2	19820128	HU 1979-SI1705	19790705
HU 179315	B	19820928		
NO 7902267	A	19800108	NO 1979-2267	19790706
NO 152213	B	19850513		
NO 152213	C	19850828		
ES 482276	A1	19800401	ES 1979-482276	19790706
ES 482281	A1	19800401	ES 1979-482281	19790706
ES 482282	A1	19800401	ES 1979-482282	19790706
DD 147355	A5	19810401	DD 1979-214179	19790706
SU 1029827	A3	19830715	SU 1979-2783746	19790706
PRIORITY APPLN. INFO.:				
			US 1978-922613	A2 19780707
			EP 1982-105188	A 19790704

OTHER SOURCE(S): MARPAT 95:80764
 GI




AB Benzazepines I (R = Me, allyl, dimethylallyl, PhCH₂CH₂, cyclopropylmethyl, HOCH₂CH₂; R¹ = Ph, F₃CC₆H₄, ClC₆H₄, MeOC₆H₄, MeC₆H₄, FC₆H₄, O₂NC₆H₄, cyclohexyl; R² = H, MeO, alkanoyloxy; R³ = H, Cl, Br, F₃C, F, Me) and their salts were prepared and possessed dopamine receptor blocking, antipsychotic, and antiemetic activities. Thus, cyclocondensation of H₂NCH₂CH(OMe)₂ and 3,4-(MeO)₂C₆H₃CH₂CO₂H gave the oxobenzazepine II, which underwent successive hydrogenation, diborane reduction, and demethylation to give dihydroxybenzazepine III. Treatment of III with dichlorodicyanobenzoquinone gave the corresponding benzazepinedione which condensed with PhSH to give I (R = R³ = H, R¹ = PhS, R² = HO). I (R = Me, R¹ = Ph, R² = HO, R³ = H) possessed antipsychotic activity in the dopamine receptor blocking test in rats with an ED₅₀ of 0.5 mg/kg.

IT 78495-62-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 78495-62-2 CAPLUS



CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7,8-dimethoxy-3-(2-phenylethyl)-6-(phenylthio)- (CA INDEX NAME)



L20 ANSWER 57 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1981:47157 CAPLUS
 DOCUMENT NUMBER: 94:47157
 ORIGINAL REFERENCE NO.: 94:7689a,7692a
 TITLE: Substituted 1,2,4,5-tetrahydro-3H,3 benzazepines
 INVENTOR(S): Shetty, Bola V.
 PATENT ASSIGNEE(S): Pennwalt Corp., USA
 SOURCE: U.S., 30 pp. Division of U.S. Ser. No. 747,151,
 abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4210749	A	19800701	US 1979-41574	19790521
US 4233217	A	19801111	US 1979-41575	19790521
PRIORITY APPLN. INFO.:			US 1968-711897	A1 19680311
			US 1972-241091	A2 19720404
			US 1974-523092	A1 19741112
			US 1976-747151	A3 19761203

OTHER SOURCE(S): MARPAT 94:47157
 GI




AB Benzazepines I (R = H, alkyl, alkenyl, aralkenyl, cycloalkylalkyl, aralkyl, heterocyclic alkyl; R1 = H, alkyl, Ph, phenylalkyl; R2 = H, alkyl; R3 = H, alkoxy, alkyl, halo, NO2, HO), useful as analgesics and narcotic antagonists, were prepared. Thus, treatment of 3,4-(NCCH2)2C6H3OMe with HBr-AcOH followed by heating at 85° with NaOAc gave II, which was treated with BH3 to give I (R = R1 = R2 = H, R3 = MeO) (III). Refluxing III in 48% HBr gave I (R = R1 = R2 = H, R3 = HO).

IT 36133-33-2
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (acylation by, of tetrahydrobenzazepine derivs.)


RN 36133-33-2 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-(1-methyl-2-phenylethyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl


IT 76208-75-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and demethylation of)
 RN 76208-75-8 CAPLUS
 CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-(1-methyl-2-phenylethyl)-
 (CA INDEX NAME)



IT 36133-31-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and hydride reduction of)
 RN 36133-31-0 CAPLUS
 CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-(phenylacetyl)- (9CI)
 (CA INDEX NAME)




IT 76208-73-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and pharmacol. of)
 RN 76208-73-6 CAPLUS
 CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-(2-phenylethyl)- (CA INDEX NAME)




IT 36133-30-9P 36133-32-1P 36133-34-3P
 36134-46-0P 76208-74-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 36133-30-9 CAPLUS
 CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-(2-phenylethyl)-,
 hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 36133-32-1 CAPLUS
 CN 1H-3-Benzazepin-7-ol, 2,3,4,5-tetrahydro-3-(2-phenylethyl)-, hydrochloride
 (9CI) (CA INDEX NAME)



● HCl


RN 36133-34-3 CAPLUS
 CN 1H-3-Benzazepin-7-ol, 2,3,4,5-tetrahydro-3-(1-methyl-2-phenylethyl)-,
 hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 36134-46-0 CAPLUS

CN 1H-3-Benzazepin-7-ol, 2,3,4,5-tetrahydro-3-(1-methyl-2-phenylethyl)- (CA INDEX NAME)



RN 76208-74-7 CAPLUS

CN 1H-3-Benzazepin-7-ol, 2,3,4,5-tetrahydro-3-(2-phenylethyl)- (CA INDEX NAME)



L20 ANSWER 58 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1980:586198 CAPLUS

DOCUMENT NUMBER: 93:186198

ORIGINAL REFERENCE NO.: 93:29675a,29678a

TITLE: 1,2,4,5-Tetrahydro-7-alkoxy (and 7,8-dialkoxy)-3H,3-benzazepines and their 3-substituted derivatives, from the corresponding phenylethylamines and their derivatives

INVENTOR(S): Davidson, Thomas A.; Griffith, Ronald C.

PATENT ASSIGNEE(S): Pennwalt Corp., USA

SOURCE: Ger. Offen., 30 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2946794	A1	19800529	DE 1979-2946794	19791120
US 4282146	A	19810804	US 1978-962223	19781120
GB 2037278	A	19800709	GB 1979-38655	19791108
GB 2037278	B	19830119		
SE 7909444	A	19800521	SE 1979-9444	19791115
JP 55108855	A	19800821	JP 1979-147878	19791116
BE 880125	A1	19800317	BE 1979-198183	19791119
FR 2441615	A1	19800613	FR 1979-28499	19791119
FR 2441615	B1	19831104		
CA 1104568	A1	19810707	CA 1979-340139	19791119
PRIORITY APPLN. INFO.:			US 1978-962223	A 19781120

OTHER SOURCE(S): CASREACT 93:186198; MARPAT 93:186198

GI




AB The benzazepines I (R = alkyl; R1 = H, alkoxy; RR1 = CH2O; R2 = H, alkyl; R3 = H, alkyl, Ph; R4 = H) were prepared by the condensation of a phenethylamine with a haloacetaldehyde dialkyl acetal, reductive cyclization of the product with BF3 to give I (R4 = alkoxy), and reductive cleavage of the ether. Thus, 3-MeOC6H4CH2CHMeNH2 reacted with BrCH2CH(OEt)2 in DMF to give 3-MeOC6H4CH2CHMeNHCH2CH(OEt)2, which was treated with BF3 in CH2Cl2 to give I (R = R3 = Me, R1 = R2 = H, R4 = OEt), which was treated with NH3 at -78° to give the corresponding I (R4 = H).

IT 74888-02-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and acylation of)

RN 74888-02-1 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7,8-dimethoxy-3-[(4-nitrophenyl)acetyl]- (9CI) (CA INDEX NAME)




IT 68318-20-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and formylation of)
 RN 68318-20-7 CAPLUS
 CN Benzenamine, 4-[2-(1,2,4,5-tetrahydro-7,8-dimethoxy-3H-3-benzazepin-3-yl)ethyl]- (CA INDEX NAME)



IT 74888-03-2P 74888-04-3P 74888-06-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reduction of)
 RN 74888-03-2 CAPLUS
 CN 1H-3-Benzazepine, 3-[(4-aminophenyl)acetyl]-2,3,4,5-tetrahydro-7,8-dimethoxy- (9CI) (CA INDEX NAME)




RN 74888-04-3 CAPLUS
 CN Formamide, N-[4-[2-(1,2,4,5-tetrahydro-7,8-dimethoxy-3H-3-benzazepin-3-yl)ethyl]phenyl]- (CA INDEX NAME)



RN 74888-06-5 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7,8-dimethoxy-3-[2-(4-nitrophenyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 67394-31-4P 74888-05-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 67394-31-4 CAPLUS

CN Benzenamine, 4-[2-(1,2,4,5-tetrahydro-7,8-dimethoxy-3H-3-benzazepin-3-yl)ethyl]-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl


RN 74888-05-4 CAPLUS

CN Benzenamine, N-methyl-4-[2-(1,2,4,5-tetrahydro-7,8-dimethoxy-3H-3-benzazepin-3-yl)ethyl]- (CA INDEX NAME)

10/598,888





L20 ANSWER 59 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1980:507010 CAPLUS
 DOCUMENT NUMBER: 93:107010
 ORIGINAL REFERENCE NO.: 93:16969a,16972a
 TITLE: Annual report: evaluation of new compounds for opioid activity (1979)
 AUTHOR(S): Swain, Henry H.; Woods, James H.; Medzihradsky, Fedor; Smith, Charles B.; Fly, Clifton L.
 CORPORATE SOURCE: Dep. Pharmacol., Univ. Michigan, Ann Arbor, MI, 48109, USA
 SOURCE: NIDA Research Monograph (1979), 27(Probl. Drug Depend.), 356-98
 CODEN: MIDAD4; ISSN: 0361-8595
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB By several evaluation techniques such as phys. dependence evaluation, self-administration (in monkeys), displacement of stereospecific 3H-etorphine binding, depression of twitch in elec. driven guinea pig ileum, and mouse vas deferens preps., 47 compds. were evaluated for opioid activity.
 IT 36134-21-1
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (opioid activity of)
 RN 36134-21-1 CAPLUS
 CN Benzenamine, 4-[2-(1,2,4,5-tetrahydro-7-methoxy-3H-3-benzazepin-3-yl)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

L20 ANSWER 60 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1980:163771 CAPLUS
 DOCUMENT NUMBER: 92:163771
 ORIGINAL REFERENCE NO.: 92:26541a,26544a
 TITLE: Neuropsychotropic activity of dopamine analogous
 4,7-methano-1H-isoindoles
 AUTHOR(S): Rhesse, Klaus; Mattern, Gerd; Kehr, Wolfgang;
 Paschelke, Gert
 CORPORATE SOURCE: Inst. Pharm., Freie Univ. Berlin, Berlin, 1000/33,
 Fed. Rep. Ger.
 SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1979),
 312(12), 982-94
 CODEN: ARPMAS; ISSN: 0365-6233
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 OTHER SOURCE(S): CASREACT 92:163771
 GI




AB The dopamine analogs I (R = Me, Ac; R1 = H, Ph; R2 = H; R1R2 = CH:CHCH:CH;
 m = 0, 1, 2; n = 1-5) and exo- and endo-II (R3 = H; R4 = Ph; R3R4 = bond)
 were prepared by the reaction of homoveratryl chloride with the appropriate
 amine, followed by reduction, or by the reaction of dicarboxylic acids with
 homoveratrylamine, followed by reduction. Tests on mice showed that aromatic
 substitution in the azacyclic system was essential for central depressant
 activity. Data on the conformationally rigid II (R3 = H, R4 = Ph)
 suggested that the optimum distance between the Ph substituent and the
 dopamine N should be .apprx.7.3 Å to give neuropsychotropic activity
 in mice at 1.56-200 mg/kg.

IT 73252-07-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and central nervous system depressant activity of)


RN 73252-07-0 CAPLUS

CN 1H-3-Benzazepine, 3-[2-(3,4-dimethoxyphenyl)ethyl]-2,3,4,5-tetrahydro-,
 hydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 73252-23-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and reduction of)
 RN 73252-23-0 CAPLUS
 CN 1H-3-Benzazepine, 3-[(3,4-dimethoxyphenyl)acetyl]-2,3,4,5-tetrahydro-
 (9CI) (CA INDEX NAME)



L20 ANSWER 61 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1977:189747 CAPLUS

DOCUMENT NUMBER: 86:189747

ORIGINAL REFERENCE NO.: 86:29753a,29756a

TITLE: 1-Phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine derivative-containing drugs with peripheral dopamine receptor-stimulating, renal vessel-dilating, diuretic and Parkinson disease-palliating activity
Kaiser, Carl; Pendleton, Robert G.; Setler, Paulette E.

INVENTOR(S):

PATENT ASSIGNEE(S): Smithkline Corp., USA

SOURCE: Ger. Offen., 48 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2629887	A1	19770120	DE 1976-2629887	19760702
US 4011319	A	19770308	US 1975-592708	19750702
US 4052506	A	19771004	US 1975-602042	19750805
GB 1561305	A	19800220	GB 1976-25008	19760617
BE 843422	A1	19761227	BE 1976-168324	19760625
FR 2315934	A1	19770128	FR 1976-19601	19760628
FR 2315934	B1	19781117		
CA 1079639	A1	19800617	CA 1976-255817	19760628
IL 49931	A	19811231	IL 1976-49931	19760629
NL 7607184	A	19770104	NL 1976-7184	19760630
JP 52007981	A	19770121	JP 1976-79404	19760701
ZA 7603917	A	19770525	ZA 1976-3917	19760701
AU 507272	B2	19800207	AU 1976-15540	19760702
JP 57163314	A	19821007	JP 1982-35696	19820305
JP 60033409	B	19850802		
PRIORITY APPLN. INFO.:			US 1975-592708	A 19750702
			US 1975-602042	A 19750805

GI



AB Benzazepines I (R = R1 = H, R2 = H, 3-Cl, 2-Cl, 4-Cl, 3-Me, 2-Me, 4-Me, 3-CF3, 4-OH, 3-OH, 2-OH; R = CH2CH2OH, Bu, Me, Et, Pr, allyl, R1 = R2 = H; R = R2 = H, R1 = Me, Ac, COCMe3, COEt) and some related compds. were prepared Thus, 3,4-(MeO)2C6H3CH2CH2NH2 was treated with styrene oxide and


3,4-(MeO)2C6H3CH2CH2NHCH2CHPhOH cyclized with HBr to give I (R-R2 = H).
 At 550 mg/kg i.v. in dogs I (R-R2 = H) gave a 22% increase in renal
 bloodflow and 47% decrease in the resistance of the renal vessels. It was
 diuretic at 12.5 mg/kg i.p. in rats and at 1.2 mg/kg i.p. in rats. It
 caused contralateral rotation in 6-hydroxydopamine brain-damaged rats.

IT 62717-11-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 62717-11-7 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, 2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-
 benzazepine-7,8-diyl ester, hydrochloride (9CI) (CA INDEX NAME)




● HCl

L20 ANSWER 62 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1974:520432 CAPLUS
 DOCUMENT NUMBER: 81:120432
 ORIGINAL REFERENCE NO.: 81:19035a,19038a
 TITLE: N-Substituted 6,9-dimethoxy-2,3,4,5-tetrahydro-1H-3-benzazepines
 AUTHOR(S): Durgaryan, A. K.; Chshmarityan, S. G.; Tatevosyan, G. T.
 CORPORATE SOURCE: Inst. Tonkoi Org. Khim. im. Mndzhoyana, Yerevan, USSR
 SOURCE: Armyanskii Khimicheskii Zhurnal (1974), 27(6), 510-15
 CODEN: AYKZAN; ISSN: 0515-9628
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 GI For diagram(s), see printed CA Issue.
 AB The tetralone I was converted (93%) to its oxime, which was converted to 83% the tosylate. Heating the tosylate in an autoclave 4 hr gave 79.5% the benzazepinone II (R = H), which was alkylated or acetylated to give 16.7-63.7% II (R = Me, PhCH₂, Me₂NCH₂CH₂, Ac). Reduction of II (R = H) gave 47.7% the benzazepine III. III (R = Me, Et, PhCH₂, CH₂CH₂NMe₂) were prepared (41.2-67.3%) similarly. III were potential tranquilizers (no data).
 IT 53970-46-0P 53970-51-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 53970-46-0 CAPLUS
 CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6,9-dimethoxy-3-(phenylmethyl)- (CA INDEX NAME)



RN 53970-51-7 CAPLUS
 CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-6,9-dimethoxy-3-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

10/598,888

L20 ANSWER 63 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1974:82731 CAPLUS
 DOCUMENT NUMBER: 80:82731
 ORIGINAL REFERENCE NO.: 80:13309a,13312a
 TITLE: 1,2,4,5-Tetrahydro-3H,3-benzazepines
 INVENTOR(S): Shetty, Bola V.
 PATENT ASSIGNEE(S): Pennwalt Corp.
 SOURCE: Fr. Demande, 73 pp.
 CODEN: FRXXBL

DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2171879	A1	19730928	FR 1972-4829	19720214
FR 2171879	B1	19750425		

PRIORITY APPLN. INFO.: FR 1972-4829 A 19720214


GI For diagram(s), see printed CA Issue.

AB Benzazepines I (R = CH₂CH:CM₂, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, allyl, 2-(4-phenylpiperazino)-ethyl, CH₂CM₂:CH₂, CH₂C.tplbond.CH, Me, Et, Pr, CH₂CH₂Ph, CHMeCH₂Ph, CH₂CH₂C₆H₄NH₂-p, CH₂CH₂C₆H₄NHAc-p, CH₂CH:CHPh, trans-2-phenylcyclopropylmethyl, CH₂CH₂OAc, CH₂CHMeOAc, CHMeCH₂C₆H₄NH₂-p) were prepared by substitution of I (R = H). I (R = H, R₁ = Me) was prepared by methylating 3,4-Me₂C₆H₃OH, oxidizing the 3,4-Me₂C₆H₃OMe, converting the 4-MeOC₆H₄(CO₂H)2-1,2 to its anhydride, reducing to 4-MeOC₆H₄(CH₂OH)2-1,2, and converting to 4-MeOC₆H₄(CH₂Br)2-1,2 and 4-MeOC₆H₄(CH₂CN)2-1,2, which was cyclized to 7-methoxy-1,2,4,5-tetrahydro-3H-3-benzazepine-2,4-dione and reduced with BH₃. Demethylation with HBr gave I (R = R₁ = H). I are analgesics and narcotic antagonists. Thus, I (R = CH₂CH₂C₆H₄NHAc-p, R₁ = Me) had an oral ED₅₀ in the writhing test of 32 mg/kg.

IT 36133-30-9P 36133-31-0P 36133-32-1P
 36133-33-2P 36133-34-3P 36134-21-1P
 36134-22-2P 36134-32-4P 36134-33-5P
 36134-34-6P 36134-39-1P 51861-96-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 36133-30-9 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-(2-phenylethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 36133-31-0 CAPLUS
 CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-(phenylacetyl)- (9CI)

(CA INDEX NAME)



RN 36133-32-1 CAPLUS


CN 1H-3-Benzazepin-7-ol, 2,3,4,5-tetrahydro-3-(2-phenylethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 36133-33-2 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-(1-methyl-2-phenylethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 36133-34-3 CAPLUS


CN 1H-3-Benzazepin-7-ol, 2,3,4,5-tetrahydro-3-(1-methyl-2-phenylethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 36134-21-1 CAPLUS


CN Benzenamine, 4-[2-(1,2,4,5-tetrahydro-7-methoxy-3H-3-benzazepin-3-yl)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 36134-22-2 CAPLUS


CN 1H-3-Benzazepin-7-ol, 3-[2-(4-aminophenyl)ethyl]-2,3,4,5-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 36134-32-4 CAPLUS


CN Benzenamine, 4-[2-(1,2,4,5-tetrahydro-7-methoxy-3H-3-benzazepin-3-yl)propyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 36134-33-5 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-[1-methyl-2-(4-nitrophenyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 36134-34-6 CAPLUS

CN Acetamide, N-[4-[2-(1,2,4,5-tetrahydro-7-methoxy-3H-3-benzazepin-3-yl)ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 36134-39-1 CAPLUS


CN Benzenamine, 4-[2-(1,2,4,5-tetrahydro-7-methoxy-3H-3-benzazepin-3-yl)ethyl]-, compd. with iodomethane (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 47229-66-3

CMF C19 H24 N2 O

10/598,888



CM 2


CRN 74-88-4

CMF C H3 I

H₃C-I

RN 51861-96-2 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-[1-methyl-2-(4-nitrophenyl)ethyl]- (CA INDEX NAME)



L20 ANSWER 64 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1973:526338 CAPLUS
 DOCUMENT NUMBER: 79:126338
 ORIGINAL REFERENCE NO.: 79:20507a,20510a
 TITLE: 1,2,4,5-Tetrahydro-3H-3-benzazepines
 INVENTOR(S): Shetty, Bola V.
 PATENT ASSIGNEE(S): Pennwalt Corp.
 SOURCE: Ger. Offen., 82 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2207430	A1	19730823	DE 1972-2207430	19720214
DE 2207430	B2	19810723		
DE 2207430	C3	19820513		

PRIORITY APPLN. INFO.: DE 1972-2207430 A 19720214


GI For diagram(s), see printed CA Issue.

AB Benzazepines I (R = H, CH₂CH:CM₂, CH₂CM₂:CH₂, CH₂CH:CHPh, allyl, CH₂C.tplbond.CH, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, trans-2-phenylcyclopropylmethyl, Me, Et, Pr, CH₂CH₂Ph, CHMeCH₂Ph, CH₂CH₂C₆H₄NH₂-p, CHMeCH₂C₆H₄NH₂-p, CH₂CH₂C₆H₄NHAc-p, CH₂CH₂OAc, (CH₂)₃OAc, 4-phenylpiperazinylethyl; R₁ = H, Me) were prepared. Thus, 3,4-Me₂C₆H₃OH was methylated and oxidized to give 3,4-(HO₂C)C₆H₃OMe, whose anhydride was reduced to 3,4-(HOCH₂)C₆H₃OMe, brominated to 3,4-(BrCH₂)C₆H₃OMe, treated with NaCN to give 3,4-(NCCH₂)C₆H₃OMe, which was cyclized with HBr-HOAc to 7-methoxy-1,2,4,5-tetrahydro-3H-3-benzazepine-2,4-dione and reduced with B₂H₆ to I (R = H, R₁ = Me) from which the other I were derived. I demonstrated antihistaminic, analgesic, anticholinergic, and morphine antagonist activity.

IT 36133-30-9P 36133-31-0P 36133-32-1P
 36133-33-2P 36133-34-3P 36134-21-1P
 36134-22-2P 36134-32-4P 36134-33-5P
 36134-34-6P 36134-39-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 36133-30-9 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-(2-phenylethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 36133-31-0 CAPLUS
 CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-(phenylacetyl)- (9CI)

(CA INDEX NAME)



RN 36133-32-1 CAPLUS


CN 1H-3-Benzazepin-7-ol, 2,3,4,5-tetrahydro-3-(2-phenylethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 36133-33-2 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-(1-methyl-2-phenylethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 36133-34-3 CAPLUS


CN 1H-3-Benzazepin-7-ol, 2,3,4,5-tetrahydro-3-(1-methyl-2-phenylethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 36134-21-1 CAPLUS


CN Benzenamine, 4-[2-(1,2,4,5-tetrahydro-7-methoxy-3H-3-benzazepin-3-yl)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 36134-22-2 CAPLUS


CN 1H-3-Benzazepin-7-ol, 3-[2-(4-aminophenyl)ethyl]-2,3,4,5-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 36134-32-4 CAPLUS


CN Benzenamine, 4-[2-(1,2,4,5-tetrahydro-7-methoxy-3H-3-benzazepin-3-yl)propyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 36134-33-5 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-[1-methyl-2-(4-nitrophenyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 36134-34-6 CAPLUS

CN Acetamide, N-[4-[2-(1,2,4,5-tetrahydro-7-methoxy-3H-3-benzazepin-3-yl)ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 36134-39-1 CAPLUS


CN Benzenamine, 4-[2-(1,2,4,5-tetrahydro-7-methoxy-3H-3-benzazepin-3-yl)ethyl]-, compd. with iodomethane (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 47229-66-3

CMF C19 H24 N2 O

10/598,888



CM 2

CRN 74-88-4

CMF C H3 I

H₃C— I

L20 ANSWER 65 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1972:461780 CAPLUS

DOCUMENT NUMBER: 77:61780

ORIGINAL REFERENCE NO.: 77:10219a,10222a

TITLE: Novel synthesis of aromatic methoxy and methylenedioxy-substituted 2,3,4,5-tetrahydro-1H-3-benzazepines

AUTHOR(S): Pecherer, B.; Sunbury, R. C.; Brossi, A.

CORPORATE SOURCE: Chem. Res. Lab., Hoffmann-La Roche Inc., Nutley, NJ, USA

SOURCE: Journal of Heterocyclic Chemistry (1972), 9(3), 609-16

CODEN: JHTCAD; ISSN: 0022-152X

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 77:61780


AB A new synthesis of aromatic methoxy and methylenedioxy substituted 2,3,4,5-tetrahydro-1H-3-benzazepines is described. Suitably substituted phenethylamines and their α -methyl homologs in the form of their N-acetyl derivs. are chloromethylated, the resulting benzyl chlorides are treated with cyanide and hydrolyzed to yield 2-(2-aminoethyl)phenylacetic acid derivs. Thermal cyclization yields the corresponding lactams. Hydride reduction of these lactams furnishes the substituted 2,3,4,5-tetrahydro-1H-3-benzazepines which may be methylated on N by H₂CO and H.

IT 37015-16-0P 37015-17-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 37015-16-0 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7,8-dimethoxy-3-(phenylmethyl)- (CA INDEX NAME)



RN 37015-17-1 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7,8-dimethoxy-3-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L20 ANSWER 66 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1972:153628 CAPLUS

DOCUMENT NUMBER: 76:153628

ORIGINAL REFERENCE NO.: 76:25036h,25037a

TITLE: 1,2,4,5-Tetrahydro-3H-3-benzazepines as analgesics and antagonists of narcotics

PATENT ASSIGNEE(S): Wallace and Tiernan, Inc.

SOURCE: Brit., 42 pp.

CODEN: BRXXAA

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1268243		19720322	GB 1969-12844	19690311
CA 974989			CA	
US 3719669		19730306	US	19720327
			US 1968-711897	19680311

PRIORITY APPLN. INFO.:

GI For diagram(s), see printed CA Issue.

AB H-3-Benzazepines (I, R was usually 7- or 8-MeO or 7-OH; R1 was, e.g., H, alkyl, cycloalkylmethyl, substituted phenethyl, p-MeC6H4SO2, a cetoxyalkyl; R2 = H3 Me), useful as analgesics, anticholinergics, antihistamines, and antagonists to narcotics, were prepared Thus, 50 g 4-methoxy-o-benzenediacetamide (II) was reduced by borane in THF at 10° to give 28 g I (R = 7-MeO, R1 = R2 = H), analyzed as the maleate. II was prepared from 3,4-dimethylphenol by methylation, oxidation to 4-methoxyphthalic acid, formation of the anhydride, reduction to 4-methoxy-o-xylene- α,α' -diol, dibromination of the diol, conversion to the dinitrile, and cyclization to the imide.

Pharmacol. test results were given.

IT 36133-30-9P 36133-31-0P 36133-32-1P

36133-33-2P 36133-34-3P 36134-21-1P

36134-22-2P 36134-32-4P 36134-33-5P


36134-34-6P 36134-39-1P 36134-46-0P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

RN 36133-30-9 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-(2-phenylethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 36133-31-0 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-(phenylacetyl)- (9CI) (CA INDEX NAME)



RN 36133-32-1 CAPLUS


CN 1H-3-Benzazepin-7-ol, 2,3,4,5-tetrahydro-3-(2-phenylethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 36133-33-2 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-(1-methyl-2-phenylethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 36133-34-3 CAPLUS


CN 1H-3-Benzazepin-7-ol, 2,3,4,5-tetrahydro-3-(1-methyl-2-phenylethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 36134-21-1 CAPLUS


CN Benzenamine, 4-[2-(1,2,4,5-tetrahydro-7-methoxy-3H-3-benzazepin-3-yl)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 36134-22-2 CAPLUS


CN 1H-3-Benzazepin-7-ol, 3-[2-(4-aminophenyl)ethyl]-2,3,4,5-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 36134-32-4 CAPLUS


CN Benzenamine, 4-[2-(1,2,4,5-tetrahydro-7-methoxy-3H-3-benzazepin-3-yl)propyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 36134-33-5 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-methoxy-3-[1-methyl-2-(4-nitrophenyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 36134-34-6 CAPLUS

CN Acetamide, N-[4-[2-(1,2,4,5-tetrahydro-7-methoxy-3H-3-benzazepin-3-yl)ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 36134-39-1 CAPLUS


CN Benzenamine, 4-[2-(1,2,4,5-tetrahydro-7-methoxy-3H-3-benzazepin-3-yl)ethyl]-, compd. with iodomethane (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 47229-66-3

CMF C19 H24 N2 O

10/598,888



CM 2


CRN 74-88-4

CMF C H3 I

H₃C-I

RN 36134-46-0 CAPLUS

CN 1H-3-Benzazepin-7-ol, 2,3,4,5-tetrahydro-3-(1-methyl-2-phenylethyl)- (CA
INDEX NAME)



L20 ANSWER 67 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1972:99535 CAPLUS

DOCUMENT NUMBER: 76:99535

ORIGINAL REFERENCE NO.: 76:16011a,16014a

TITLE: Blood sugar-lowering sulfonylureas

INVENTOR(S): Grell, Wolfgang; Griss, Gerhart; Kleemann, Manfred; Kutter, Eberhard

PATENT ASSIGNEE(S): Thomae, Dr. Karl, G.m.b.H.

SOURCE: Ger. Offen., 23 pp. Addn. to Ger. Offen. 1,933,388 (CA 74:99903j).

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2027436	A	19711216	DE 1970-2027436	19700604
FI 49828	B	19750630	FI 1970-1712	19700617
SE 357745	B	19730709	SE 1970-8771	19700624
RO 56857	A1	19741215	RO 1970-63739	19700625
RO 62509	A1	19780415	RO 1970-71660	19700625
CH 536842	A	19730629	CH 1970-9824	19700629
BE 752760	A	19701230	BE 1970-752760	19700630
AT 301568	B	19720911	AT 1970-5868	19700630
GB 1313539	A	19730411	GB 1970-31722	19700630
IL 34820	A	19730829	IL 1970-34820	19700630
DK 127928	B	19740204	DK 1970-3389	19700630
NO 132094	B	19750609	NO 1970-2575	19700630
PL 81112	B1	19750830	PL 1970-141708	19700630
NL 7009704	A	19710105	NL 1970-9704	19700701
RO 62803	A2	19770915	RO 1971-74529	19711208
RO 62804	A2	19771001	RO 1971-74534	19711208
PRIORITY APPLN. INFO.:			DE 1969-1933388	A 19690701
			DE 1970-2027436	A 19700604

GI For diagram(s), see printed CA Issue.

AB The tetrahydroisoquinolylsulfonyl-ureas I (n = 1, R = p-FC6H4, 3,4-Cl2C6H3, p-MeC6H4, p-F3C-C6H4, p-EtOC6H4, p-PrOC6H4, p-PhC6H4, p-ClC6H4, p-BrC6H4, α -naphthyl) and the tetrahydrobenzazepinylsulfonylureas I (n = 2, R = p-ClC6H4, p-BrC6H4) are hypoglycemics. They are prepared by treating the corresponding isoquinolinesulfonamide or benzazepinesulfonamide with cyclohexyl isocyanate. The starting sulfonamides are prepared by N-substitution with a suitably substituted hydratropic acid. Thus 3.99 g 2-[2-(p-fluorophenyl)-propionyl]-1,2,3,4-tetrahydro-7-isoquinolinesulfonamide was converted to its Na salt and treated with 1.52 g cyclohexyl isocyanate to give 2.6 g Na salt of I (n = 1, R = p-FC6H4).


IT 35759-09-2P 35759-19-4P 35759-20-7P

35760-17-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 35759-09-2 CAPLUS

CN 1H-3-Benzazepine-7-sulfonamide, 3-[2-(4-chlorophenyl)-1-oxopropyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 35759-19-4 CAPLUS

CN 1H-3-Benzazepine-7-sulfonamide, 3-[2-(4-bromophenyl)-1-oxopropyl]-N-[(cyclohexylamino)carbonyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 35759-20-7 CAPLUS

CN 1H-3-Benzazepine-7-sulfonamide, 3-[2-(4-chlorophenyl)-1-oxopropyl]-N-[(cyclohexylamino)carbonyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 35760-17-9 CAPLUS

CN 1H-3-Benzazepine-7-sulfonamide, 3-[2-(4-bromophenyl)-1-oxopropyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)



L20 ANSWER 68 OF 68 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1951:3787 CAPLUS
 DOCUMENT NUMBER: 45:3787
 ORIGINAL REFERENCE NO.: 45:675c-d
 TITLE: 2,3,4,5-Tetrahydro-3,1-benzazepines
 INVENTOR(S): Walter, Lewis A.
 PATENT ASSIGNEE(S): Maltbie Laboratories, Inc.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	US 2520264		19500829	US 1947-77074747	19470826
AB	2,3,4,5-Tetrahydro-3,1-benzazepine (I) and CH ₂ O or alkyl halides form the following 3-substituted derivs. of I (R, b.p./mm. of Hg, and m.p. of HCl salt given): Me, 73-5°/2, 244-5°; Et, 90-100°/3, 238-9°; iso-Pr, 95-105°/2, 260-1°; allyl, 97-102°/1, 210-12°; Pr, 95-105°/1.5-2, 236-7°; Bu, 107-10°/2-3, 226-7°; PhCH ₂ , 248-50°; Ph(CH ₂) ₂ , -, 260-3°; Ph(CH ₂) ₃ , -, 211.5-13°. These substances have analgesic properties.				
IT	153030-10-5P, 1H-3-Benzazepine, 3-benzyl-2,3,4,5-tetrahydro-, hydrochloride 860686-30-2P, 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(3-phenylpropyl)-, hydrochloride 860686-32-4P, 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-phenethyl-, hydrochloride RL: PREP (Preparation) (preparation of)				
RN	153030-10-5 CAPLUS				
CN	1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(phenylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)				



● HCl

RN 860686-30-2 CAPLUS
 CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(3-phenylpropyl)-, hydrochloride (1:1) (CA INDEX NAME)


10/598,888



● HCl

RN 860686-32-4 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(2-phenylethyl)-, hydrochloride
(1:1) (CA INDEX NAME)




● HCl

10/598,888

=> => d 118 41

10/598,888

L18 ANSWER 41 OF 41 REGISTRY COPYRIGHT 2008 ACS on STN
RN 215042-56-1 REGISTRY
ED Entered STN: 03 Dec 1998
CN Benzoic acid, 3-[[4-[4-oxo-4-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]butyl]-1-piperidinyl]methyl]- (CA INDEX NAME)
MF C34 H40 N2 O3
CI COM
SR CA




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,888

=> d 118 40

10/598,888

L18 ANSWER 40 OF 41 REGISTRY COPYRIGHT 2008 ACS on STN
RN 343821-18-1 REGISTRY
ED Entered STN: 28 Jun 2001
CN 1H-3-Benzazepine, 3-[2-(3,4-dimethoxyphenyl)ethyl]-2,3,4,5-tetrahydro-
(CA INDEX NAME)
MF C20 H25 N O2
CI COM
SR Reaction Database
LC STN Files: CASREACT




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,888

=> d 118 39

10/598,888

L18 ANSWER 39 OF 41 REGISTRY COPYRIGHT 2008 ACS on STN
RN 387875-87-8 REGISTRY
ED Entered STN: 29 Jan 2002
CN 1-Butanone, 4-[4-(diphenylmethyl)-1-piperazinyl]-1-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)
MF C38 H43 N3 O
CI COM
SR CA




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,888

=> d 118 38

10/598,888

L18 ANSWER 38 OF 41 REGISTRY COPYRIGHT 2008 ACS on STN
RN 425653-86-7 REGISTRY
ED Entered STN: 05 Jun 2002
CN 1-Propanone, 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(1,2,4,5-tetrahydro-3H-
3-benzazepin-3-yl)- (CA INDEX NAME)
MF C21 H23 N O3
SR Chemical Library
Supplier: ChemBridge Corporation
LC STN Files: CHEMCATS




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,888

=> d 118 37

10/598,888

L18 ANSWER 37 OF 41 REGISTRY COPYRIGHT 2008 ACS on STN
RN 691352-04-2 REGISTRY
ED Entered STN: 09 Jun 2004
CN Acetamide, N-[2-[[2-[[4-[(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)methyl]phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]ethyl]-
(CA INDEX NAME)
MF C26 H29 F3 N6 O
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/598,888

=>